var title_f35_11_36016="Diagram cervical effacement";
var content_f35_11_36016=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F72366&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F72366&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Diagram of cervical effacement",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 364px; height: 278px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Progression of cervical effacement at the internal cervical os from completely uneffaced (T) to completely effaced (U).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Zilianti, M, Azuaga, A, Calderon, F, et al, J Ultrasound Med 1995; 14:719.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_11_36016=[""].join("\n");
var outline_f35_11_36016=null;
var title_f35_11_36017="Cutaneous arteriovenous malformation";
var content_f35_11_36017=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F83553&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F83553&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Cutaneous arteriovenous malformation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAF6AfgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6Nl5j45Pcr/hVaQ7R0Ayeo5H4irB6884/A1HPjIxznuv9a3KKpYdMAL+YppKqDkDaeQp6GmzkqSc4AJJI/wAKrs+5d4xj0zkflTGTDoB/46Tz+dMV8MTg8cbWpnmAA8f1X/61AlAPOOncZGfrQAhJO4E8+jccVa05C9yMjIAzhjj9az5G2ADjcfXv+NbOmhYrRpZumOd3NJgUtXmR59ibH2jkH7wNZVwfL2qWxgcMKlmdLy6luIwNp5yvfFR7HlYcED+LHIpofQrxArvlxgD5iwP61L4ZQM8+oTRgp/A3THvUv2QagDbR5jtwczTjgfQVX8TakljAbS12qQNnHpjrSeo0zB8RX5vdQYAllU7Rz96sZ5EV1wCHUYbNRSXUcMZkOGIONp6896yJrzAHzHLGtEQzobNwFBC853ZrQhJK8Hr6VkWUu6MYI4FaUc20bhQyEWwSQQex4qZX44HIqorFm4OAetWI3GRjtSGWNiOoD5ByCRnGfapmYgcHAqru5DDjNBlIbBPPYetAicuHAIz7UjOre/vVfeR7EUxpjxkc+tAC3BBIwc80xZAcjnFQy4CllPOajLEKR0J6UxEkkhzxjHSnwKTkt0HrUO08Emps4HQ5P4UBYu7jtBznNKjgKRkVU8xh+A6UquAvFSUTOxGT3zipIvuYHI/lVZW3HB+oqWPD8A7fWmIlYkKdtIu3cDxx1FJI42bTt69+lSRjJX5uOuBSGSCVScH/AOtUxJJHPB6e1VigXJUZJ7GlV2J3AjGMc0CLO7GAvA55piuoBIySeSOlNjyEG/GT6UqKN2RyKAsEmWHv6VZsxkljxtH61CclMDgmriLtChhke1FwJfPJGSmMDnNOyxCkLg9Qc/0pQq5yQfxpwQ5J3ZPbNIQwM0fX+IdqVGb5cj8aGGFDMF3juBR94ZPXtmgB5kIBUKPqDTXkLrz0J7DpTJX6A9/7tBBEe053fpQA5grn3p/l9+h96bDEcgM3vg1bBwuVBouBQKAA4+9nkiq2zdjrkcmr7gdR1P6VEIwHIA+tNCKzkLnI6cYzUZlwoIxwasTwgKefmzkcVVPEmCBxTAsrKOxz65p29HAV81UOFBK9aEmJPzAcdKBFplCRkhOcdcmmf6wfMcUB90ffHpT41yylB+BoEQTBlwD19fao8cnafxq253HadoYGq8kYZ8x5BoBDTJhdrr+I6U234JwcimEsuRIOAeKA2DmPjmgsuSRK5HGCOc5pRGBwR29agiuChJIyM8irCzFs5IBPHHFAEU0KiTI4Pv3qJrZl6ZIzxVt23EFuRn0zmlTJQ71XAbgZz+NAjPMRTd8vHqKK0ZB8uFT60UxG40mcH+FfWo3kDAtk9O/H61UebJOAPqagknIYgEfhUHRYmklDNwefU9f/AK9Qu3zBgcN3zxxSGRcjPWoJpSSRuAHpQOw8OOTnGf5fSmq4LAITgDkY6VVLsVOOR79qXzMAqASx6kc0BYshl3gJ+Y5rRv7hoNMVRGeuMqP8aq6XAfMDyD5R6ms3xfrLCaGxsUW4vZG/dqvJPoMd6TYWKs2sWOmmNbuXbcO2BGOWY9hiti2trrUY/NnjNnbD5trD52FZvhrwm8d2+r+KljkvD/q06rF3/Oqfi/xukDCC0fc4yDjpx60tw3NbX9bttNtWtrMqFZDwO1eaavq7TOzO+XY4+lZF7q8tyXLkEn17VlvKxyD3qk0gsXbm8eRyzvk4rLN75l7uJyqj9aztc1MWluQh/fNwB6Cs/Q5jJbnLEkMck0c2pEj0LTdSG9QTgGulil3qMHIrze1kKnPpXdaLN58C4POMVd7km3ExxyPxqRdxYbD81Qcgj2qeF+pY0gJdzbQDyfanFo24KgH1qMuCRyKa+5jyPyoELtORl856Cicqgwx5HpUTOIxg/e61VYszgnkU0BN5jSMR/DQAQ3HNIgK5Ip2WVcjjJ5NICVFOQOPenPKeF4pqygLgjr0PrTSwJ46UDRLG6Fio4I/GnowbgjAHrVYEBsjIY+lPhLNnPGOlAEzsFII5PpSrJ6HjH4VJGg74Ge9VmXZLwfl/nSAtDbt3enNS2sw35A60xACAOORmoz+5J557igC453HD/hxUa89D+VRI5fgenHsaVXKqTjHagRbLYOOCT6VIvyoNnpzVGF2YbRk471bUgx4AHtQxk8J5z/CvNWkOEyxGevvVBSFUbjj3FW4yrKuePUmkBajckAAZHXNTB+MDOf0qnHKAWK9KneVTEA3A9DxQKw+TLICCpA7UgxgqT78Go/PYY+UBR1ojIJJPJP6UCHhMkAA+vFIqMmTg49zUwO1Mk+2acm7O1mB75oAroSVBIyM8VMrMkeSQe/AqMhRINo7809mHBJIAPTNADWjaTmMgtTTlGIzuIqWIjB9fWkOAfnXOT+dAED/OACOeoNRSW3y5cDdVx9mCwwAOwqIysy4OeeAMUxFBkMb4I+lIwDjHSrkipyuTuFVJI9sgZeBTAIyVXBzx0p0UkgJCnOe1AbOBjr3poJXIwP8AGgRbdVZd3Rh1qBweowPxqKK4ZCw6t24qUEsBvXb7UCIHxkjAYfSozEHHycZ5xU2zDHGc+9RShlzgYI9KCkNCuo+YfU0oPIwOe1JDKwO1hwanEUcvO8KR0oGIs/AVzjmp3m+Usgz0BqEwFo9ykEY9KhUOjBcHGKBGjHJxyf14oqjECjLzx3BNFAi9K7LlRwTyaryv5QBOSx/SoJbtQMDJY9xyKpzXgY5kZQfQVJ1xiXXueQepPemGXeQGwB6etYtxq+n2kqLeXUMG7oXcc1zOs/EXSLCQi3uPPZCVZcZAPsalzS3L5GeiLjBLEL7HgfnUc+qabpswGoXMSYbnDDgf1rwXXviZe3rSx2JMUbHI54Fc1p99Nd3vmXMjSMxySxzWcqttgUO57pqHxKnkv1s9IsVkRiQNwyrDsw7/AIGu78J+HVlurfWNS8xr8x5cvgDJ/ugdBXmPge9sbELPKEaTjrwR9K9JtfF1usewsGHUEcGnbmCUWiH4qa+dNsPs9ucSS/KDnp614hLMXLFmJJ9e9d94vQa9O0iPh1J289a83uVkt5GjnUq68c1e2hm9B7PVPUL9LOAs5yx4VfU1lapriWwKRfvJT6dq58zTXc2+ZyzehpXJciWWSW7laWTJLVpaODGzL7ZqbSdOeVVzGfyro7bRgNpwA+aqMG9TJshgB644rqvC0h3OgPbIqvaaUOA2AB1zWppdh9mvlKn5CPWrasNG8GJ780occbefwqHau/I69yKsRJ8o4PXrSAcGHcjNS+Y2MZ9qrvGA3HJp24BcMDj60AMcEn5u3eo9pyFGaRpAGxzipYzg5JPPSmIkQFVIPH1qXhxjvUBfco3DipfNAUdB9aAGyptII7djULcNkHn27VMzhsD/ANCqGTaq/KMUDD+LLE4qRWKnIbgVGDlD79vWnKoKkBfpQBaSQlSwI+lNdgV3ZOccg1BHgLzzSHg/0pAW4JuPm596WYhiCRg9veqsZIfBHerjKHiBPUd6AFSTZkGgMWGeMEVEHHQjJ7Gl87nkEUATxyfLjB46gVNbcuAenU1RSTD4GRVjzCiHruagCx5nzYA6k1Olwdoz06e1ZhclwxP5VYi6HknPbrRYRpbzhcLwKkDs3UCs8SBTtY9asQzDPOAPrzQBO7ZbHGRUqSbec8nrVVWC/Nnp69aInAckcgmkBpZYqWzz79KbvZSC57c1Esg24zn2z0qMOzyFcgqBnDUAWFkydwz+NOX5yTnJ96rOzhwV6d6kWQYAA5HtQInJKD374NHTnseeveow+B0z70RP945yPegBRuAw2fXjuaXOcKeCe9LvDgdcDnJocrg9RxQAbQ+QB0qCSAoPReue9Tx4B+XqB1ptwzKTnJHSmIpEFGI5ANKCCuMHr1qYxO5G4tgcYFR+WQOPX0pgRSJ828DLVJBOsjhZM7+mTTRw/t0qvdAhsqDnsRxQItyZWQ571FKC3U8gVWgu/NyG++vUVYU7uc4zRawyMEAAMOTTnXK/IfyqMtubIORmlUgSLnNMZLFPt+Rj3xyKf5qupDAg1XfklufT3FRY5I3dOlAizuG4Ljn8zRVUblYFCPx60UAeN6344v7stHpoMSYGJSDv/wAK526uNX1CUS3F1cM+McMQP0rqVsbeMfIgp4iVeMCvIlVk92e7GikcQ+k3MvzSlnP+0SaibQpSuNozXdNHnHFRmIHk/lUczK9kjz2bRJgMqOfaqggurCXeYzgelekSQqR7VTms43ByuQe1P2jIdFGRpWvxuoQyFXA6Gt631eXgpISPrXNanoCSHfB+7k9u9Yu+8099k24c9exFXGo+hDi47o9RstXl80b3OwHoTWvqtlba9pzrG/lXG35ZFHOfevK7DVS4wxFdLpuryxMCGOP0rqpVVszmqQT1RxM+lTw38sE/+sRyre5rb0rTAJFAX5u9X9WVZ9aE3GXUHj1rS0+MRqGPB61vGKucj7GrYWiQoOAcdc9K0RsT+7n27VmpcDAKtlev0NRSzbSMnHfNaXEom1HOrMFDAZ96twgrLnex56E5rm4nJZWBPBretX3hecUhtG1EQwyucelWoZCpOT2xWdC/Qc4PXJ71bUHbnnPTpQIshwemMmoJW4+lPwABxyRUEjHk9qEJjQAxBAz+NTgblBx3qFEJAPrUhR1YDduHX3piJeMDHIH6UwDkY6j0pWG1cYIzSRg7fl4PqaAFKluMZbrzQY/Yg45z0FKr8jIw3pU6OCpOOO+aBlEhkOD0pFkPTP0q05WQ4UcGqbr5fykdaALAcbecGgsNwJHWqinHToaeZcEDrQBYOAcqT71NHKRtx+tU0YAEdO5qeLBxzj60gJp1IZWGMUwsSuOh9TUw2OnP3h71WPLHJwaYEsZy45/+vTXkBbjqOntUQJVPQ+tMDnJxyelAE6SENnqO9TiYswweB1rPMmCQDgmhWK5HagRpGUl8gY+tSxzjgbvrVBWOznJPsKb5hQZ5B6YIoA2hMoUhu/eo1mYNyeO2KyftDM20EtU8czNg7Tkcc0Aayz4yQeffpSGbkkYJ9cVnC429fvU77QG6nmgDT+1DaoPy/SnidcnpkdeetZImwCQMU/zmQhu1FhM1Ypz82D8ueBQJn3NjO0VlifkFePWpxIGXIbOB0HemkBrRyZVSOx9advLMcnpWZFOMc5X0PvUyXGWOcHHepAvxv0yepqQTAPyc4/Ks5ZwxBGQQaJJDkEMce4oA0zONhyoPp7VG5V+vHFUfPA2kHr1pxmwACc8UASyR/IDnPoahcFjhsZFBueDzgDjGKjdg289/r0poDMvYJxJ5kP3wfudM/jTIdU2kpNG0D9Dnp+daZPyjOQR1xVe4gjuVw4yvuKr1ERLcLncrg5HFJ9pKnAIrNuLKW3LGJjgc4ql9qYEiQkfhTsgub/2vB5bv0FKLgbgWFYJu0Azkk1NHeKRjcKVhm2JAORRWWtyuM7hx70UDRwRbHHWgnntSYw2cZobqMDg14J9LYOtRv7AZpxK4zkj2pjECgBMD/GmtHz8uPxpeoyM01vSgViB4sk9M1SurNZlZXRWB7EVp4zxjNRsM8Y5oJcTjr3Q3gk820JI7oew9qksnbODkHpg9q6h0BGMVTmtFaTeoG8e1bU5a6nLVpN/CVzEz3cJHOABW2gYHbjkcVm7wknTBFakVwrAYOPWvTi0eY4u+pSuN8MxKklW6inROW6EsPerVwsboWBG7HFUl/d8+vYUndAuxq22N2M9K2rAkgVz9tnIPBYdDW/Y42jjFUgZrwrke9WojzhuMd6qREquADtqaIdKZNifJUE7vaolJkb2p0jZXAGaWGMjGTgHqKCWPOMqXJB9ulPJyQOcetM2l3O3tThuwwIP1pgG8E88gdzT9wC9c0xcEEY5FJGnzAdT2z2oEK6FjlSc0hD5wOfXtU7blHzdTQpVsbhwKBkSZV+eBSSx7l3dRUrjA5GfTFGTkZHy9qQFDaVbjBAqNhhvlPXmrzgcgjk+lVZYxuOBj3pgRg5IxnIqcOwwSO+ahiIRiDyalOGBJbn0pAWIZcsCR7U1zl/l5JqGNvlIHWpc4AYdcc0ANkJ6Ht3phYYxzntTJm+XIzntxUKEnPQk9famBLuGMkcCnhwyH0PX2qEJwxJ+UelCtg9OB0+lAEyS7QPmOPTNI8hZTycVAy85ToaQk9ASCe1AE8TAHA6+tWTIPK6n8KzZNyk9QaPMkxjOKANJW4Hv2pF4xzx7VnJcSIRuBI74oF3jghlHrTA1JJNqZyaFuARyc1niZnHHU1GJmBKkYFArGvFIrDJOXJ5qZJAh659qxlmIzinmcgAUBY1mmKsegGR071L5/UAdaxfPAx0yeKeJyMYOOKAsbK3IByp56c095lOAxIHasZJMng5JoErDAU9elFgsbBmAPynn25pDMT1Y/WswSkc9MUG4I5ycUDNJptygnkmn/AGnj0x15rK83jPT0OaX7QSQeOKBWNd9QXaocYB9KdFKjfdYn3NYnm54bvTkuBFnHX0oCxuPHk47euaoXVlFKuDjPsKrren3wPU05Lr5SVbg+lMRlXulyKNyHIHQ+lY07zWzEuD+FdcbsYywz2xWdfFJUI8sEU0+4rGKl7u5BwT1BoqpeQ+VIzKNtFBRUZuhzz6VEXySCDkUvXOTkVGxy2R1xg188fTgWJPuKQjn19KQ55wMA/rQoxgHmgQ4HHYfWmgkn/GlJIyCflpOT0+lABk5xTM7hn0707J701ieKAG9T0xQV5p2Acn+I0hJx707kNXIniVuGyTUJRo/uAGrW4Dgc0bcitadVw1RhVoKa8yGNmdCWPA7VBNJ3weKtsp7E9O9Urr5Qe3Fd8KiqR0PNnSdN6mjZZfDDoK6CxJAGM5rl9NOGwM46iuk0/dx3NaxIZuR5xnFTwqcZ5OKZBu4DcfWrAGAffjHeqJsIqknJ/Snk4OMA+hqSIBs54wPWjYp4wQc+lMhkTZU5zn0qQMxDYznHSiNRyAMY9RUg+UHKn8KBEYBPQdTUscfB6HvSiQDCg545FKq5PqvWgLC/MRgdxjFQsAmN2eO2M1OrjOR1p7oGG4g89MUDsQJJ8pwCQPXtQSTnpjqMU8dSuAp9utQlQclfWgViKUlnU4I9aY+CrZ69qmYcjdwaidckYIzTAquMP0+tKp568VJMgBOBz/OmRgsBkYoQDoxyfenXXyDaPTmhVAyT8o9R3qF2Z2BB49TSAax3AHOTTkGD3PrilEY25Y8jt2puGA9vT0pgS7wgK9j1FQSKSTyMnp7UGQt8vahVBiLE9Ow60ANWQ4Ckc96TGTnHA7mkB+b5jgipAuU3NjHp3NADjICoHII74qPPUDjnr70mCvQHZ3A60suCuACD196AHLwvzk88Go3CqPl/WmI5PGenJzU8Q3k57UAQ7gEB4U09WRsZ7daJLYucqfoPWo/KKls0wFfjoDg9CKTIGMk596YWYcDqOmaHYkcnafT1oAXHXZjI55qSOVRyx56YFRh124ABbtzTGjIPHWi4FsShSo49c0hmyQSenrVRSRwDwOop5YKRliRQBb80FSQSCPSofNYtwCAPbOaZvG7gnpSMeAR9BQA+SRiMIfqKalxjgZ3enrUbsxHOARTDgg4ANAFkTknkfiKVpTuyM/n1qqG6EHIHSmmQtkAkH2pgX/OBXkjJqSORVAIbisrLA9x65FPDtnK4IFAjT81WJ4znjpUqvGUAHft6VmxNn1+lKZCGyp3A9aAEvIQQxJ5oqfzUkGGwBiigDkGXng9vyowMjJx+tSsM8Hg+vWjABz3PFfPn1A0D6HNBUY9x39ac3Ck4x9Kj56jikKw18Dp+NMzk8fSnMM9eB19KTGB0z70AIBxkZpCw7mggKepNRvnHHUUXAXcccUhbnPpUbtnoPxppPH4d6LgTZx2zSk4wQecVCGJJwCTUyo5GcUaktocWzzUNxGJUKjg+tTiM9CAKTyyNv8q1i2ncxmoyVilZM0cgVxhgcYrp9PkwqselYjQ7mDZ56Zx2rSspETAkb6V6NKqmtTzJ0XF6I6q2mBXOMirEeSc9D7isyzdGxskRh2FaUe4KARwe1bJ32MH5lgNhegOaMGT6jjilQYj5/WnRjoRkD26VRD3JMbcE8jvTXIAAxlfWpW27BnFMWMsvHPegCFiAxPf1pUkK8nkdKcYSB1+X0pqwseew6AUwJWcAcDrxTllPAPBHTNRKnOR+VLtyQSMUgHs4LHA+ao4yEfIwR0NKWXbgYPvQcEAjr3oAQxjblT15wDTWQ+lOViDgAY75pJSFxjv+NAFOXBB56dKYhYc9RSz4DAflmkUdzzigCC6fClSe/So4JAeDz+PFNuDvbrnNRAmN8j7vvTEXuoYBsntQSQCpINRIN4yuSPapnVSoBIDetADViA5HH65oB8s5CkA+1PGYxjgio5XUuBnFAAwB+YcnvTzjBOM+g9KbkL8ozg0BDsJXr60ATImT0J788VFMoJzjBHAxS282GKuQKm2gtuPPbFA0UjEMjsepp0fD46AetWWiUKcqc+uelVnkjbg8Y6cUAW2mVY+M5x1qAbXQ/n9ahjfsSWA7+tIBhyFPB/DFACyKWwRk49KqspaQfMQB1GOtX04+Y9hiqrvj7oyM8UCGIpTI9fwzTnfCgdsVKr5XnpUMmGPQle2aAGA7vXjoKe2NoU4461Ew+ZTzn09aHYg46D0zTAFU5wORUmDnAPIHGRTFfqdpz6ilUkjJoAeqbwTmlwByMZ9QM0xWYA4IGeOaVTtH9aAGyg4+Vce1RdeSMntUyncT1Y048D5QCR09qARXViD83XHSljHHzc/0pzqHHc49803YWJ3ZCigBWbaThenf/wCtTo5dy9cGkMZxgn5etN8vIyOtMByIW4ycUVJGjDoDz1NFFwMHIHcgCkY8EZBFSAFR834Gmlc8g8Gvnz6cYox2HNNZfTn2qXaEPOcYqKRse3pQJDS2ATwcetRswyfXvTZZAATnn1qqXaTOwEn1pDJmYAZzioGmGcLy3tyTUkdoWGZWJHoKtxQpHwigUKNyGykkEr8kBF9zmp47RQRnJPvVnAAPHelQEA5FWkkTqxoi28CnhMUM2AMcCk3EgD9adw5RWxx6imrj0FGcjB9etGQGI5AFCkHKLwCFzTSFHWk3HG4YpNxJHHFNSE4ix/LypIJPUcVpW2q3NuCDJ5ij+F+azsH/AAp2cHnmtI1GtjOpSUtzrtP1y3uFVJv3Mh4+blfzrbRowo755Hoa83UgYP6GtCw1Oa0YbHZ0/uMePwrqhiO5w1MJ1idwdrDGApFRo+wgPg4PJqHSb+HUAPJIWYY3xtVmeERs3A5PbtXUmnqjjlFxdmPDg4yfyoLjdwOveq4+9/Onk578UyRGfJJyCPamOxAOBzTwmct0AGaUAMQeeewoAgMmGyMbe9PGHwU706SJQABmoxuj5FAEZVlYjPfNBbgdsc1JJiQZxgjrUQPQkcUAQ3DB+nX3FNlYJAOevAFPlG7uOvGaoX0uWx/EBjg0DQwuPTk9BTAcjGPx9KYnzcEU/BA4OOOMUxDoHK4yeBVsMOvXngCsxyUfjj175q7AcrkigCYuQOeAfWmKcsV60jZbgcDtTkTLDJORxQIlX5doOB7GpFAB+Uf/AF6j/iBHQc+9PRlGM9KAGzQFzkdO4pULQ8sD75NWYpSsi5Hy0+YCUZ4B9RQxkW9ZUI4A61XkswTuVs+1SSQOvzDt6UiOSMBfzoAgSL5CGprAjoSR3BFXRCQMevpUTR565yBjjtQBXXgdmFRSAkZAwamwyyc9R1qUruQkcD0oEUd5xtOee/SmscYHUY496lZGBA4NOCk5DD5fTtQBCw3LyPyqMfQD6VJKrI3B4HpzTETdkk4z60ARkHd3x0pRjPpjrmp/KEa/Me/4U1owHz/EeuaAI96ldyk59D0FCyHcffrmpRwpHGSecdKaygcgbj/OmA5Dk7SwA60ki4PfbnjmnKoLZCkdM04hcbm4PpQA1FBzjGfypwiBzkn8eRTkUdSSSegoJKE9x70AIIuRgjB707CjgH8u9ODDbg/eFNwefQn8KAFyMe1FCgknjjtRQBz74wc5z9aiYjOTjp0pztg8jP0qFuQfQjmvAPpxskgHXnj1qCSQk/X9aVvvYxwOnvUiR57HgetFribsQCAscvye2alji2kbRzU0aY680r4HQVRDdxAp6mjOAPTNAIHUjFOHPJ/CgLDdynoOaUfc9qRxz8o+tKvC8k0AhMYHTP1pKepyef1pGXP0oKIm4ye1IMMcggVIwwegx39KaU78EflSGR5NGccjkU4Jk56CkKdMdaYmOLN2wR0oB59aRlI+h60q55AIAxSuKwp9+gp4Kc9ajcdmycd80gX0Jq0yXFFqKRopFeN9jL0Ydq6/RtWW/Xyp2C3PQH+9XEqcA5qRZCrblJDD7pHGK6KVRxZyVqKkj0SSM4zxwOgpIxjgHBPtWdouqm+h2P8A65Oo9R61pbNw3Dknse1egpKSujy5RcXZjx93DDk9KQq0YJHfpS/MoxkkevpTw4YY4PrTEQks4GRk9qGVgv3f6VLt+XOM49KNxHTBFAWZRdWB3EcVGTgkjvV8x55AHNU7uN4gR1TPUUCRXlYCMuvyt29KxiSXORnnrVnUbnGEUhc8nJqgtzbof3kyDHbNK66lqLfQsRk8gkDNTKuELdfpWeL22zzKPwqQanaJkF2Y+oXNHPHuHs5didnBPGcZqWJjggkAdqz21O0y2C//AHyaRdUtx98tt/3aPaR7h7OXY1hL8pC8inxKM7sdKy11a0BBBbHutW4dVs9pzOBnrkHijnj3D2cuxejYbyRyDTghZyR3/KqSXloW+SdMHqSamS7jGQskZB/2hxT5k9hcr6otSKR3NMXcNpzn15pVkEi5VgR3xT12qCSOPamiSSOQrwVPHakb72VA56g0xnUkbSSD2Pagtj8elFgJDKqgcfN6VAXLk9hnmlKBsEc+2ai5zznjrxSuA9xtzjGT70xiwHXPvTnwTzxkdaT+EF+ncYpiGHawHHFCKc5z8p7HtT1HzZB+X3qRQeqkUwISuVYgVEUJ6DBq2rEkg7WHtUUyH7wP4UgKshwcPn64pqEZ5Gc9OetW44SwHAD96PKG9g6jHuKYFZ+cjjPcU0AHAznHYmrgt2OD144pxszn5uO55oQFDjfjn+n50EDJ259eKsyWx/gBGfSkVTEfmHB70ANgBPIBHp605lYNgqDmlyQewFOjbJJP05oAYqkEswwKm+VwFwf60wEMSGOFHOapWd7cXdjJc29uoPP2dJHx5gHQn0zQBeBTZmNw46ZByPpRVTSZ4J7FXtoPIUs26IfwOD8360UAYD9eASahYZ5BG49qsyKfT60zbtwBx9K8E+muRLGeuBnvTwpGMg4p4TI5yfanhCf9n2oJepEByeBz2ppXHrjPGasBMHkcUjqAcr0pgtyFQevceope45wetKEPJHI+tO2ZwARkUFuwzHI759aRxUwXAwMfUDrTXXgE8EUE2IEJzTixwRxipPLzzke9MKYPUH1FA7DQcDPHXvTcE4yT9Kl2gZJxt96FUE8DigLDAvJyCAKQgDjrUhDK2M898mk69B0pBYhz83T5acPuk+lKQc7T19aGPy44+ooFYZIwA74pEbLe1IWIzlePalT1HWqQmhQOeelOPpxQQAcEjNNBPcZqkzKSLFrcvbTpLGdrL6d67CC8eeJZYzkMAeK4OQuAeldD4QvFe3uIHJURNnk4x612YefRnBiaelzce7fbwevUVC920fLOETuScVj6xrcYHlWSh37ydh9K5qe4mnbMzlq1nXitjKnhpS1Z2kviC1iyRPuxxheaqSeKwFIhibnuxxXIZOcVIM555FYPENnSsHFbm/N4jvWGEdYx2wtZs+o3M3+uuJGPYbjzVILtOOdppVDZJyeves3Vk+ptGjFdCTd83zHJ7VXM370Kyke5FOYrG2TvO44wOafjjBP9DUcxpypADjhju9xQSCM4/MUijPApwGVwenpSuPlBCcAHJpksrICQhY+1Of5IzjJIHAzWZ9sLXLYUqno3BpORUafMaayggcHkdCKVSQOg96rkq8eS3yn0qSNk2jBJH1zVJkuI95MKOnHTmmxTM/BRl/GmvEsgOeRTdgRQvp0zT5ieVFmO6ccK7A+3FT/2hMowJn4HTdWcGOCB17VE7DHOd31qlNrZkukn0NlNWu1I2zMf96pP7evccyqwPqornlnBB+QgilZmOAzAegFNVZLqS6ENrHRr4jvQQCsRHrtqUeJpwuHiib6cVzeQQCece9GQTkfrVe3l1ZP1aHY6dPEXTfbD/vupP+EjiAOYHx6hs4rlshicYyO1OVh07+hp/WZdyPqkOx2Nr4gsmXLiRAe5FXk1GylA8qdDnseDXBAgkAc+1TLkdO/pVrEvqQ8HHud+DyAuGz6f41YZAyjIwa4GG4mh/wBW7r9DWpaa1eR/xJIP9sf1rRYmL3MJYSS2OqQDPA6frTwofJKnOMVz0XiFl4ltwf8AdOMVL/wkSAf6iTPruFae2h3M/q9TsbadCG9etJg9euKwW8RNtwtuPX5mqB9fuWOVSNT9CaXt4LqNYeo+h0qMCGx1706aFXTcMAda5JtavuzqPYKKjfWr8g/vsf8AARU/WYFfVZnTywMFLEA9+KgKMT05I5NcxJq2oOMfaXx6DAqnLeXT5LTSE/71L6zHoilhJPdnY5AYK7D054rlzdw2DPbWmv20cCMQFaLzGj9gfast5HIKksfx5rJs7mW3tUhawmITOGCj5vc+9Q8TfoX9TS6ne6Xd6fBp8QtrxZY8k+afvMxOST75orkoJi8WTG0TZ+62Mj8qKTxdjRYJdzpmwB0zn1pnljGeW9KmK5GSOaaRweteceoNw2aUD+8OacmAQDmnjAOMHjuaYiE4AOeT2pjHtnBqU85YdM0uz5gWoAjVNwx09KVUA+8ec1P5fdSKcExkMPegCBhzwSR7Uxl5PrVluTxnPpTGTcOuP5UAiBhgEZyOvFMxkjHX2qV12j7w/nQFOBgcnvQVYiVQckkYzTmUfxHjtipTHnqenSkZCRwaAICCT6gUw9DtGfUVOQFHPWmbM/N3NAEOPmORxTGKg5GfapvLJOeefemvGc4PQ0guV8A8DJNIMqRjOal8skHnkUm386EDQh5HLYPrTQenGD60oU8+1NJwf60zNxGyZwelVoyyu5YFC33ufvVZdckA/Wo3AHrmnGVhOF9CPfg4HShn4+boKbJgE4P1qoXZjtyOKfMUqZZ8wDORj3piSktgciq12zRwl4zlvSqtndFgM5z/ACo5iuQ1mnCEjaSPUdqI5RIQQ3H86hilIBz1p8AXkLgA8ntSFZWJ2cDv7cdqaXKkn8qb5ah2bj5upqMqRnknmgLJjizb1dSQO47VPuBGckf1qtAd33jgjtUqelO4miZzgZGCD7VlalExzKFBHcVoSzeTjdnDHAwM0vySR8jI9KGXC8Hcw7ESNMDGcJ3yeK2gwRQABSxxIgPlrj1xTtqqCSQTTQTlzMYVLk5YimPlF5Oe/HWpWYDAHGfSmsvmDr7UzLlIecbhn8arzjc2V6+1Syq3ABwRTFBOckYFAmRpkAZ61IcDnHFNOFJI70jZA7YoKsL5mQNo60g3MdpHTvmoSX3cqSPUVKkjcnBH40htEyDbxxx6U9G3d+vtUSs3oAfpTvmXtgZzSuKxNu24A656VIkmDwR9Kqq3PzHipYzgnIB96akJxLYcgZbHNTxnIxmqqsNo5zUyHBxTuQ1clY/N15NAZs01s56c00tkjIxRcnlJNx9fyqRW9P1FV1J7D8KerHFHMPlJeMfLTHbAwOtAz/hQwGPejmDlGO4PGKjIHOcc805hnpURBP3s8cUcw1Er3NuLnYBPLFt/55tjP1qo+mkf8vd3/wB91oMQrds0GQEdM57ijmB07u5Uhg8mLZveQg53OcmiiB5G3ebFsGTg7s/nRRuUjstox82frQVOO2Kl24XufYUEYxxWZoQEZb5hxQcsCSal2fMacIxy3XPagZCFAOT34p5wvb6CpWUDgDg+1NVRk54x+tAhg7dR6gCl6DJPWnqAATjNNfGex/pQAxgQOQMduaYfmI4yBz7CnOQRj7xpoXvg5pXGN27j2x3NPCZ6ZwKeqr60P17fhQDGEY44JNDLhTnFKEBx60NliQKAsVmXd0Io8vhexq1tAOMdaY4UdckdKYXIVHYDiklXIxnkVIqgAkjk9qcV/KgCoVHUjmmFNuTj/wCtVp1PpTGX5eQaRRRcdcDj19aZICik5q4YwfpTJIsggjj0NAjNDGVA20ow/h9aSXJX5QN3bd0q75ZHKgkjtURXJJ2kHGcYoWhWj2ICg2HcMEdaq7FBz0ANXmbgZGB/KoNgLEnJ9BTBFaSFWGGOc9Kijtoo2xj3q2R83+yajkjJBP8AEKBELDBPPA6Gmp94En6Ck8zA2SJge9NRxI23jjoaAasXS+F55wKRgWj3BenI5qJcsQOQP51YQYfBz0pk2I0YbgTkmpkXHJzimsgVjk8+vemSzXKlRGgKn8c0DUebRFlkVg2D9M0kXMeMdKbuK5GMcg1IgAGMEU7AKihWOTjNKUC8dc96QRjzcnJ96kYNjOeM00SQom4EHqKPIAXI/SnqpbJ4x70M5VgOKB2uVHOTtx83rUUkZYGrUi/OGIGR2FNfdu6YHek2DSKTR7FXOD60w7mbABIHar4CHrniqkjKJggJD47DimJpitGAuSD6Hmm+SOdp61LgbDvBJpwY8YTB6ZoDoMiXYcE8kfWklbJUDk1JG4EhPU+3ahQGdieD2yOKVgIo4uA2Of5VMVAGV4z39ak29MYx3xTFwXIyQPSkNaj4s9B+NWFDdcYquD0I57YxU8Z+UYH50IlomQAjkUjcmnISOwqTGOcj8qdybDBHznOTT0jyaegBxTxSQDGXI9CKiZC30qx6cYNBOOOfanYdioEcNzTCeeR3q+iqTgDmmPEMEACiwGfKFwxX5j1xWAkr3SQRPcNlt0s7A4KAcbfaugmXyweOmTxWVb3E0kqHyYBFdIxCBBnjgFj/AEoiE1sSaUHmsFZiXAZgGPVlB4NFW9NkNxaqWVUdSUYL0yDjj2opN6jjHRHZdDzwKMEHOeKXyyp9j3NLgdOD7+lIojBOTkc09Rhsg/WnCPfUhTKnPQUARMD1UUm3vxjHepsYyTUZIwSTmkwRC+M8AkntRjI7emDTgCT1Ao4JxQMhVCrfORj2FKMkEAYHvUzRgYppwFyTzmgBgXjrx70Nx90gDHWjcSSFHHqabjIBP3aBWGZyPc96RRk8nkelPYcjJwM8UqgHdjPPcUDHKMc96Y5xnGMjrS54+lRuckjj2xQFtRhYD3zQMg9yP5UqgHGCKeVK7SO4plBjc1I2QwBB/KngZwTx9aUgn60EsjaMEgLgjvUbp8pwOfarOOMdM8DtTWUeooJsZ0sgQ4bqfSs6Z7lLvJT9yenqa25YUZgzLlgOtQtGpAyp47HtRY1i0igELnng96RIgjEAZzVuWNgAwB9T6fnSSD5Rxx607CuUZwGBxwo9KgUgDIOT6GrsiAIc8ZGaqTxhwFUn8KQWM+5/eSZAwgPWoxGeSmAPpVx4gqDPX0PSkRFMbYzTEyOBSQCSeOKnAwfmzikiwBnoB1qcFX+4fegRG+SuTUtqAVBIxio2yBg9van2kLRsd7bgeQKA6EoCs/XIPtTlQAjrxwKlRQshJH5UkjfwrVE2uEq9eeCOaVOYhgZoVcj5uP61JF9046DpTAjkQmFsZVsYzVRImjQAgknqTVyQNkFuR6U2UEYPagdyELuPQUhj+TBPNTqEADKDSSD5twHHpSsNFfyyBgryehqvNAm/cc5HerNzMwTd09qcFDJu7nHahA1Yq+WduPanzQFoVCEZHX3qYoQcHqaE3KCep6c0xIrrFtYFQQcc0nlkMW6g9hVhv4gP1p0ZCrhjg+1IZB5fy4AA9qesDso449u1K+AVYE4qaFioJb7pphaw1kAwpB/KiG32R7V5/GpeGY5B9qmCkr1FShMYkQ6EVKEGMN0p8aAt8p59alUZJJ5Ap2JZGIR1HSpVi4xnmpo1yTgcVJsBIPbvQkIpGA9enPWmOjDrn8q0tg/KmFBt6cUxpmb/ABfT8KCzKvINW5osjpz2qsUKn1GeaRaRXnAZd3Q/0rnH+xearQajLEse4KvlE7M9QDjiuluIyUypI75xWZYyTWlsLZ9PnkdSfnTBWT3JNJCqLYbp0tsFFvZybtozhgQTzyeetFLbWdzHLZRPEAYS8jydl3fwD6UUpLsVTTa1O55wcH8KRFJbtjvUyoNnf601UO/jAzSJGkkY2DOetPbIHJ/OlCc7icLTWwcc5zSFuMdiew/rTW6dqVwS2B0pgGeOceuKCrEMrFTwMf0ohLYOByfWp2UEdBj61WbjnP0FIpaokeTbyxJHrUJIdgT936Uu0Zyx3ECnA8/TnNAhMFuq5A/SnMBjAweM/ShcFfvEc800ryQDxj86AS6kQA3ZJyTx/wDWp5XoMDPpT40BIJXLY/Kn4yxwoBHNA2QY59+9R4IHuegq03TJ4wKgOdpBHTtTEhiEL0zxUgbPX8KYqjryKeBhgRQDHAcdMn+VABDc9KUMR3468U4DOCMAmgQ5V3dcikljVQM4I96ejZBA3HFV9TcxWsjISGCn8KYJNtIZhdxOefTNK8ZIJHFc/pFy73G0tuyPmJ7VumQtjBxn9KZrOm6crMhudsagPxn0qJwAB/EuOKnkCSYXgnvRLF1IUDGACDQT0M64j3EN0A6j1qFl+b+RFWpwRgf3qrneMgLlT6UARTxlh0zxUMMSqMEYPsauMQRtLc44NVn2ghQ3PtTbFYgkxuO3gdCaeqlVG3kVKEDJkfKaEBBKhTn19aQCkbT8p4PXNSJlsc5pm7PJPIp4wRn3zmq6EksYUPgHJpxj3SYzhaiSeNyQhBK9cVKG7uOnShMCRBg9PmXjFNwAy5HWnIPmLDJ460rrg8UwI5PnyvOBxkU1Yju2s2QOhNTYBUgjJoKK7ZGV9cUCInjAB+bIPSm7cYDZ5qbGW+XB+lDruA4Oc/lQMgljRjsYfhUars3IB+tWmXAGTzmmFWV2+6c0gI3H3c/eH6UjLuXp+NPJILc5z3prPhcEY7elMLDI4mJJB4PWnxw7TjGfqacc44+7TlBBBJyDSKY0pwQAPypy/KOOuKey7VJzzTRg85AFNBYQbMYyC30qXyzIpxgfXrUYHzdcDp0q1Hg4HYUMT0JraNQgXvUwiOPTFOhVQvyjOOanbB6dOOKCGRKDnjIx+FBQE9OferGAARjOetOUcg57UCuRrxjPpSPhhkcY9anKk5A4FQsoBYdRQF9SqxB57ZqEkY5x6c1adNwIqtLGA2AKm5cStOCApXGR2rm4bZJkspZruYG4Z0lYSYCP1A9seldNJlWUtnaOfyrMjhu9QsVlW3sBb3DbxG4JJPqcd+KIiqq9h2hEPpoRcna7qXJzuIPX8aK0LC3eG2VZUiRlyNsQwoHbFFJjjorHTSH5RtGAKaq/Llu9SkKTkdR+tVySGI7Dk0hIdIGPb2ApjAAerdh6U9W+YY7fpSsABkfnUgQyDBGeW6U35c89ae/b+XpUDNxwOen0oKCU7jtz2qEKBk5z6VK33cYI9TQFIHygUD2I1BBOSM9zQUOMgDHpUpj6EDmmtn3x9KQIi4z159cUgBJGOOPXNSBAeM8UFMZ2/hQNDQ2AQTT0dTndTV4xjnNNZm3dBn3pisSSDKgk5zxiq7EhMcg5/Onb9wx3NMIIJwcigSQhBK5z0oUkkAdTTuNgA/GmnqMAAD0plD8HGMflUkZOcGmqQeh/KpQRiglgrDJ2/kKq3q5R+pDD7varTcEHpUU7BBkkYx3pocNzMtNMSEFj8zZ4Jq/twucdPWpFfJGOR70wkknHX9KC5ScndlOL/XlgcLjpnqaklBkXpgnnApzx4AYjk+lIzFSABimD1dyu8OAOeKjlHlDpx7VZPU7zzUEsYddg7jtQSUZU8wqcYHv1qNozHkjGOlW3jz3IGMdKpXbvE6IP4jxQNE8IBxt+6OxqYbWBIJ/wqvG7Rr3+biplByeeMdKCWgRQXxjj3pGUDIAGOmKdyozilIOM45qhMy7Y+VfOgTJbrzWkSwcovSopowHEm0bumadE252OMgdqEipO+pZjcjIPepeGGGPAqOIAZPb39ahvCyL8hJzTJWrsT5BK8dKVwMHcMZpAd0KngevY0oTb0oEMjjATKZ96UScnJxipGyOnc1DIEZ8YJPf60XAUR7skDGeaRkYjnOBTozhcA8jtT3kROGbBPrQGpVkAUBjjJ6ZqFJQxKsOexqS4IOTkbOuaqKwZBLCMg5GKRS0L6kHjHanqwAAHBH61SDScbR16+1SKzICQMk9c0CLJbceOSD+VQvhVy3OPSkWRlxuBA9RQmWcnB5PXNAx5diBkcduatwFuOnPYVXijKtndn046Vato8NknBNO4mXoGJHt6Gpc4bOPxqqoxJwe9WVJ3DI4NBBKpDE96dvAIB521EeuAAD396RS+SMUCsWkBIyOh70xhg8c56inK2xB1+lRucHJOOKBLciY5bpx3puAWAAoK5AKnk8GmqGDBucCpsaIgu48RZXG4cjNc7pyWL2avPqksc7EmRFnCAN7CtvV7q4jjH2a2E+c7vmC7agQXO1P+JDbn5evmJz+lOJlUeq/4JZsBELMCCZpoyTiRn3k/jRUlopFqpeBbVwxBiUg4H4etFDRrFqxvH7nuelLtxg5xkU5SR1GccUHk4BOagQzbyTxQ3J7baXjovf8AWlIyM5GO1ICGTG70FVXH7zrgnrVlgTUZQ5HGfekyyEjnGSQBQp4bnAxxmpTlRjkds+1RkDI+XOO/SkA4kgAkZ44poB249qb8wc559MVIoAXnOP50ARk4AAHJprDjPr0p0gPfgY49aaADgZ4FAxB0Ibj0pp4bGPxqUIWHc0xztzx09aAGAZUnnI60jYXp+NP6knjPamEZPGCM4oEIoOeOVNKVz90U5EH8XNKehB6+1UAgAx0yfUUxiVI+bIqUZBIHcVGFLHntQA/72Ap5ppG4cmlxt+tPG1WPamGxXkzHgN0J4NRowbIBHBqHWLoQxDdxk8VX0+8Se8eNOcjJpXRuqb5bl52PO3t1NI+AVOTz2qWVNpBHU9qjALc9DTM/QiYHPpz3pWG1c4wSOtTKC0fJz7moJW6AtTEUi25mXPPWqsKSefJ5i5Xja1PuYJRdb0JK9SKtAKUBbAOOaRTsthgUAnPWmt/e4yO1Px+7ypzziqhYjIHIB7VZmWAxx7mkmZtue3fNJF1HOBTzEDwenWgADZjw3p1psCB5MLnIHNNCsGOOV75qWA7XJUdaBEjLgDcaYrZbkcUsrhmAoK7fY5yD60xDkUkE+lOMnGP4vShcKrYBLVDwT3DZ60gJgTjgc1mfbGe9Ee3Cng5H61pbMcqTjPU1EsaeY7ZyT3pMpNLcczBR8ueRVXUEd0TH3ulWGjKkEMRUhGV5zTFsVIY2EASTB9aFQI2FHyjpjpU8oB4BI4qMYAoC9xDwQenfFK+7K5GAfSnKNx5HPtRnb1GR2oGSYAU4wSOozQUXGQMD0pI1BYHnB5FSrtHHUUCI1Q/e3ZPpVhAwwc8+9QBtuFIHtUiS5bODgd+tAFuHI5Y/lVpOQM1UjbPzY4q5CAcnPtTRMiUYAGf0p4b5sdveoX4Yfy9aaWPPJ47UCLvBGM5qNuAVAwajSXJwc4FNkkwQR1FBGwx8Lk5+YU0NuAGePaoJnJf5SaiBZGyMZ6VLZaGaxdW9nCpuH27s7cKTn8qrR6/YiFP3xzj+43+FW7iU+Wc9MZ+tYVtd6ncRWmye3jW5DmMeXnbjoCacdWZzk0zoLO8ivIPMgbKEnkjGcUVn6TO8lgHmfdMGZXIGMEHBHFFBSd1c7BmIycnmlA4BPUd6hBy2C3bg09W3HB+761BRMvK7utMlwTgUrsAnynJFNIBHI4xmgaGMD0H4U4Jx82T9KAAcAnqM09x8mBnA5JpFFeVQcKOo/SoSmCSOferGznJJPGfpUTKeQR9DSKRDgls4xipAMfewaUgjlhnsKdz0A47UAQuT69fwpuAAcDkDrmpGQ7gTioyMdcCiwxEbcw5zQ4HTGaeAM/KNoAoXnuOKLEvQhYcDA/CjBAqRuGGMbj0oOB970osPYjTGQKJOowaU8YGKa2CfSgBYxxzT2HOccUgPHIpGJJ78UxdRp+/gDpUmPlx+tAHIz0FKWI4HTtTDqZ2tQ77ZwoBbscZrD0S1dbwSYOAuDnjBrqyMkkjqOtNgiVCVUAZ56Umrm8KzjDlI7mNniBBAI4FQKoz8uRjqauyrnkcAVGYsYJbK9faqM09LMrXIKoFBzmq4UkkHAAGcVZkdS+HAyBkYFKUz09OPekGxVYYyD7ECmyqMFm/KpX+8QOW6AEVFKGAKkgk8Z9KaJZU2tyEbg+vXFJGgYqF6jvUrgBlUdccUkMeNy4yxOc5qhMaoJZgCMDtUq56A5x1pMbGLdugFSbc/OBkdMUxEDKAxwcmkjJ2nB57GgMS7HnOcEEVX0+GZPNMvQt8ufSpZXRlxtq456/rSHGOQBjpSSLgA9qIzkEGqJGpOPtAjwd5Hap3wrZ5xjmoCBnnAI55qWX5YQEXJYjAFIH0sLLJ5ceT07cVCo3MWGckVMu4qqPnd708xnByB7GmhFZJCWzIOnOKlV1IOwj1zmgYDkHpiopYFTewIA64FMNxjyr3wT3xSMwaM9s+tNREkjDLnBpk/7gZIJHSlYpdidAPLwQTxnrTgQ+3J5HaoYnKxkKOvODQBl1LNz7cUWAmLFX6cAcU+MrJnPBHSoty7gOg9SepqVCM8HkfrSAk2bkOeh60RLt6Ec07cFAORk0gJ3duetMluxbiBzir0ZCkZAXIqlbyKG4AIqcuMdcj0oRnJks4BXrg+9QjJGGNI0mOeOe9NaTBJHA9KATsSxqMZB/GkZwT05qu03YdPemPKTwDQQ2PkOCc8ZqBmBYcngc0x3O/luO1QnIPJPrRZMTlYnlYMvJAAFYtpFDNpkj2qXIWKVnhKH5s99me3WrzOCwQnLNkBc8t9Kz7Nb2yhEME+nyRqTsZ5sMo9CO9aRpvexhOqr7l/S2h+woLcsYzk5f72c85980Uun27RWYCsZQWLNIvQsTzjFFP2b7DVZW3OrPouPoDzTkcjAI+tQhjuJ9KcGAI7+tYJHYWh15I56UDGcDJ46VDvJBPp+lPTpknn2qRomUFjgYx609umPx9KE+8MAYx2604DcPQe/Wgd9SMg4B461EQXfkYJ/KrCLuOMZOeOe9LtOSWIyD060rFJlYrkd8Um07cYHP51YaMscYwB1NKy/KDjvgEHmiwJlZQeenTHNQyYxwpP0q0q5cjpgHrULoN4OQMflQK5V5bJ/ShCV4x1GelTHGCCByaY6hW78DigLjWG4c5/wpFwcj/61PI7Z59KCoUqBQx7iMmQajxjtg/zqfrxkkU1l6biD6ZoEmRsh29e3akwDjjFSj04/Ckxnj0oAFXGG7UrDPBHFOGNuMHpTVXAx6d6YkxqgkEDrng1DLMLeUBzweAcd6mHTAIGar3SecFDdFO7mmVF3dnsSmbJHI2Y9KhIZ/lzkdeKcqhPlYcY6ilXkhSTgDinYr0I/LAk3N0ocYXJPHbNLOrLh89O1QyTBVzkH60mFriBdrg4xnqfSq8h3yMAckdadcM7JtTIBpqDIx0fqeOtUkIz4ZZDcspI4IwKfe3a20mGUkN0Aq28aswcDDnuetRzxLMBnBI9OuaWvQpOPUaBuCFuFPPPWnjAG3OB61Ddqw2ovOKkQfIp4JHXNNa7ktD/AJVB2EcdadycDHOOtKDkghAaY+/zBxgY9eBTJEO0gqx5FIVULiljADHeAxPPFPZcpx0oFsU7iGR2QIdo71aTIJ2/Nxg5oX7xGOB0pUyrMTz7UD5gMYJRienc9qlVC68EE9B71C7HPzABfrSgmMAjG30poWoSKS3bKioCzbGyV/DpU4dlUscFs5pjfOC2McdaQyGH5VAUDB6+1RFFYsGYk56VYQHy+3riohjdyME/hzTAldU25CgjgCogjbiFAx61MuTGQSABTCQucHqOlAJjdqkEBs4696RSUOQ3J4pcsy9Bn3psknIGMGkFx6cuCenfPBqbJIxwR2qsDuPGPpU8f3QOlCIbJo3IYFsj2qZJCSR6VAvJ5+9Tl4JBPXvRZmcmTscjIqHfkHPQdacrbR7+vWoWfnAHFVYhyFJ6c/hTJWA/wqUqz8gDmmXFpctGGgZeOSCK2hQlI5qldRI0EkgyowOmfSpkgUf6zLN2zwKpNcX9u372IMvqBTW1jkCaFgRxxzXXCnCO5xzqzkam2HzEd0TemdpxjHHODWHDIZ4jNHodiyZO0l8FvccVbGo20nGcNjHI61mC8FoptbXUo/IU4GYS5j9tw4/OtbroYPXc2dH1MMLeN7NLeOYt5ZibK7h1UjsaKrWdosZtJYZxJbxAuvH33bqxNFNX6gdHG42gkD6ml3HnAqmjHAzn2wakV+OcV4p9ApF2OTcBgYqVCc4HTpVGKUE8njvVqN88gkipsXcuwtjOeD7mpQwOMde/1quh4JBHTPNPVjs9DnNAy0hxwefSnKAGVcfjVSNjzzzipN+CM9T60AWGOQSp5zn60hVdu4AAnkDPSmCTGCWHI4FR+YWAGefSm2AyUEvhR83ORmq8km5h79jTnII3dfr2qpIcM+4frUlEm445JHGM00nJJHHPWo1bJySdvWmtIDt6njFICcFsZPJNOXBHzDGKrLJgADqRkU8SZHJxgY60AWEIGMf40jkk5Bzimq+1Oc+3FBbKkkYIpgKqgEE9Dz1pGJD/AFFAfjHHNNzgcjI7UCA8fLjIPSjLZA5wPSmF8kEZ4oD8HDZagBLhyF4xu7Vh6tNcRTQMhPznHHStiaQINxwfWqMVzHPNhTlkzkUM1puzvYinuXW4VfQc89sVft5BIgKdG4zWFrrg7CrYxnAFXdEkW6skIGNpIOP507mkoe4pGhI5kbacADjjvUIiXkgZ9BVlggQhTiocbuEA9zTWxlciYZIwAAPfmoPKZroybyoAxjHJq0RtIVcH1NNkQZ9DjJpiuAHmPtHAHUk1lz+dBclNjEM3DgYrVVSVDIPm6DHH41E8hwyuNxxjI70WuEZWv1I1JCluMnjJoVfmz1Tuaeu3Hz8EDgelOUBV4Ofwpkg2wnPQ0jAFSAe9RspQHhT6ZpFLDGPvUCFZVDck5FQrO5mKLhowMk+hqZnDZyO3JoACRZHG7knHWgLoaAQdw4JHOR/Kk3bQOtOY/LwfzpisckA5Pc0BcJVVuFJ98VJjCjAyelQp99mB4PrTYZ5WmO5MRg4BHGaYDpVYsOSPWjJUe2KZOoLBlJyD2qKRzv7dMZoC+hJvOCgqFtwwWOWH3eaceFyep9KEdVJyOtKwr9iwsoKZIwahbaQRjOf0oJJVSBjJprnGQOGPSmK9hzDaQAxNMYbnwemOTn9KYyuUA3EHP50ozjJJwOBRYnmHjBfPQkYpwYq3tUQOT0IqRUbg8HNNRM5TJ4nycnvUi5JxmlSHocVYWIKMnBA7Ct6dFy2OWpXjHcjwcgEduOcU4wiPDHJJ569KV1DqdoKn86aCIsfMSfQmuqNCK1ZxTxEpaITzQoPGc96ljnBUqxIz3pRH5g5Ax9KX7Lx8o47DpW9zAZuJHD5HoBmq8yxyA7gpPqaum0LAjPPXpUf2Jt2duTjrS3AwLm0U528cVi2pksoVgaCcOufuISH9/wAa669SKDaZ5Ejz2dgKy5ZrcONtzAoP/TQVEootMo6ZJd2dqsbgrlmbZ/dBOcUUuklns+WLAyPg5z/EaKSuDsetap4QGGk09ypPPlv0/A1y93a3Fm5W5jaNumT0/CvVoJFfIb73b2ourK3vYTHcRK6H1rKph1JablUcZOD97Y8iViMZqeGbDNk4Pauh13wlLbFpdOzLD1KfxD6etcq6OjkOGVhwQwwa4p0pQdmetSxEKiumaqygrjgVIJNoOOh6VlQy4HXn3qz52cEHpWbR0XLyyHPByB270GTccgg9OKqJMD3yfWlLjPHapsO5aZ26AjBzxTPMZV6Gq3mAd+vamtL1welKw+YmZ88gmoS/HQ1G8vHbNQ+YM4J/+tQPmJjJtbHOD1zTVbA6ZAPPNRO4yD1BpI2Bbtn+VKwr6F2LBGe2O9S/eJIxjHSq6tkDrz1p44wD0osK5I2c4zkenpSrn1ABNN3BiM9aQtwRxTsO4/dzSMflYZH4VEXIOccj1pVYYJ4x6UCuIxJwADilP3jgYpobqQT+BxUYcjcTkHOOlA7kE77AxzkYqrapHON8A2s2QatXEKzRON2MjrWM9x/ZsccEDGRsZzjOaNjen70bLckmwkDi/iyiP39PrWpbiMWCfYhsjI4qvBGt7aRC6+/95hVww/MMH92vUf0o8xzl0ZPATsy3zY70iEF842p6+9NR9+Qv3QeDjFV76RoYcKD15x1NVcytcskDhhUK7nY5bA6Y9qggeR4wZeCe3oKkkf8AhQYz69Ka1BqxKHChgTwP5VWf94+9PuinqOPmYdaj3bpP9nP3R3qhAhyh45qXI2qc59aae+RjHrTVJPBJ/A4pCbFfkgnIA9qRuACeD1p+V2jd+XrULuBLhvxFAri7s56GlY/L8vNNwM9AB160iYUkHPP60CbAnaB+uaYRySDx6etK5DDaePSmEbU2gnjv600JsXOQcYAH8NN3l4wSCp9KaWIXHH5UISow31+tOwrjW5YnJqOQkYwcg9akmITk5APXJphy4PK4b1oC9hqyFhnBb6UHDEnvTVUxphelKQQo7Z9aEhOQruAoUjkUqsQ2cZz3NIgO4Z59BVkRMx7LVKNyHNEY3nHy5xTwm7BPfrgVatrGWdh5aM/vjFa8GjqqkykFuDtFbQotnNUxEYbsxIbdjhVHJq7FabPmIyW/StP7MQrLHgAcYzSJDICeD6e1dUKCjucNTEyloimiv02Y/CnxxEtgL27VoRWRbJOcH9auw2wA+XO8D0rbbRHO7syhaHomS5HarEOnYALRK2a3rSxjCnPzt3NW4LfDc4x9MUgOeTTIshdpU9xU6aaVU4UkfzroY4UR8lST1zVgwpnjAzyaQ7nMLZNxuA+h7VFPYqwypx71032fHcn1BqOW2UKWYcewoTA4i80qG4GLqBJQp4LqDisi80GzXO20h2+uzFdhrXniaxs7KUQveOwaYoG2qq5+UeprIuBdWF1HbanKJrWY7Ybrbtw39xwOnsaLoDmBaRwjZGgVR0VRwKKtaYHmsyZmLTebIuT1wGIop2Q7nq9rMzbWStCORlzkYNcxpN5ujVc5I4rW+1McAknFU43Oc1Y5A3IOTmqer6NZaooM8WJP+eicNTYJwMY7+lX4pkKgc/WocU9GUpOOsWef6t4PvLT57ZhcR9gOGrnZYpYJCsyOrjqGGK9mLAg56HrVe6soLhSssMci/wC0oNc08Mnqjtp46cdHqeQCU5x2p4kJznmu8vPCunygsivEf9g8VkXHg58n7Pdgr6OMVzyw0kdccdB7s5YuSeeCKa0nXI/Wt5/C9+n3TC/0bFVZfDWpgH9yD9GFQ6M+xosVB9TEdyScGmB2J/zzWx/wjmpcYtmH5Uh8P6nwBavwfUVLoy7F/WIdGZm8k8DknPNPXOeg9Kuto2orndaSnHcDOKY1jdxDMlrMq+uw1PspdhqtHa4iMRjHBxzSbmHJbIpjFkPzqVPuMUm7jgUuVmimmWFkIXjp704MDjnP1FVdxHPaniT5cVNirk+7qPWhWA4NQF8jPekMmRx17mm0LmJS/QDOM0gzyTwfbvUIfNShskGlZhcyNQM73ccSkxxdyKgu2ggRTbFfNHGScmt5wrjBA/Ksq50jzGdkcDPIGOlFjpp1o2SloVdLuSLt5CSsZGBnua3oXGM9j+FYUWmzJIJZZUwvbk1uRgmIbT19aSHWnFyuiXeoYKcD1HpTScEgA/U1VckNyQPxpsUxIIOcHoRTM7k5bJwx4qCPG9uf92h1y3JwO1NXh9yjgd+5qhcxK4yMsR9KYi/NwM57g0hyBuPfsaTKj5gxA9aYuYWRgR83br61CobsTx19qmByMHimhSxDHhR0pichQTgADNKwwCcdT19aiHyktnOe1BcEZ6DoM0yeYc7dO2KYzEZZj+NK5JXIKkjsKjyDyOMds0Bce5A9PrUQLbCecChGx6fjSly5wBgdMAU+UjnGls8/oadHycnHNIwbgLj6+lSRITwSM+5oUWyZTIJ4hKcMTgHIxT125HGMeoq5DZyTHbHE7n2BNaVp4eu5RuKeWvq3FaxpNmUq8VuzEKAJ0606CKScbURue3U12Nn4ahVlNxIXz2HFbMFvb2wAghRMdwK3jh+5zTxiWxxlh4cuZSGYCFfVuprpLLw/aw/NIpkbqA3Az9K2uGJweOxIpYjvAB6jpk1vGnGJyTrzkU1t1BMaqFA9BihrQEdMDqMVopBjhcgmra2xOCSMD+E1Zjuc7NpHmYdCyt3wabHprxEFlPPcdK6gwruVT0PTtVgQHsvHAxjrRe4XObi06VgSmFHc9xVuLT0TavO7HVq2hDsODwPTNR+XsOc/lSC5SWz2sNo4HXvVjyQq/KoyelWgMplACcYwabE5K4Pbg8UguVTCzg4H4UikoSrJkDuavruQZwGJP6U1kWRgGPX+7QMr7EJG1+fpjNRXCDI3rlKtvHyCgAI7dKZINyFc8mgDn9dt9Nmt401aWKCPduiLSeWwI7qexqnfX2g3Fo0E1/YSxMNrK0oOR/jW3q+mwahp8kF5tEQBKyEgGMjowJ9DWZZNozvFFLPpk0wUKzAIu9vXFAinp+j6adLjispFltgzMkivuyc8jd35orovKihykSLGnZVAAGfaimByNopt5wyn5Twa0nm5BQ81TI5+lTpx061sZWL0F0Qcng1Mt0wxgmsxmy3pSFyyew6UrDOggvlIIZsntmrwuEwoGATzxXJxSHdljjBwKuLdZwM8+tTygmdKSkgwMCoJYuf8KzReNt4PPpVmG/8AuiTkUrDuOKkHnnH6UhBH3u1TKyS8xkEHsKYxOaSBMjXJII4FK4yaXcV9qN3HPSnYYzZhd2RnuKeNw5Ukg+lIcjlWJxSZ29aLCHusUg/exRv67kBqGTRNLucmSyiGe6DaalUkr1Bx2pcsRlTzUOmnuUpyjszIufBunSZMLyx49DmsyfwXgZguuP8AaSuwSYgYYHNOBBXjJ9azdGD3RrHE1I6XOAl8H3w+5NC3tyMVX/4RXUtxVUjZvZxXopQ7mLY5ogQZOfTrU/VoGixdVdTzZvDerKP+PNiPVSD/AFqJ9H1CMfPZzfgua9TTbwPSnhSudo4HQVP1aI1jZ9jyN7K7iG5reUDHdDULh1UB0bP0r2Mu3XqPQ1DIkbj541IP+yKX1XzNFjmt4njp64xikLOAMY6/pXrcul2Mu3fbQZ9doFUZfD2ms5Js0+nSoeEfc0WPj1R5e/zjHRajxtAIFejzeGNMY4WOSIn/AGjxWfdeEEXLQyOV7DOan6rJGix0GcR5m/PXinE5A9R3reuNDMZPzsPqtVDpm3+Oj6vPsX9cpvqYru2Dk9/SkOGPOQMdq2jprOceaoA9qnTQWkHNxHn020ewn2H9bh3OdwMHc56ZAp/mN/CMYro/+EakY83EfvxUkPhvLANccdyEprDT7EPF0+5zAwwJckH0qKaISIUYkL7d67SPwxFkBp3OfYVKnhm053PK2PcCn9WkL65BHComF2xgAL0p6QsyqBk5PavQo9B0+M/6jcR0yc1oR2sERxHDGhPcKBVxwvcxljU9kedQ6XPKuEick+1XoPD9+wP7vao/vnFegxx8FW7dOKilh2cggH0xWiw8UZPFy6I5G18Ngn99KR7KK2rDRtOiYboQ2Opbn9KvyIHAY5z6imEMhzg+mc1qoRRk605dS/HBCo2RxoijkBVxSeUO6nHf2qrHO/Izn69qtW8hZuQcHg+9VsZu5XmTEhABBPQ0IrY/vf0rUjtw4yh59cZqRbReoJzRcRnWkRLZGA2Omaux2o384b2q3BbBFyRlvaphDhue/cUmwKqRfN8v3s9qsx4UncFJ6CrHkkKpJBBHU9qcYtzgAAnqMfyoEUZY2WQMyg4PXOcfhV5d5AAwDn9KWRCQvI4HSnRR7cjdz346UCI2UK2cD8e1Ryf1/OrACjg4P1pAoWTH3gaQyv5RSM84UjrVYKocHd06e9aDxjGPWoTGok57Dk0wIZDsYKCdwGeelMTj7p+Un8M1amUAYxwRxiqpGzbklueccUBcmZQFywH1FQYABbGBnipUAMWMj8aa0YUbM8HmgDmfFyLL/Z81zbSXGmRSlrqKMFiePlJUdVB6is86j4Se1ZDb28gP/LJLQ7/wG2tnXrm8S70+w06SOGe7dh5zjd5aqMnA7mq1rqN1Y6jFY615UkUzYtr2OMRh2/uOOzenrUvcYnhq2nh0SFLkPG2XMccuS0ce7KBj6gUVN4curi70fzrtzK5nmUtgDhXIA/KirWwjKwM8jNDZPanLGc5IPPFTJBg88/StSCuEJxShSG4FWmTpjtSrGWAOOKAK5jBXJpBEd2QTirflY69KkWHDe2KGwIMEMO/pUiBieenf2qQAE4IwfXFOCk5A6VNwLdi3lyDPToMVfZA/zDg1kRvsbntWlbSMyjPT61LAa445GcUw8Zwc1bdAw3cYqtKpGD2oGICMcUhBORTcHseTS4KknGRTAFOCM5H0pWBI45NKSCfSk+8DjqKAFUkjAbmk3mPlW+ooHv17UjBsZJBpWAlSQMBuBxVgEbMgZJrPU4+tTRliBjrnpRYZYAHXGT+VPVj06VCm8njaee1WMjkOOvb1pCArkKckGmyZ6j9adyGG3JFNkwwxnINCATOeTSNkDnANM3HO0AccD3pVcNuX+IetOwEjMpAyfxqMgDJyQBTkOFw2M04gkDI4HUVI7lSeGGZSJUBz0IFZdzoqSKTHx7Vv+WAMjp6VE6FW3L16HFA72OJurCaDPy/LVeOaSEjI5zXeGISLtkQMBxj1rMvNIimDbcZ6kd6a02KUrnPR3TdW49qvxXSjB4A6Zqpd6XJCTgEgdzVEGSJsGmgN9JiCMDI9anY7zknH0GOaxoLrHAwPWraT7gOMjPTNAi8pCtgZ3AcVIf4dpO7HNVSxI/u/SrEPzAZOR3PqaALUTBQN3JqQhXTCEgDiq6xlsHoAemOat28efmP596QEP2dWOGJD+lRG3YEc9eoBxWsI0yAASR14zmneUDhWwcHpQBkraqH4I549amS1YYwD9Aa04YQGJPXtVhYedoxn1IpXC5QiRuSzA57VagA4XtU8kIxngkDqajQqOnSkBOq9wvfuOKeYwSTz+FMSToAeB2FTLIWORjb3oE2QsctgDoOmOc0blJ4+8PTtSyDLnAII70wKfLYqck+nrTsK5OME5xyKBKAmRyf5VXBZAvPJ7mpPMBBAOe9IBJG3AbgcHoaRA3mggZUUjk9VxtxyKcCSF2tn2p2C5KSVbOMD6VE3LZwOOtDyHJ4znvTCSVJxz1NAXJJE39OfX2qEx5UqMhjTVfzQAxIAPpU5AyVOOOh9aARXMZH+6OtI5wvI69zUjZ2nk8HrVd2UxjOQ3p3oAytU0221S3VbgSo0bbopY22vG3qp9asXNlDd2D2l5CJLdgAwbOSR/FnsfcVW166+yQQ29u/kNIryyT7dxhiQZdgO7cgD61mXNqkFlbXinVLSaVlDzPcGRod3CmRCcMMkZA6ZoA1dO06DS9MS1tHeSMMzgyHLfMcnJoo0q5e6sQZUWOeNmilVOV3qcHHt3H1oqkguQvGoySOtNIVRkCpJ+30pp+5TEV9uWGenpTgMfSnfxCnNTEMJwTkZFAYMMUqd/pQvagBsgOBz9DSxsQvXOe9Kei/SmUAKTzVmFyGA4war/wAAqSLtQBrRtlcL196HAOQOlQ23X8Kmi6GoEVSuCf50nJHH3qmm6D60xepplEeMZIOfal3DOelKKZTAWmjuOnvTz0pv8VAEJJU5J/KpbbLBhUcn3qdZdGoAuRrtXJOBQW4A5PvTh/qm+lJ2NIB0Z2k4yR6U4qTnHHHSox92pI+gqQEVwv3gM4prnO1sU1v9a1Pb7ooAaee+c0/+DGc59KZ3FCfe/Cq6ASbioB7jikDAP069aH7UqdKkBsjLnIBGetJjdkNwfWhvvUv8LfQVSAjaIlSpUMOvIxWddaRDcdMI3pWun+rNSSD90aBnGXOhSxlmjDEZqqsTxP8AMGAFd5BzHz61l36KWOVH5UXKuZFuzNjb07itOPa6j5gD7is0cE445q9B/q6GBehToGOGPpVq0QN8pxgVTT7yfQVqJxEce1SwJUTapA6HsR/WlVVTqOakH3DTZPvGkAhcJyuc+lTpyMgbc+1Qr0P0p8JJU5NACSEc85I71GFwcr+PGKkl+6PpTh0P0oArSfKcgk1KjYHJFMHR6bcAELkA/wD66ZLLe9XGG4x0po4b5Pumox95qkTp+FBIu0bcrgVDuCkgjG7rmpx1qCfrQMCOrDBI4OKVychV60J/FUVv1H0/rQAMcNnOR1GKeCcdOT2zQoGOnanp1H1oArIrtIcdj61YDLnGTnr9Khi/18v1qZ/uD6UAE/C8AY61XiG9y5JIHQYpz02x/wBS9AGZr9jNdrFPBCsskYdHgdtvnROMOoPY9CPcVgsZniitt+r33llStpNaCLdjkCSXoVBAzjriuxPKoT1yajlY70GTiiw27FPSbJ7GwWKd/MnZmlmcdGdjk49u34UVdl+9+FFUhH//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: www.visualdx.com. Copyright Logical Images, Inc.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_11_36017=[""].join("\n");
var outline_f35_11_36017=null;
var title_f35_11_36018="Florbetapir F18: Patient drug information";
var content_f35_11_36018=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Florbetapir F18: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?18/60/19395?source=see_link\">",
"     see \"Florbetapir F18: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F14385998\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Amyvid&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F15964458\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3546407",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used with a PET scan to see parts of the brain better.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F15964457\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s4101031",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to florbetapir F 18 or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F15964461\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F15964462\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F15964463\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F15964460\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695991",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is given as a shot into a vein.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F15964464\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 87669 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-4554544F47-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_11_36018=[""].join("\n");
var outline_f35_11_36018=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14385998\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15964458\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15964457\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15964461\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15964462\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15964463\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15964460\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F15964464\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?18/60/19395?source=related_link\">",
"      Florbetapir F18: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_11_36019="Plasmodium vivax thin smear";
var content_f35_11_36019=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F59872%7EID%2F78176&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F59872%7EID%2F78176&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Plasmodium vivax",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 359px; height: 238px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Giemsa-stained thin smear of blood (x1000) shows a ring trophozoite of Plasmodium vivax. Red blood cells infected by P. vivax are enlarged and contain Sch&uuml;ffner's dots.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Blood smear of falciparum malaria",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 368px; height: 292px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Giemsa- stained thin smear of blood showing the characteristic banana-shaped gametocyte of Plasmodium falciparum (arrow).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Stephen B Calderwood, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_11_36019=[""].join("\n");
var outline_f35_11_36019=null;
var title_f35_11_36020="Mesorectal excision rect CA";
var content_f35_11_36020=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F65765&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F65765&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 537px\">",
"   <div class=\"ttl\">",
"    Mesorectal excision",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 517px; height: 409px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This illustration of a median (sagittal) section of a male pelvis depicts the boundaries for mesorectal excision of a rectal adenocarcinoma.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_11_36020=[""].join("\n");
var outline_f35_11_36020=null;
var title_f35_11_36021="Orphenadrine: Drug information";
var content_f35_11_36021=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Orphenadrine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/11/29876?source=see_link\">",
"    see \"Orphenadrine: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F203990\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Norflex&trade;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F203991\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Norflex&trade;;",
"     </li>",
"     <li>",
"      Orphenace&reg;;",
"     </li>",
"     <li>",
"      Rhoxal-orphendrine",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F204027\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Skeletal Muscle Relaxant",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F203993\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Muscle spasms:",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: 100 mg twice daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     I.M., I.V.: 60 mg every 12 hours",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F203994\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use caution; generally not recommended for use in the elderly.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F203970\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as citrate: 30 mg/mL (2 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Norflex&trade;: 30 mg/mL (2 mL) [contains sodium bisulfite]",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as citrate [preservative free]: 30 mg/mL (2 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, extended release, oral, as citrate: 100 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F203957\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F203974\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Do not crush sustained release drug product.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F203973\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Treatment of muscle spasm associated with acute painful musculoskeletal conditions",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F204034\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       Norflex&trade; may be confused with norfloxacin, Noroxin&reg;",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      BEERS Criteria medication:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;\">",
"       This drug may be potentially inappropriate for use in geriatric patients (Quality of evidence - moderate; Strength of recommendation - strong).",
"      </p>",
"     </div>",
"    </div>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      International issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Flexin: Brand name for orphenadrine [Israel] but is also the brand name for cyclobenzaprine [Chile] and diclofenac [Argentina]",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Flexin [Israel] may be confused with Floxin which is a brand name for flunarizine [Thailand], norfloxacin [South Africa], ofloxacin [U.S., Canada], and perfloxacin [Philippines]",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F204025\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Frequency not defined.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Palpitation, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Agitation, dizziness, drowsiness, euphoria, hallucination, headache, mental confusion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Dermatologic: Pruritus, urticaria",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Constipation, gastric irritation, nausea, vomiting, xerostomia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Genitourinary: Urination hesitancy, urinary retention",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Hematologic: Aplastic anemia (rare)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Tremor, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ocular: Blurred vision, intraocular pressure increased, nystagmus, pupil dilation",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Respiratory: Nasal congestion",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Anaphylactic reaction (injection, rare), hypersensitivity",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F203977\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to orphenadrine or any component of the formulation; glaucoma; GI obstruction, stenosing peptic ulcer; prostatic hypertrophy, bladder neck obstruction; cardiospasm; myasthenia gravis",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F203961\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings/Precautions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Concerns related to adverse effects:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; CNS depression: May cause CNS depression, which may impair physical or mental abilities; patients must be cautioned about performing tasks which require mental alertness (eg, operating machinery or driving).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Disease-related concerns:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Cardiovascular disease: Use with caution in patients with HF, cardiac decompensation, coronary insufficiency, tachycardia, or cardiac arrhythmias.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Drug abuse: Use with caution in patients with a history of drug abuse or acute alcoholism; potential for abuse exists.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Special populations:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Elderly: Muscle relaxants are poorly tolerated by the elderly due to potent anticholinergic effects, sedation, and risk of fracture. Efficacy is questionable at dosages tolerated by elderly patients; avoid use (Beers Criteria).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Dosage form specific issues:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Sulfites: Injection contains sodium bisulfite which may cause allergic reaction in some individuals.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      <i>",
"       Other warnings/precautions:",
"      </i>",
"     </b>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     &bull; Long-term use: Has not been evaluated for continuous long-term use; monitor closely.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F204022\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     <b>",
"      Substrate",
"     </b>",
"     of CYP1A2 (minor), CYP2B6 (minor), CYP2D6 (minor), CYP3A4 (minor);",
"     <b>",
"      Note:",
"     </b>",
"     Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential;",
"     <b>",
"      Inhibits",
"     </b>",
"     CYP1A2 (weak), CYP2A6 (weak), CYP2B6 (weak), CYP2C19 (weak), CYP2C9 (weak), CYP2D6 (weak), CYP2E1 (weak), CYP3A4 (weak)",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F203966\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AbobotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of AbobotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Acetylcholinesterase Inhibitors (Central): Anticholinergics may diminish the therapeutic effect of Acetylcholinesterase Inhibitors (Central). Acetylcholinesterase Inhibitors (Central) may diminish the therapeutic effect of Anticholinergics. If the anticholinergic action is a side effect of the agent, the result may be beneficial.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Aclidinium: May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alcohol (Ethyl): CNS Depressants may enhance the CNS depressant effect of Alcohol (Ethyl).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Anticholinergics: May enhance the adverse/toxic effect of other Anticholinergics.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP3A4 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ARIPiprazole: CYP2D6 Inhibitors (Weak) may increase the serum concentration of ARIPiprazole.  Management: Monitor for increased aripiprazole pharmacologic effects. Aripiprazole dose adjustments may or may not be required based on concomitant therapy and/or indication. Consult full interaction monograph for specific recommendations.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Azelastine (Nasal): CNS Depressants may enhance the CNS depressant effect of Azelastine (Nasal).",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Buprenorphine: CNS Depressants may enhance the CNS depressant effect of Buprenorphine.  Management: Consider reduced doses of CNS depressants used in combination with buprenorphine.  Consider avoiding other CNS depressants in patients thought to be at high risk of buprenorphine overuse or self-injection.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: Anticholinergic Agents may enhance the tachycardic effect of Cannabinoids.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     CNS Depressants: May enhance the adverse/toxic effect of other CNS Depressants.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Levocabastine (Nasal).",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Droperidol: May enhance the CNS depressant effect of CNS Depressants. Management: Consider dose reductions of droperidol or of other CNS agents (e.g., opioids, barbiturates) with concomitant use.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     HydrOXYzine: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ipratropium (Oral Inhalation): May enhance the anticholinergic effect of Anticholinergics.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Lomitapide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Lomitapide.  Management: Limit the maximum adult dose of lomitapide to 30 mg daily when used in combination with any weak CYP3A4 inhibitor.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Magnesium Sulfate: May enhance the CNS depressant effect of CNS Depressants.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Methotrimeprazine: CNS Depressants may enhance the CNS depressant effect of Methotrimeprazine. Methotrimeprazine may enhance the CNS depressant effect of CNS Depressants.  Management: Reduce adult dose of CNS depressant agents by 50% with initiation of concomitant methotrimeprazine therapy. Further CNS depressant dosage adjustments should be initiated only after clinically effective methotrimeprazine dose is established.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Metyrosine: CNS Depressants may enhance the sedative effect of Metyrosine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirabegron: Anticholinergic Agents may enhance the therapeutic effect of Mirabegron. This may result in acute urinary retention.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Mirtazapine: CNS Depressants may enhance the CNS depressant effect of Mirtazapine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     OnabotulinumtoxinA: Anticholinergic Agents may enhance the anticholinergic effect of OnabotulinumtoxinA.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Paraldehyde: CNS Depressants may enhance the CNS depressant effect of Paraldehyde.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Peginterferon Alfa-2b: May decrease the serum concentration of CYP2D6 Substrates.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Perampanel: May enhance the CNS depressant effect of CNS Depressants. Management: Patients taking perampanel with any other drug that has CNS depressant activities should avoid complex and high-risk activities, particularly those such as driving that require alertness and coordination, until they have experience using the combination.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pimozide: CYP3A4 Inhibitors (Weak) may increase the serum concentration of Pimozide.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Potassium Chloride: Anticholinergic Agents may enhance the ulcerogenic effect of Potassium Chloride.  Management: Patients on drugs with substantial anticholinergic effects should avoid using any solid oral dosage form of potassium chloride.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramipexole: CNS Depressants may enhance the sedative effect of Pramipexole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Pramlintide: May enhance the anticholinergic effect of Anticholinergics. These effects are specific to the GI tract.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     RimabotulinumtoxinB: Anticholinergic Agents may enhance the anticholinergic effect of RimabotulinumtoxinB.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     ROPINIRole: CNS Depressants may enhance the sedative effect of ROPINIRole.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Rotigotine: CNS Depressants may enhance the sedative effect of Rotigotine.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Secretin: Anticholinergic Agents may diminish the therapeutic effect of Secretin.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Selective Serotonin Reuptake Inhibitors: CNS Depressants may enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sodium Oxybate: May enhance the CNS depressant effect of CNS Depressants. Management: Consider alternatives to combined use. When combined use is needed, consider minimizing doses of one or more drugs. Use of sodium oxybate with alcohol or sedative hypnotics is contraindicated.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tiotropium: Anticholinergics may enhance the anticholinergic effect of Tiotropium.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Topiramate: Anticholinergic Agents may enhance the adverse/toxic effect of Topiramate. Specifically, the risk of oligohidrosis and hyperthermia may be enhanced.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Zolpidem: CNS Depressants may enhance the CNS depressant effect of Zolpidem.  Management: Reduce the Intermezzo brand sublingual zolpidem dose to 1.75 mg for men who are also receiving other CNS depressants.  No such dose change is recommended for women.  Avoid use with other CNS depressants at bedtime; avoid use with alcohol.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block foi drugH1Div\" id=\"F203987\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Ethanol/Nutrition/Herb Interactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Ethanol: Avoid ethanol (may increase CNS depression).",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Herb/Nutraceutical: Avoid valerian, St John's wort, kava kava, gotu kola (may increase CNS depression).",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F203967\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F4627430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted. There are no adequate and well-controlled studies in pregnant women. Use during pregnancy only if clearly needed.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F203997\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F203979\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Norflex Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg/mL (2 mL): $28.62",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Orphenadrine Citrate Injection)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     30 mg/mL (2 mL): $19.20",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Tablet, 12-hour",
"     </b>",
"     (Orphenadrine Citrate ER Oral)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     100 mg (100): $217.29",
"    </p>",
"   </div>",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F203980\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Biorphen (GB);",
"     </li>",
"     <li>",
"      Disipal (CH, CZ, IE, IT, LU, NO, SE);",
"     </li>",
"     <li>",
"      Drinexin (PE);",
"     </li>",
"     <li>",
"      Erilax (KP);",
"     </li>",
"     <li>",
"      Lysantin (DK);",
"     </li>",
"     <li>",
"      Mefeamina (ES);",
"     </li>",
"     <li>",
"      Norflex (AE, AU, BB, BE, BH, BM, BS, BZ, CH, CR, CY, DE, DO, EG, FI, GR, GT, GY, HK, HN, IE, IL, IQ, IR, JM, JO, KE, KW, LB, LU, LY, MU, MX, MY, NG, NL, NZ, OM, PA, PE, PK, PT, QA, SA, SE, SR, SV, SY, TH, TT, TW, UY, VE, YE, ZA);",
"     </li>",
"     <li>",
"      Onacrine (SG);",
"     </li>",
"     <li>",
"      Opheryl (KP);",
"     </li>",
"     <li>",
"      Orpherin (KP);",
"     </li>",
"     <li>",
"      Orphipal (IN);",
"     </li>",
"     <li>",
"      Phemax (TH);",
"     </li>",
"     <li>",
"      Plenactol (CN);",
"     </li>",
"     <li>",
"      Relaflex (GT, HN, NI, SV);",
"     </li>",
"     <li>",
"      Slakin (KP)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F203960\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Indirect skeletal muscle relaxant thought to work by central atropine-like effects; has some euphorigenic and analgesic properties",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F203976\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of effect: Peak effect: Oral: 2-4 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration: 4-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Protein binding: 20%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Extensively hepatic",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life elimination: 14-16 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Excretion: Primarily urine (8% as unchanged drug)",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      American Geriatrics Society 2012 Beers Criteria Update Expert Panel, \"American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults,\"",
"      <i>",
"       J Am Geriatr Soc",
"      </i>",
"      , 2012, 60(4):616-31.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/11/36021/abstract-text/22376048/pubmed\" id=\"22376048\" target=\"_blank\">",
"        22376048",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Beech M, Hell C, and Nightingale P, &ldquo;Central Anticholinergic Syndrome,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1987, 1(8541):1089.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Boyson SJ, &ldquo;Bethanechol for Anticholinergic Side Effects,&rdquo;",
"      <i>",
"       Ann Neurol",
"      </i>",
"      , 1988, 23(4):422-3.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"mobipreview.htm?35/11/36021/abstract-text/3382184/pubmed\" id=\"3382184\" target=\"_blank\">",
"        3382184",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Clarke B, Mair J, and Rudolf M, &ldquo;Acute Poisoning With Orphenadrine,&rdquo;",
"      <i>",
"       Lancet",
"      </i>",
"      , 1985, 1(8442):1386.",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 9722 Version 45.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-58.240.65.66-BC5B390E05-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_11_36021=[""].join("\n");
var outline_f35_11_36021=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203990\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203991\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204027\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203993\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203994\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203970\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203957\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203974\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203973\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204034\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204025\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203977\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203961\">",
"      Warnings/Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F204022\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203966\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203987\">",
"      Ethanol/Nutrition/Herb Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203967\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4627430\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203997\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203979\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203980\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203960\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F203976\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9722\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/9722|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"mobipreview.htm?29/11/29876?source=related_link\">",
"      Orphenadrine: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_11_36022="Gastric xanthoma CPC Light";
var content_f35_11_36022=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F51475&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F51475&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gastric xanthoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 385px; height: 567px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAI3AYEDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigAooooA6LwD4Uu/Gvii10PTpoIbm4DFXmJCjapJzge1esf8Mx+Kf+gto//fb/APxNcz+zH/yWTRv9yb/0W1fb9bU6aktRNnyN/wAMx+Kf+gto/wD32/8A8TSj9mLxUf8AmLaP/wB9v/8AE19cUA1p7GIrnyP/AMMxeKf+gto3/fb/APxNH/DMPir/AKC2j/8Afb//ABNfXGaUdKPYxC58jf8ADMPir/oLaP8A99v/APE0f8Mw+Kv+gto//fb/APxNfXNFHsYhc+Rv+GYfFX/QW0f/AL7f/wCJpR+zB4qIz/a2jf8Afb//ABNfXFLnil7FBc+R/wDhl/xV/wBBbRv++3/+Jo/4Zf8AFX/QW0b/AL7f/wCJr68BzSgZpeyQXPkP/hl/xV/0FtG/77f/AOJo/wCGXvFf/QW0b/vt/wD4mvr0cCngetL2aC58gf8ADLviv/oLaN/32/8A8TR/wy74rxn+1tG/77f/AOJr7BAxQRml7NBc+Pv+GXfFeP8AkLaN/wB9v/8AE0o/Zc8Vn/mL6N/32/8A8TX2ABiij2aC58f/APDLniv/AKC+jf8Afb//ABNH/DLniv8A6C+jf99v/wDE19gUUezQXPj/AP4Zc8V/9BfRv++3/wDiaP8AhlzxX/0F9G/77f8A+Jr7Aoo9mgufH/8Awy54r/6C+jf99v8A/E0f8MueK/8AoL6N/wB9v/8AE19gUUezQXPj/wD4Zc8V/wDQX0b/AL7f/wCJoP7Lniv/AKC+jf8Afb//ABNfYFFHs0Fz49/4Ze8V/wDQW0b/AL7f/wCJo/4Ze8V/9BbRv++3/wDia+wSO4puO+afs0Fz5A/4Ze8V/wDQW0b/AL7f/wCJo/4Ze8V/9BbRv++3/wDia+vqKPZoLnyD/wAMveK/+gto3/fb/wDxNH/DL3ir/oLaN/32/wD8TX19TTT9kgufIX/DL/ir/oLaN/32/wD8TR/wy/4q/wCgto3/AH2//wATX15S0eyQXPzo8f8AhO78E+KbrQtRmgmubcKWeEkqdygjGR71zlerftP/APJZtZ/3If8A0WteU1g9ygooopAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeqfsx/wDJZNG/3Jv/AEW1fb9fEH7Mf/JZNG/3Jv8A0W1fb9dNDYlhRSUvatyQoFAoFACg0UCikMKcozRt96cowKTYC04DApFp1SwCnjNIo706pAKUDNA5pw4pNgNxRinUUXAb+FRSTRxyxRyOqPKSEB43EckD3qeop7eO42eYoJU7lPcH1FCYDhSkYqnaX0Uk3kNIvm5KjkfMR1H1xzj0q9Td07AMop2OaCKLgNooooAPpTdvPNOooAYR1pKkPIqMjFMApD0paQ9aYCY460UUUCPhv9p//ks2s/7kP/ota8pr1b9p/wD5LNrP+5D/AOi1rymuR7miCiiikAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB6p+zIcfGPRv9yb/wBFtX28ORXxD+zIM/GTRv8Acm/9FtX29nGBiuqhsS9xaQ0UvatiRBThim04UMEFLSU9BzmkMUDApw60Uq1IC0UUo5NSA4e3SlpF6UtIBy9KWkXpS1LAKXFAxSk5FIBKbI6xRvJIcIgLE+gFOBx0qprbKNMuUZgPMQoBnBYnsPemldpAtWcVdSnzbC+WK1Gpo7yO0eDnHBIHfIwCa7iwuo720iuIiCrrnGeR7GvJXjiS/jaaUwmBpEgWPcshUj5gq9/rXX+GbsWOpyW7KkVlOEaHyxwXPykN+P0rvr0vcuuhtOOl0dlRR3orgMBMUhFOooGMpucdaeetMbrVIBwNNenAcU1jk0IBtITilppzVAFFCig0AfDf7T//ACWbWf8Ach/9FrXlNerftP8A/JZtZ/3If/Ra15TXI9y0FFFFIAooooAKKKKACiiigAooooAKKKKACiiigD1T9mP/AJLJo3+5N/6Lavt6viH9mT/ksmjf7k3/AKLavt6uqhsRIKKKUCtyUJSilxmikAU9eOKZT1HOTUsofSr0pKVakBacvWkUZNPpMApQKSnDr70mBFc3EdrGHmJ5OAAMkn2FU5NZiTGIJ2B/2RUetX9nYI8l66ycZWEjJ+tc+PENhcXHmkMd/wAu9cYH0H9a3pUedXszWEE1ex1sGoWkzKizKJG6IeGq1Xmet66+l6pDFbxK1ueVZ13A9xz2+tacvjZzAYmRLedmEYuMb4wx9qqWDlo4bDlR/lOh8Q+IbDQRbi+kbzJyfLRRkkDqfoK4HX9b1LxPqU9hHYC00uzZZEndtzzP24HC461d8aXFtrem28ctqzalDL5SSqcBSfQ9gevPpV/w3eRR6TdWd48ZubXd57KOH4yGz71tRpxpRU2ry/rUunGMVdrU5/TryK6nH2vyPN+Zd8jZfzAOcEDt7djUMdzJHZSq8sc8EMYdY0YqsjMCo59e+etQ6ffaTLPqKyxmVoxulyvy+YMFVz64xxWy9lBeobieUpduEklMBOMdCOPpXTPRtMqTtdHdeGb7+0tBsrkgiRowJFJyVYcEGtM1yvgxbi0lnguS5MrM3zHJOOhJz0IxjH411bc15FWPLNo5ZKzG0hFKaMVAhlGBTiKaaoBD/OmGnlc03FMBKCOKKKYAKRulLSN0oA+Gv2n/APks2s/7kP8A6LWvKa9X/ag/5LNrP+5D/wCi1ryiuR7loKKKKQBRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHqn7Mf/JZNG/3Jv/RbV9vV8Rfsx/8AJZNG/wByb/0W1fbtdVDZmcwp1Np3atmJBTlGTTaeo5zSGAXnnpTqAPelqQClFIOtOFJjHqOKWkUGlqQCs7X72Wx053tx++b5VP8Ad9T+ArRrz/4meLJdIvLDTLOATT3jeUcnhSwJXI9OOa1o03UmopF043kc/qT2+pXd3aTNPdqkiIZUlMchJIP8WMj3H0rO8R6HPo1nLq1lIgvUZnaEPlZODgY7Dpk+prUSxmvdRea/ka3uWtxGiWsZ5DY5LnhiOT7DNbk1uYPPjFmHjkLJDkbwxAB2tkfdPcmvTdTkatsdE5WZxPh/VRq+mx+eiMQu14mPSQgbsDrjmq6zi0vpLPUTn7UpghckqMDJCZHOR61R1O3GhauNWUqLOV/JuxGuFiY8qSP4evPtitbxFbjU9EEsDKt+i5icgErJ/C3sK6LLpsx3L0ipDa2iaxMqOY/Iii3lkDAZ3SEffIYDkcjpSaabu0sbz+z7GWYT5TKclpAcMCCc46n6dqydB8TWzWy2F5arFrEMomjjcZCzsMMvphl53HjrXTakt3p1jFe2yrbRmUjysnduJ4dSe5GRjpjvWTTg7NCje+hmrbSaVbPbfZphceY1zJLCQyytwGkJHIj7YxXVR6MZXvoHEDCR0eIb9uVVeoAxtxk5+uTWdFBd6dqDwQ23n2twoBuXfITJyY8enPXsSau2d3Mmm3s1xpBhm87yyFk84qu0KCB15GMjisZydrozbe50ui2D/wBqRS3gSSaFG8tg2PL7AYHXj1rp8fLXE6XfTW99YT3kymyZTHvZArxlvlUPg4xwAD3rt+QTnmvNxF+ZXMp7jCKSnHrTTWKJCmnrTqQ81SAbQeRS0lMBh60lOYd6bTAKQnigcZpOppiPhv8Aaf8A+Szaz/uQ/wDota8pr1f9qD/ks2tf7kP/AKLWvKK5HuWtgooopDCiiigAooooAKKKKACiiigAooooAKKKKAPVP2Y/+SyaN/uTf+i2r7fAr4h/Zj/5LJo3+5N/6Lavt+umhsZy3ENKOlGKK3EgqRRgVHUinIqWMdRRSrUiQtOUgGm0q9aTKH0UUUgCvPvijpMp+z6xbRhpLY53ZxtbBAOO+c4r0MCqmqWa3+nz2zg4dSBj17VpRqezmpF05csjzLw9fz6pbWxUxm5hQ5Lkqu8jG3b3GcVbu9Wg1G9njjuQxhXBMZ2vGVOGCD+IgjJGOlcibfVPD97dyWts0tueNpY5QngrjsO+araZH4l1OaMW0UVu5c/vY4tz5bg5OPTuea9Z0lJ8yasbyXU6PxJp66tpSRbUNqMw3EQXLIW2/KygfM3Qk9gOtc14C1JtM1yfSdTRnm06Tyj53zebASdrdMcrjp6VuG4v9J1yfTNV1CS6kslDiSFAGmPqqjrjuDn2rmfGdjc6hfz61o8Mkmo2yLkRyBhInVlUdwBnHvmrpJNcjej2J2F8RS6Q3xW02O/K6fay20mJt2xS+793lzxgc16Kkc91bWd1f3SfupkQrGBtbA6j0J6j2Ncjott4b8eaVBBd3MUd+6lIzMAQ49PUEV0Xhrw9qGgx3Okap59xaWswks5ZJdyBNuAp7kDnrxg+1RVktI3tKOln+hSk9LMksrqz1Ge4n0+eO4kh3RR3AwUTc2TnHBwR16mteyiktZyjRiKFgGIIZ9zAcnPXOB3rzTw9rFppHii1tJ0W0t2aSC8TYUEgDHEgI4yp7Dt9a9AE1qVkig1FL4yYEBWYLKxJx39FPB7fjWdWDg7EstPHFLJZXNxJue5cxgBS4ZMjjA+gwW6cmu5066+22ccxjaMnqrdQa5SSO3Rn8qGKSO0QpsZ8Ywc8Ad+TnvzW94aZU06K3VUXy14CA7QM9MHkVwV9Y3M5amoVpMdM0+gjNchmM2jHBpuKkUYzTXpoBtNIxTqaetUgGMTTaeRmmHiqQhOxpKOaKZJ8N/tQf8lm1r/ch/8ARa15TXq37T//ACWbWf8Ach/9FrXlNcj3NVsFFFFIYUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB6r+zH/yWTRv9yb/ANFtX2/XxB+zF/yWTRv9yb/0W1fb9dNDYzluFFFLW7EhVGTT6RRgU6obEwpwpopRSHYWnDr0ptOXrSYx1FFKtIYoFOApKelS2BSutMtLyTzLm3SVsbfmFWLW2itYvLt41iT0UYqeik5NqwXPI/iXpV9a+JINWtZJBbMOBHGHJbuPbAGRXNWHiGTVLGzvNOgUhECmJ1CylCT5hK9s+3oa9x1C1TUo5reTfGq/KJFAzk9cV5J4u+Fk6BZ9LkZTEwEQt28thk9MD1PWvUw1enKKhUdmjaLVjmNZ8K6ZeyXF1p0UunauiZR1kz577h8j9skcnBB7V6boQuIrCyTUZ1kjhjILhmbzMdRz256HniuH0DUl1yznszaxyajpkpWWIMVWRt20yIB1wQQffPrXTXXiWx0ZXsZ7+2hkiC4DOu6NiSNqr3J6geldFXnlaD1sUjcvtCs/EFi1peobm0wGDwqFnL7vvBh93GM1x134YOkeJHjuLGLWJ1t8W0sylZAQcggjAJ6/XFdDYeKJ4Ipp7SC4eMN5clxImVQHkEqvTHbI71pT3Cakn23yX1C3kiChyf3YAOTjBxuyM5IHpXOpVaTs9gSafkc54Z1oSXMlpqxuYpICFWWXC7GOD8w7/XtXofht9Puo2uNPaKXb8haM5x6iudv/AA7pF3E+s3btbXMELb7hBuz6nDd+36VzWn6xqFlcyrZPLaTTOGn3xCQgdiQBgHH86mcFiE+TR/gEkprQ9iI9qTFY/hKfUbjTZJNVYu3nMIXeLy2aPsSvbnNbRrzJJxbiznatoMprgkg+lP60h5FAEWKD0pxX05pKq4EdMYYNSHrTGNUgGmkalppqkKx8N/tQf8lm1r/ch/8ARa15TXq37T//ACWbWf8Ach/9FrXlNcj3LQUUUUhhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHqv7MX/JZNG/3Jv8A0W1fb9fEH7MX/JZNG/3Jv/RbV9v100NjOW4o5NPUYpqnBp46VqyWLSUtFILhTqaOtOpAhQCafSJ0p1SyxKeBikApwGTSbAco9RTqBxRUAFFFR3ABgkznG09OvSgBIWMkQYrgkng/Wud8f6rb6V4fle6eJZGwYlduMqd2T7DFZ2reKpdLgWGwiikEeAy45QE9T6dzXiPxN8RXWsXscEUklxfXUqpAg5BUMM7R0Ir0sLgZTqK+xt7Ozuy9d+Hdc1t5b+C1vIr2ZyzSwzrGNjnLIzZGM+mM1q+HvAGlNdm51SzjeaJwbaEA+UrjA3bjzIc85PHp61Lqni54lvIILW+F9axbHngG+FJdnGe+eRk49KzvOs7vTrNtOutVvNdlQebalmRo5COOB0/HgV6fNV5bXsvIeh6ZF4UtoRLcpapHczAee0WVEnHIAB657nNXfDui32kI0EVvJb211IzuXk3ovA5bPIPHHvXPWEOv2ujmO8c3N3tKGPcD823IBORjk1jWE+qWulO0E95a6lI265ilzLCXI+4FbjH/ANauCVOc00pJjs3sej+KUNn4f1C0jNxdKY1mAdS7ffGRu6HPJA+tS/D9oZINVeJSrm8bcxTbn5QRjPUCn6bdane6RGuo2qC6MaN5ZXA3Ed/T6Y4rb0rTo9NikjieR1dt2XbJHAGAfTiuCc+Wm6ct7mbdo8pcxTWGKexAxnucUEVymZHTSKkIptNMBlMcYqQimsM9KpARNTSBTyOaaRVoCKkbrTyvPFNxVITPhn9p/wD5LNrP+5D/AOi1rymvV/2oP+Sz61/uQ/8Aota8orle5a2CiiikMKKKKACiiigAooooAKKKKACiiigAooooA9V/Zi/5LLo3+5N/6Lavt+viD9mP/ksmjf7s3/otq+366aGxnLcKcuc+1NpynkVsySSiigDNSIB7U6ilAzSKSHJ0pw60gGKcoqWMWnpTQM08DFQxigYoopcUgBetOOMGkHTioZ7hI5Y4sFpXbAVe3Gcmla+wJN7GTqGkaa1vdXN/Cq/IWd8kZA6Zx1rybwYLZfEbSPBGyzCTY7jc0TKAfk9AQf0r2fXrJ7/Sbu1jkEcksZUORnH4fhXhmlo9t4l0i1hkZEa9nSZFUgOBGCGH44HHFeng5OcJXZtGTa1NUaE0V3ftbakYoL2Vlu4JI/MZ32gkAr0zgce1a3iLWjotjAbSzYahe4jiiTYjNjksW5PAHv1q3Gjy3F0PPkSRVO5SMnBHD84x9B7VzGoqLL4heFrq5US280PlK5JxGVJaQ4+gFdKfO/e1t+NlsW7onv8AUv7RsZJtOt5bGQR+Zcc72gmDdWPQryCD33D0rc0zWrlPDOkXj6W80tzHhnibdj5jlyewOAc+9cxp8sVymr3dlqclpp1xcrC0pi8xJTIpBUHoCAq89vrXUwzXaaLplkPKsmuXNpaJACTGg4z8wycqCcH1FTVSVo26/oSjpUniESWtsJbtSSSyPlou4Jwc496mXV0gmM7yspZd0kbHLbUBJwpP6iuMvta022ldbDSXsruOQwRzIpLNzySBweRnFSTwQXFpDqTxXE1rblvMmQgyo2cEZz93npWDw6t72gWTOv0fxTBq99LY/ZpbW5aLzrdZmGJkxncMdPcV0dvIZI/mxvX5WxyM98V5H4OmsLG9utSLwpLD+7ti8gEkkLcthSegbuOtetwnhdvzB/nOSPlzXFiqUacrR2MpRtsS0xwccHmn0HpXOSR9uaZT6aRVIBjL1NMNSnkVGetUgI6aw708jBpCM1YHwt+1D/yWfWv9yH/0WteUV6v+1D/yWjWv9yH/ANFrXlFcz3LCiiikAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB6r+zH/yWTRv9yb/ANFtX29mviD9mP8A5LJo3+5N/wCi2r7fBrqobGc9xacnWm09ePxrVkj6VelJSrUALTkFNp68UmNC04dKbTl/SpYxwqSoqlBqWMKcDhST2qveyvDayyxpvdBkL61k2mnXd3Obye7mt945ijbKSAjjOfSmoXV27FRimrtm5FmRdxBAPQe1JDaRxSvKMl3OTk96VQFj29OMZqZPujvWbZNw2jBHrxXi/iaxi8MeMba4upZUsWLStPIxcZxgBf7vHUD0zXo3iTxQmkSmG3g+1XCDdIu7aFXr+J9q8417x34f8SSQNqkSfYreGR5LfzQXYtwpB/CvQwVOrF8yj7rNYJrc6O5LvFdRWiI8t1EAs7udoA53H/x3B+tZN3bW2qTMhP2u3Lm4WVSYkjfaFYZ64I7jrmq3hiOay8P2JvAYbmDMkMUzZcQ5O0OeegP5VYvnIsY2i3W8c0w8vzZCQIlU5OB2POD3yK6uXllZFvUZHdHQbMWOjw2sZQBYraC2AijLHd8zMcH/AHuvFWVlaS5u2juY7a+gxI10g3jcw6A9ByT9etcza6bfy6VCy3Q8uY7lsYUbPyEjIPZcHNdJZ2cTzJa6UMQeSRPJI2IyVA5K9wD0wcirlGKELY28P2UTTXEtveQ5PmTkEs2CG2nu5B6dhXa2ejx3Oj3NusZgt7hNv2eNBF5XHTjvnnNcjMsvlfYklaWO6dtohhB2nGTkk57V29pJeWnhzcFnnvTxiVQp3dOAOMelceJ5laz3YndHGS+DtUt9EuLF/wCy7q2lKlJLmHc0C9GwAMk4x9auLfa5Zav4fstOks4tKMSI0d0VSV1UEOTk5yOMAfjWl4jvJk0ixaeaW2vI8PL5Yzweoz+HbmuM/tCOa6e6ufPukkja2Yz8GPAyD82OTkAY645q4RnWV52e47XWp61YX1tfRFrS5guNuA5hcMAasnpXnfhDWLPR7yezvgLd50jYMseI2IU85+g5z3Br0MOpQODlTggj0rz61L2UrdDGSsxp6009KkOabWaER0hXNPIptUBGRzTCMVIe9R1SA+Fv2ov+S0a1/uQ/+i1ryevV/wBqL/ktGtf7kP8A6LWvKKwZYUUUUgCiiigAooooAKKKKACiiigAooooAKKKKAPVP2Y/+SyaN/uTf+i2r7fFfEP7Mf8AyWTRv9yb/wBFtX2/XVQ2M57hUijimDk4qQdK0ZLFpw6U0U6pBAMd6kFMXrUgqWUkFAz2owadSAUDNSAYFRqMmpKljFdNyFemeKcOAABgDsKztb1SLSrB7iZlB5CBuhOO/tXGSeKL+63RmeBXgPmP9lB3crlR9CPzrSnQnUV1sXGm5K503iHxPaaS4gC+dOWCFQeFY9AfeuF1X4hySyS26zgNGQskVuPmDZxjnnqQM+9cHq19da9qzW0UsqWyyN5s2zDkjBwTnkds9a2fCvhuGG+uxeC2/cqzO0nzu7nhWJ6HAycHivUhhKVGN5q7NvZqKMLxDrkvi3UbDRdGmlNxNKZFk3FCAoPDH6g11Gj+B9CsryC9nMR1OxZVcuqkOxAIIA+7jIB/+vV2DQtBeeWHC2OpbxIkav8AeBwSV9Acfma04pI4oL55rsQT3VwyxsyrG5GQCVPqdv8AWtp1XZRp6L8/+AOxYvIjbRzXsMAZt2CshzJvBIG3PY565rLvomuHs2nht7m9X94karhTjjBHcDPT1rWSWG7vLdWRo7W4ZY38w4G0AHBzwxyccd6YDLaahdyWkbwagv8AowN0AOnIeNj8uCD0rmTtvuJqxjaNrM63Woqs0S6hFIRJaQsd0QxwMnsRyasaaYnmMkMym1x83mIcs5GSFx90cck55FJDpN09/wD2pqF1Fai5j8p2Dhmz15A6HBJ9MVrW0lvBaEGYzQwLmSbAACYyGP48YHetZTj9kSstyH7JDHp8srT3USuuQiqC+W4DL6Dnp3FaVvrtzZwRQjyUgEexRuyfMU4x14HT+tZV7eQGxgmsfs9zK+FiY/IoUnAKkjKnAJ9sVUWVYobkG4UwRxp5UsuXbLEEYPtgkn6VlKHtNZDevoX9U1OERXbRzLL9mmCyIp53EYYL7j19axkivpXja/vAo8rztsEYLjJypyc8AcHvzxWK7XV3LCsUfnzIzLmL5/PbJIZnPOMZ9+Tium0m6sINDUyTyIJFTzBcKVDs+eFB+bCgYx71o48kbE3KesC4vXIjh8nYozNkkZ2k7Vx1zjvXr9gVeyt5FJKtGpGfpXjKyXNl9ljspZrVkgFzchSEjyrfdIHUba9H8L6ys+oXGm7FVQPOgK90PJyPqa5cbCUop9iZptHT9RimkYp1NbNeYZDabTj3phGRVICJu9Mp54zTa0QHwt+1F/yWjWv9yH/0WteT16x+1F/yWjWv9yH/ANFrXk9c7LCiiikAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB6r+zH/yWTRv92b/0W1fb9fEH7MX/ACWXRv8Acm/9FtX2/XTQ2M5bir94VLTEp9aslhThTacOlSBImMcUo9aB0p1QNBT1HemU9T2qWUOAxRRSgZpAcb8QN84htRLGkRjYsHOBzwST2wOlebpo9zNp9g8sUsV3dyrHLPuP+kLHkRu+OmFHbrXdfFC5S2iD7gpaMp8wyDz39veuf8K6VqwsLSU3oKRyG4lRkIV8g9COoHUCvWw75aKd7HXBpRTZDd6Eunf2bHawxCTdtSQfdBOSGPGePetP5riS+mthALi2BCySJwGU5z06Hk0XmqXX25CkRnaNd6lFzhOM8Hr1zkHNS2WowXN1bNYyBV2MEYHKyJnJBB6HPXPStXzW1Kd0kNhCz20MusQZxErgqN5cDkkAc8Z4ql4u8PreLaNGDMbM+akZYiMbl2qQx6kDnB6Gtx2MbCMh3XzJJVaQ/NnuEXuPSnRjAczyNHan91J9owY5Sf8A0E4ycCo53FqSJkjPtwU0uFNRjMTw/JsY5U8/eJ7c1rvbTwyxQtOrLPuCxONyqxXkHPJ5yc+9ZaalYxXM80ut2kcZgCFHKmPnAGGz144roIIbS6SA237xmiVg+/O5VONw5weT1rOpLqyW+5iu9np8cdtbIrS5Ae3Zh8wP8RPJwOaffQxx232i+gtYFkkAmJcKYlHOSPTJ/h9frV1tJTzmlODMjja7qSysAeg9Mfqa5wm51fxPcpdRSRW0UMcts7k7COrKR1zuHQ9aatLZ7bhZPRE2q28KXy3Vy9tc/Z7RRGxULvJ4Zx7YOMVm6bd2+i6wTexGWVGfzCoyCpAHJzjpjp09K6q9077ZoeozXEpgBU5JAYhNvOARwDXDvcx6jPYWFusSm68sXMmRu+TCZHoWyvI7CtKb5k0JvoR21g5vbidY/IuLVmkba5DAdVBI64wOnfIroLe2Gow6hq19J+9yDBuYseT90/hnAFc/ZavNYa/Mq2ou47GV45rhpMZXJ+V+x4IP60s1+13Jcyac4nhi+e6t7bJeEFuHAwNy/TNazTb/AFJTLZiNvHazPE0891EybUbJY7+EHpxg47c10OjyLaa/p91FuIYJE4kbBGeNze+MDFVbTR559Pi8xmgM0jvboxIeLAA3keh5IH0rNht1hWaNTItxEzyqS3zk7sYLdxwDUPlmnEtbWPbaaxqno959u0q2uTje6DeAc4YcH9assa8LladmczVnYRutMY4+tKT3qM1SARqjYkU9jUb9atAfDH7UP/JZ9a/3If8A0WteUV6v+1D/AMln1r/ch/8ARa15RXO9ywooopAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeq/sxf8lk0b/cm/8ARbV9v18Qfsxf8ll0b/cm/wDRbV9wDmumjszOW49eRTqaoxTq0IFFOXqKatKDg5pMZL35pRimqcjmnAd6hjTHCnJ0plPT1qWMeOtKAO1Np44qWM4D4uyRWWjnUJLRrp4YmEUY6F88ZHfr0NYmhazdXUEcVoSk8MUMk6Rrlgh5I545/MV2fxEsDf8Ah91EjIqn5toycGvMdAu0g1E31rC6boNlw24+WoXIXrwSMZ/PmvWwrU6Frao7qMYypu+/9foddoypqT3yNC5kAZ485O5cjj69fyrmNV1KbSb27uL+GI2bxb51T7sXUAnHIJKj3rZ0W4lsr63u4vOW0uGGP4iS3Tp2JJ+lb11DpeoA/btP3u0g8wIByy8/Me+PercuWWqumDVzldI1VNWeCDRw0sgKu7NufZGcZRW/vHrn0rpk8PgXkl1czwLC4y1nO+5FzjJx68dRzzTra9shcXVppNmtl5ZCmROAwPYenNYuoa5Zi9vNOiiuWkt7Uy3O2MlISOgLevfik+abtHRfeDT9C/q/ht7e2imS1sZbKLJzGA3lp1GRjnr17Vz88V3o1jH/AGZeSx6e0qebbgZADHlozn5ccH0PpXT2F29pbQtEu790qvEGz5gK88eveub8VXi2GnJ50WUkmijYMpKruIAxj+VVS578stTOUdDdj1S4kjmbf9quI8hlyIgTgEMOOu0jPbn1qV76KZUeBpYhIhZoggY+wx/CTuBz1p8sMKW1l5EJ23LMY3UYZRy3y55GcAbTT7a6+2CISRNbtl2VeAN4xgN1xx2NY3W6Wwr21Kj2R+wLdWxSVlJO6VyysMEFeD7dTxXP+INNvLm1sr2C5Rbsr5TIIlb5CdylcdT2wK6a9JSOaISMkRHmrsAIOB2AxySDwPWqyQefqdvJGj5cB+UGUXGcrnpngHHetITkveY3rqzz/StPtJrFtQmlwsbljZytwME/OV9cY5P0qK38QeRrc+oWMux/IWKK5b7ix9WwOhyePfHFdvb+DdN+2T6jd2I86dyZWV22M2Qdxj6AcY75xUd94LsU17+0vLkuL+4CvsmZhCu37pC9Bgdux7Vt7am209TJRMS+8Q6gbvSIp7G5jdrT7W6JwXAcJ5eG6EcNnJrrkthNL9qZ8GeMAu+0qPm5XbnHI71keP7RkOm3kUM1xcWlu9tMi4LvG/Bf3wcH1rHvpr211DT4IxcEQ2cqRF1zGzbBjI7sT37VKSnFOOhornpHw5lna01KG4KbI7k+UqtkIMAFfXgg/nXWtXnPgHUP+KnuIHhRDeWsc6v5nLnYC+F/3q9GbpXlYmPLVfnqYTWoxuhqI1I33TUfWskSNNMY0+mP1q0B8MftQ/8AJZ9a/wByH/0WteUV6v8AtQ/8ln1r/ch/9FrXlFcz3LCiiikAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB6r+zH/yWTRv9yb/0W1fcA6818P8A7Mf/ACWTRv8Acm/9FtX2/XTR2M57kqgY4paYp7U+tCBRS0gNLSGPToaeDTVORS1DAdTl4NNFOXrUsdx9PFMp4qWMg1G0S/sJ7WQ4WVCufQ9jXg2oaWPDlzeWN9dMjzP5srBCUfGBj2HAIHfNfQQHNZPiDQLTWLaRJkQSshQORkc+vrXThcR7F2lszehV9m9TyTT7a9hupBbTt5MqiSNZMsjA8Dp0x97itH7deafq8p1N5RLnHllPkZcdMjo2cZPYHmp3tNX0rxJpVtZ6daQ2VnGINu7KmMfd6+uSc+tS+L3WTWLXyjEUWTMoj+YucYIIz93kc+xr0lPmkl0aOtScnqZ+t2eoXOl3EkklvaWszgC9ikOVBI6D+96HvitBrJY7VIkuribyyZftMoBaRh3JHb1XpitC+vvIsYY7W4e4jaNTIyoFUEN0GRkfj2FVJSr2sjW5CtK4YlxgIDj7p7knjB7mlGba1ITvqzDg1ae61APBbXVzOB++WIbLbds4O89M8Yq/Zi+u5Uk1WGO3tTlhbQfMVOMh5SemMcAVYgvdNS2uIbxZra2aNpJmWTCrICDsIPfj6VkXHjG30p5k0M3V9LNblre0kQgbs4JDnjBHT3FW+aWkYky3Nu2uwskkd1IJLO5coltKSvksCCwyOGxjIPA61j2GiDxv4rvHuLqY2NlEvlbGMbSMGwSQpGc4HJ7CsOCbXNSjNrctFa2zJ88SR5c5JyjHvnn36V6ToGkR6Ro93AJI7bULi22Rx+YNyKM4/Goqv2KbT95/1ciWi0PMINfutD8ejRtQmvP7OuZGaJZlGYGAwR6mM+vb6V6HAYLS+gaFlYsuXdskgDoqjoBz0rxXxXpGpXWtDT4bWa+1dImW3kVtsgPQE57Zz+Fet6PcarYaXENYtY5dRjVLeY4DBTx86YPQ8DHqK3rxioxa37fqJeZtvc3r3Vu9soSFZAspGGkbuAFz09+vtVlZ573aJCEni+VoWB2nB+U+oPQ4pY/sc1xZ3pV/tDKYNjDA3ZPzHt2pT9o04SPdzpK5cOMAjbgcE+3avOdnstQG5vIZCbl1ZioVbdyoJZuWKn+lcz4iheS8gmXynWCMxCJVL5LN8jnHPDfyNdG0klzbRxSSxEiTc88Yy8bjqCD27Vi6417FapJpMnzIwDxMgzKM/Mq85B5zitKWjHsrFDwvJFouteH5dQkg86QS2RaM5ILHIJ+uB/KvXD0rwfVvDa2l5YS2sjxi6uW86NpNqpNkbeME5BB+te26XcC7023mDbiyAE+44P6iscbFNqaZnUXUsHmo2GDUlRscmuNGQw9ajNSEU1hxVoD4X/ag/wCSz61/uQ/+i1ryivV/2of+Sz61/uQ/+i1ryiuZ7lhRRRSAKKKKACiiigAooooAKKKKACiiigAooooA9U/Zj/5LJo3+7N/6Lavt8CviD9mT/ksmjf7k3/otq+4O1dNHYznuLnBqQdBUVSKcitWQOHWnUynA1I0LUo6VFT06VLAeKdTaUVLAkTpTweKiU4NPqWikSqcU+oQaeDgVDQzO1/Sk1WxkiDCOcj5JcZKnt+FeVzaXP4YnNnbSNskXzG+0N88aL95g3dRycGvZ6o6vpVtqcSi4T51ztdfvL/8AW9q6cPiXS917GkJ20Z4z4q8RQroV86piEqLiIj5gMgKX+pGeO1ZJ8QXkFk0f9i3AYiKWZiw2IpwR16tjHTpW1rHww1e6v7goFEckhchGxHJxxkdskk119v4K1H5POuLZ1aONZfMBZsrnGCO2DXq/WKFOKs0zqc1tsjzS10nUteuRc6pLbz2UBUrEAdhk5O456gcDHtmvQtD8ArM8V1LJ5Ufl4Qlcscklj9OeK6Kw8P6fpki24f7Rc4D7ZCAqrn720ds1heN/E0o0+5ttL1BrSYAFLgJuzzzx2XHGRWEsRUry5aOnmZtt/CaV7Zab4ciK6eImvpWyTIQWQd2A/KvN9U1XUZtcOnwXFtLLdMURVBRozwQzHvnniobXxU1/cRxWNhPcXKMGF0FygBO1sl+ex49qlk8Lahc68usy38VtJFNmJbdN3lgcjezevcV00qXsv4j18w5W0aekeFNQ0rWIdb8T3y5t1eKEW6kj5j0b2x+VbZYajeJIlkFhklJkjmxiM9BsI4PrVjUhqc+n2sctzGAWAmkZdrKG7nnA5GPxFJprGGxk0lY1lmtZd5ckgx5PU7u+D2rFzc/ee/5ISQO0PkTwX8sbNbOWZrdyBtB4A9/UdM1NDdQvcLY36AsspaOZWDuO6/mM5/Ss+6uIZYRL9reaOVWVmjP7skfdxkZB9x6Vpo9pFES8LQXCR/vGccnP9PepcbrUe4XtskpVhIzRlt0pU7HYY6cdMVkact7q+tWk8u2zsrCdpfKX5mm+XajlumOc46+tR+K9aj0nQ5Y7tWDXsmyH5N6xE8by+Pl47GpfBemXNvp9z9qcNGsGJk6qxyMbSO1Uk4wcn6A9DSmtbZofszvG8sdy2QpJBP3iR3yCefrW/wCEz5dvcWrSl2Rw4DDBAPX9Qa5mW7t5Y5ZLJrmH5iEOzPPOevYnIwfStzwtcwl5lidjPOQ7K6kbCFxj2rnrJum7mc37p01McYNPpr9a4EYkZ6UxulPPSm1aA+Fv2of+Sz61/uQ/+i1ryivV/wBqL/ktGtf7kP8A6LWvKK53uWgooopAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAeq/sx8/GTRv9yb/0W1fb4r4f/Zj/AOSyaN/uTf8Aotq+3xmumhszOe4tOVsU2lXrWpA5c5z2p9IAB0paQDqVTg00UtSMlFKDUSnFSVLQD6ch59qYKXvSYEo608UwU4VDKQ9elPXrTBxxTlqGMfSUUGkB558QNRhsp5BCsgM+ElljPJbsv06ZxXDN4fm1m3U65FeG3ScyiK3YMwAAO07ew5HHXNafjETQ62YtWHlJuLQsoJEhznkfToeua0vCrlJLx0kjitZo8xskmWilJ+b6Hmvep3o0k4Hcl7ug+y020srN4h51ujIPKiLBQFwMEnkg9snvxWlpSjZ9n89XiOTFuKu+0d/U46ZPpVKXW7e8kv7aQwLHGfKeQ/vBID0UnqG4z3xxVxYbe53pHZG8UIojcyKnlHbjOOCAcc+uaxfNa8jPXqV0ubdoJ7ZbqJpBcZihJJOPvYO7jPXj6VFeW8sdu7TXINzkyR4izG46BDk9d3PWpzptjrdlBbapMIHVi8KOm0ntkN3HtVS60i40Aw2M96LyyuVVAsy8sxcn39uevAqoyjflT1/rqD7D9TaO409bi1imuMxBPNWTBQZ5Ue5Pf2qpfanb6daLPdPLNcRkjYu0yOo5CnsfxqSOVjAomuZIWUMp+zD5F+bAHTqP0zXA39xP4hvLnTU+0wSqwjeSM5MkecsM9SOcHvXRSp30exSVlcm0O8m8Vy2+sSPJFYrKz21kOMFv4zxhupA7V6Prsp8K+DZYvlF7cEOqZI2jIAyQDVXwX4ZCNb2pQCKAq7sBjAHQfjxU/j3xHYpq8dnMxkhhI85o03mI5GMjv1yQORwaxq1FOqoR2Wv+REnbRlCPVbeHSWunv455YldpdgH7xwBk4/XNX9AlktTBqs7iOzkZQykj5FIAUfqT+Nc34l0u8trzUIbCGMwShQ+VBb0DDuBg4Prmt/TreaX4cSwhknuxIUBdAqiQYwMHjiiolyq3X9RuOh6OeKjJzVfRp5LrSbWadNkrRjeuc4bof1qy4weK8m1nY5XoRk0lPIzTSMVSA+Fv2ouPjRrX+5D/AOi1ryevWP2o/wDktGtf7kP/AKLWvJ652WFFFFIAooooAKKKKACiiigAooooAKKKKACiiigD1T9mP/ksmjf7s3/otq+3yeK+IP2Y/wDksmjf7s3/AKLavt6uijsZz3HCpEwe1R1InStSB1FFFABThTaUUhoWpVORUVSJyKlgOHWnr15pope9SwJaeKjByKcDioYJkgI9KWmA08HJqShQcU+mUopDKmoaZaagE+2QJKU5RiOVPsa5nTPBGnabIsju7RQuZtzNjPHQ+w612dNIBBBAIPBB71pGtUguWL0LU5JWTOB1DTLHS9Hu7/T1gu7ZZPOcdSD0z7npWO9s2pwCXT7poJ5Sd4iIBZuxLDnp6cHivQdT0+GWAwQQFRK4Z/KwAcdM+3avOLYXHhPUbu3vrBJ7VS81sQMkoexPYj16dK9HD1eeL1946IS5k77nTaqgNqoWIM0I/dqwJDdFJwPx/E5qslhGjzS3O9VyNgPAQYzjI64I61z+o+LJJrVv7KmiSRmCozYZgMZJAzjjpTdG8SNp63cmqKNzy4RI5OZGYfNnP06VoqNSMdClSly81yPxHdW1vriQOWAdQsoV/wB3lzw2B1Jx3qHQdBZt0nmyJfvMyj5twwTxzgHpiq+oLLrGq3cumiFbSTbifJ3A4BwoxyR1wevNel+D9IewtBc6gS97LzjH3R0zj1NXVrKlTvfUdSSgrmzNH9h0qVLOMCVYzsVRnc2P1rwe/sLq11O9RtRe5MlwWigWIfLhApweTn1zXr174y0qG7u4FnSSS0bbOAf9X056c4JGcdM1la7bWGuW8V7CEfZl5BakZkHZjjG7HNcmFlKi25rRnNDfUreDrC11bw7aag9xMLy0MlrNJJ3CsflYHrgdDU2tTWieFrjT9KLNLu3fN94knJYVV8ObdOlnsY7pJbO9jCwMpG1ZRn7w6jOcEn0rh7u1vtUv2Ed60E0cknm9cbQvO4/yxXRCnzTbk9E7o0Sbdmey+FIBbeHbGAP5gRMB853c+taTdao+HIYbfQdPitv9SsKhTgjPHvzV09a82XxM55biU00p6UxjgUIk+F/2of8AktGtf7kP/ota8or1f9qH/ks+tf7kP/ota8orne5a2CiiikMKKKKACiiigAooooAKKKKACiiigAooooA9U/Zj/wCSyaN/uzf+i2r7er4h/Zj/AOSyaN/uzf8Aotq+3q6KOxnPccOlOBwDTBS1sQSZ5HNOqNeoqSkAUq9KSlFIYtPQjHWmUopMCWlFNpw6VIIcCRT6jFSA5PSoYhwOacD6UzNPFSxoevSnCmr0pakodRTQacKQwqC9tIL2B4bqNZInBVlPcGrFJQm1qhnD6h8ONImRVtc2iq24FBjB9RVW18AaJZPIZriWaVjuIL5AOc55ziu/nQyQugxkggZ6Vwmt6dPYaVM9xO73d5J5ccfBRCfU8Z4Fd9GvUn7rmzeFSUtGzc0vRbLTQskFmzMudrMQ2Oc8AVFqd5rf23fp1vbi2WNt6XOVkZ8jBBzgKBk+prjdEvtes/EdtbeVK6SMBKNuECjqcfy6V0uo+K7VPEp0Zo5UdMH7R/Dk9qqdGan/ADaDlF83c5rT/Bt2yapd6hf2sMl6waYpgfdJ4B/hVhtyPUUeGtO0fw607nWDK8u4YihIRAx6DPYHn86yfG2r39nbQ21tbpLMQY0QyCMPJ357t1rkP7MumgSS81DzpNm7YjhdnPO4egOcnpxXcqcpxvOWj7D5V1Z6A58Nw6nJNaRX0xim8yUicrHvGDnHtxxVPxZs025Gt2SyTWV6QkksSn5TnOCo4HJJrL0XSIZbSSe11BjFvzNCj7gF6EnHVSeT71PpWrar4Z1eKB4o73RLr5pXkO4bM4VVA6nvuNHJZ3i7td+o7K90emeDblptM2NcJKsT4UDqqEZUE9/Xmt0nJrF0TT7WykaTThsspFDIi8Alu/vW1XlVLOTaOWdr6DTUb/eqQ1Ex5pIzufDP7UP/ACWfWv8Ach/9FrXlFer/ALUH/JZ9a/3If/Ra15RXM9zVbBRRRSGFFFFABRRRQAUUUUAdzL8NdYj+GK+NzLamwLqGtgx89I2do1lIxgIXUgHPNcNXsUnxrElpd6S3hiy/4R2bR10eO1EoE8aKvyuZ9nzEOWfG3q3rzXjtABRRRQAUUUUAeqfsx/8AJZNG/wB2b/0W1fb1fEP7Mf8AyWTRv92b/wBFtX29XRR2M57gOtOpFpa2IHx9DT6jU4qSkAUoFJTqQ0FSKuOajqROnNJgx1KKSipAdT1zn2qMdKcpNSwH09TTRSrUsQ9TTgfSmCnLUsu46nDFNopAPpM00GjNAxc1XvLWC8hMN1EksROdrjPNTUtC01QFUWcS2rW8ZeNCpQEN8yj2NcU/w7g+0RSrqNwzJOJTv575/Ou8Ynmm1tTrVKd+V2uONRx1R5Z4z8E315r8F3bmU28YcxSQn5o2buR6jJwa5kfDtvtN19phujbywrAsOeEQcnnOSWPJPeveazdaspLyzeO2ZUmPQnuPQ110sdUVos2jX1s0eHy+A5oW3aPutLq2gb7LKpKhGznlfusMknBrVvLo3nh0w6hHG2oWzLESqYR5QOHH93IzxXUWPgTVY1Hn67tydzrHHkDnovpxXQ6T4YstOhkQs9zLJKJmlmAJ3gYyB2roni4dXexXtYIt6N/yA9PCpsXyUJXPTitDOaaoIXaR049qXpXnPV3OWTuxH+7URpzNmmGmkQfDf7UH/JZta/3If/Ra15TXq37UH/JZta/3If8A0WteU1yvc2WwUUUUhhRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHqn7Mn/ACWTRv8Adm/9FtX26DnNfAnwb8UWPg74gafrWqpO9pbrIHEKgt8yEDAJHrX0eP2kvBYP/HrrH/flP/iq3pSSWpEk2z22nCvEv+Gk/BX/AD66x/35T/4qgftJ+Cv+fXWf+/Kf/FVp7SPcjlZ7bUinIrw//hpTwV/z66z/AN+U/wDiqUftK+Ch/wAuus/9+U/+Ko9pEfKz3GnCvDv+Gl/BPe01n/vyn/xVL/w0v4J/59dZ/wC/Kf8AxVTzxDlZ7hSgkV4f/wANMeCP+fTWf+/Kf/FUf8NMeCP+fTWf+/Kf/FUc8Q5We5Ic8U+vCx+0z4IH/LprP/flP/iqcP2m/BH/AD6az/35T/4qp50HKz3IGnr1614X/wANN+CP+fTWf+/Kf/FUo/ab8Ef8+ms/9+U/+KpOSDlZ7suAMCnA14QP2nfBA/5dNZ/78p/8VS/8NPeCP+fTWf8Avyn/AMVU8yDlZ7vTgcV4P/w094I/59NZ/wC/Kf8AxVL/AMNP+CP+fTWf+/Kf/FUm0HKz3gHJoJ9K8H/4ag8Ef8+ms/8Aflf/AIqj/hp/wR/z6az/AN+U/wDiqV0NJnvIOaCRXg3/AA1B4I/59NZ/78p/8VR/w1B4I/59NZ/78p/8VRcLM943UmT614R/w0/4I/59NZ/78p/8VR/w0/4I/wCfTWf+/Kf/ABVF0HKz3Ymm5rwr/hp/wR/z6az/AN+U/wDiqT/hp7wR/wA+ms/9+U/+Kp3QuVnuuaSvC/8Ahp7wR/z6az/35T/4qkP7Tvgg/wDLprP/AH5T/wCKp8yDlZ7qTgVH3rw3/hpzwQf+XTWf+/Kf/FUf8NOeCP8An01n/vyn/wAVTUkHKz3Co2Oa8RP7TXgj/n01r/vyn/xVM/4aY8Ef8+ms/wDflP8A4qqU0Fme3npTa8RP7S/gn/n01n/vyn/xVIf2lvBOOLXWf+/Kf/FVXPEOVnhX7Txz8ZtZ/wByH/0WteU12/xm8U2HjL4g6hrekpOlpcLGEEygN8qAHIBPpXEVzvc0WwUUUUhhRRRQAUUUUAFFFFABRRRQAV7f+z3Dt0DxNfRaFpmtTwS24WG9tFn4IkztyMjoOnpXiFfSv7IEgFn4ni28vLbYPpxJXRhbe1i5K67F01eVj13wdodhf+Gkvdc8E6DY3TOdif2ZEysO2crkA10keh+CWsTM3hTQRKOPK+wQ7mb0Hy1pm/mWya1IVkI2B+4H8qitJ4YoJ4xHtJB2SEAkH1zXZUpwqNy5La9Oxcab6nNeIfB2jCx+2W/hPQFkJCRW6WMeTn1+XrUWneD/AA+IkXUPCuiJKx522UfT8uK6BYJPLM0Ts7Kec559antlM6q67twGSprW0Yw5bI15VHdmFd+CPCUMqBfD2krG52hhZRtz9NtEHgzQE3KvhnRJQP72nxZx/wB810AhkySjsEzyvXn1qvrfiBPDdpHK8TXKvwVXgg+ufSo5b+7FXZDfL5mJq3gzw5FYmU+GdEdeN7Q2UWYgRwWG2uej8G+HYd1zeaTo0Nsi7sNZRnv34qh4K17xV/wuG9i1Wxn/ALB1CEhCV3Jsx8hVhwc+nbmtfVPCOtW3h3UNAmvmvVvpGa3ZFy0QyWCk55xjFd0aKpP2c2tbP5Pf7jPnXQkg0Lwa+nfaoNF0WaBgTvWwiYYHJxxTNB0rwj4l0c3lj4c0j7MkrQ7jp8QbIxnovuKd8NPC91o/hTWQsy3QbrGUxzjkAHpxXU+BLHT7Lw5FaWMJtoYGeaVDnhnOSPes68aNPm5dWmhqo3ujDXwX4YVlWTRNGIIwAbGIf0rCPh/QbTXZoG8PaO0R6BrKI4z6fLWz4+sLy/0Z49Lmk098h4pOV3gHlS3amWejXs4003kpeeKJPtMqgtuPXP4+taU6cFHnlbXoF+hs6L4F8LXYldvDWjsqjBBtIhk9f7vFVk0/4d33nW+naL4dluIH2Oi2URK+ucLzg+ldTZTPe2CNF/oxKGI+Uev1rhvC3hC68N6zaSm6ia1jMm19uWbcMEH+dcUaVOTk5uzWyId7mnH8OfCZImtvD2lurkEKLSNgfxxWvN4K8K21mpXwnoZB4LtYRZ/LbXK/EGHxJcWcWm+EJjBNLcKssyuFZEPXb7ZxwKjs38TC707RvtF5emBlEtxIPm4PzEn6etavCe0ipuS9OtvMb0djaPhDwsIZVbw5pCR5AEn9nRYx7nbn8agn8I+GUmVP+Ed0SMEM5JsIsIoGc5288CvRntYhA8RJ8tl2tuPX61yJtLprkw27KRA25N3OV6YPtXNRlCd+hStI4rw9B4G1LVDLa6Ho81or7Dv06JevfGOleh/8IV4QcGRPC+gmPsy2EJBH/fNZFh4b03Rb6W6jjihnkG9lG7a3+6MY7mtK2vxZ3UqKC1q5BVf7p74rTE0oVXekth2c+mo3U/A/hJtPlA8NaDGSPvrp8QI+h215F4N8A+ELK81W0KWGp3EkpC+bApMS9gAR1FeyajJdapp8sUEyw5RsOTjaf6muD8FeBpNDluL65mW4nLFgUXBIPXJJ7VrhFGlSmpvXTQhxs0mjJ0nwZodtrF21xoWlvbsAE32kZGfbit288LeG42triDwzobOuVObGPBHXkYxVfxot4kNtfW7jZBKImjHHB6mqviDxNPpui2dxBEssrBDKjdlY9f8APrXX7FVWmktS7xT5X0N/xP4C8Nat4fex/wCEb0uynnjBW4hsY1MTdjkDOPatXQ/h/wCF9O0Sxsm8OaLcvDEqtPLYxO7nHLE7aueHNdS/shCpMoKYz04wOCD7V0SkWaxRSHO4EBscZ7V5NbmjH2TXW5m1YwH8EeEywX/hF9DY4/h06HHP/AagbwR4XWIOnhnQgw+8rafFj6/d4rroygCgcMw7CqUE0VxcXAjYsFbByc8nFc0fQSZgyeEfCKMrSeE9FU9x/Z0RB4/3a4D4neHPDR02GTTfD2lwMG4eKxjTnuD8vNew3q77Ty/l3ORGcjp/kVxPiv7PGiW922bRn3pu42Z9xXbgVH2ilbUuFmeAa+nh21ge7g0Sxku4gEuLa2jjwn+3tKnH8q5S3huBavf6aujSWCON8V3aQh48+oK8j3Brt9e8M29/rzX1jO9pMjZEqEEcf3l/qPxo02803UNZn0DXLWO3NxEUD7QI5ZP4WUjpntX00Y0VHSKffTb+v+HIe5Z0ybQE1S1spPDekzwXi+ZHdwW0ciHjnHHGCDx2rsLDwzoEl8Db6BpMqryytax9/bbXAeBNIn0TWp/s7v8AZE3ZikHzRyeqnuDXqNqJNOu4tQIlmUpiURjIAbofeuXEUqcXaKRondEt1oHh6G5jMfhfRw/HyNYRkH1GcVb1PQvDIspSvhTSEfbnd/Z8XH/jtWZp/wC2bYCzjlE6/Mh27SrD1zVjS57y7ga3vk+zXY42kY3e4B7V57pQVm47ErU5DxDoPh5NLN5a+GNMil8s7T9ijKtx6AfrXLfDfWfD9zNNp3iXwhpa3keSkw06PEij1+X9a9Mu/D88dtBE7tLZox3KpwVGc/lVGPQVtNVtriyAaJm2SW55DqT7966IqhKm4NJ9mWkmJqnhbw3Fc2t5FoOjrYTKN4+wxfLnocbeK8P/AGmdI0zSbXw+mlWFlbBpJ90lvCsZcYjIBwOcZP519RxeH5bm3kL7vKBwsbc8Cvn79sGLyNJ8JR+WE2y3WMDGeIq8zEzp+ycY7hNxUbI+ZaKKK8kxCiiigAooooAKKKKACvo39k+Y2+n+JZREZCJ7YHHYESc185V9G/slXRtLbxI7Rl4jJbhvQHEmK6cIr1UXT+I+n9OVb21aNQBJG24k8cVPPb2lucLy2c4IrAW+eW5CxFliI+baw49quW7l5BHGr7cceYc/jXdOlJO99Dosr3voXZJFedIogdpIBA461qalZsuk3MdgVguWjIjkK5CMRwSPTNc8yTJO24kiJwRj2rsImBhVgQQRkGuWv7nK0Z1dLWPL/hr/AMJe4u4PERhuJ4mMbs+B9CjLwwrptTtU8xUvY43BXcYm546ZFdSkSpIWVQAecD19ayfE2mSahBE9qUW7hbKFu6nqP8+lafW1Vrc1lFPsRGetjivEmp2Phy/s7KNXNzqBUW5GcHHBGTxwcVZuPGVjpun3B1m1vraS3cmTZHuKt6irPizSF1ZNP/tK3VZ7GTzI5FbocYPHpTb61Gpaa0E6xPFO4jk3nl/949cYrsj7OcI8+r66/wBdPxHyNlbw14lTWdOXUbYyQwXjbm3xbNxHHT3x1rUhnNmY9isUkUvIAPmTJ64HXn+Vc/e+Fb7StWS6tLxfsAjWMW6AlUUcDHp2rltRvPiDN8TIbXRLB7fRrd0LzvGPKlTjcSx7dcAc5rRUadW7ptWtfVkOS5btHffEcaudBjv/AA3Nme1xKYtu4SDHcHrj0qj4D159f8O6drbRCB3ZoLlUU4V1PXHpXeX6BjGVX5mHbg4rKsEgjhuLWONLdo2PyIAqnuTiuOnWi6HJy6p7+XVDjdiajnTnjmhk3xzY8zCgDIHX2rH8WPqdxpQutLtfOMJ3CNevPGQv8VWLtPNtog777dZMfKOcn1rY024KQtCwP7k4+Xjnsad/ZJTSu0VNWWhwXgHVL2WaCTW7b7JOszR4K9O4OD9a9TjYSKGQqCecrxkds1yeuqjyxiWMkswQyHOc9uK4Zfimuna7PpklpcK1nIIXY4xIM9h16mtauHljffpLXsTJaJtnsN46w2zyM+dgy2T+dcgL0RzvMGWJGBDNjr+HvxV291SS9tvKSCRPMIbr2x0rN18G0tppIpLd7pgGeArhcdxntWWGpcvuy3ZUVZal6a6jdIjC28hAQw5GPTHrWJfyXBklMEiiQocBx8qn1Nctf30k1o817cTwwkjakUZCn0we/Sui8E61CLgrey7IgANsgBZua7vYujFyWocyWhzd5D43gQSWpttRKnc0axqEI/2T1B+tSaz461HRYrNL7Q7zz5Y9zMhARTyAueea9JNpFf3slzB+4tiRuwOvvjtXG/F/UtX0D/hHLjwxFHLBLcGK4hKb/MHGM/rzTo1416kaUoK7+XS9mxOVupF4N8Sw+JbSUTaZLENuT567kJz0z61tav4cstdgeJoCY3i8tzF8uQOnPatixVp9Ou7ySOJY3C+VGDyOOp961bLEem7OFOAScfr+dctXEcknKmra9xt+7d6nH+HdKl8LTqJpJZQ2NpmAPAGMZHtXVw3duylmk+VeQJByMntVrUOLSSZkV1RSSjDr/hXlviHxl/ZWlvcQ2FxfwRTCOQ265MROcZ+uKVOEsY721F7rjd6WPVJnjALB8qoOGHLbu1ZT7oLuQRAhFGflOD/9f6V51a+KY9X0e51CwN7aXNsRviuocB8kcA5Oetchr3jvX7e+aQWEstpEwB2k4C9jkVtRy2bbin94rR7nulxfW8KCXULtsxkvlCB16HHrXDXupy30F4WsJL0BQIQO6j73HXjrxXP6X4pa7so9RktbdXX54/NchWYfwnPr61xs3xO1e61hpLXTEjuIJCZLYMQyj1QjqPXiuuhgZRb5VqvkO8Y9R/iK6j0/W7E3ttJbxSY2Xigsqk9Ucfz9q0PD3ha2uNTmtkeC5bzB5cLHIhPXIPYD261j+ODe30cfiDTreUiRB9t0+U71kHXcB+PbkdRTvCv+i+J9M1jTnlSOWMZilGd2O2fUdPwr0Gn7K8XbT8V+RK1Z6JrXh+80mSCVGjuIHxHLtGNpxx161fsNCkvIzPp128DRsAyS5KOfp/Wr/iPxBYzaDcSxyBpPLL+S3DZAzXI+APG39rRzS2iKJY8Ca3c4Oc8Mh/xrzo+2nScraod3sdloUWr200wkihMi8NHvILD1U1JeM+pvthgkhuoDkFjgj6GnW13LqUyXVvHJa3CDARxnI98VWuptTh1Nf9GC7gd0kZ3rj1x1H61hZuV3a4+pas7hsbLi+kWVGyyELzius0GC2uLMXLwNFKWPzNwSB3HtXISJZXDRGOUSTlwSy8k8/nXo6IPKTn+HgGuPGy5UktLhU0QoI2hY1+Wvl/8AbeGLLwhxgeZdfyir6lAAAA6V8uftxf8AHl4P/wCul1/KKvKbMep8oUUUVJQUUUUAFFFFABRRRQAV9MfsexrLZ+J42K/PLbDDHj7stfM9fQv7L2iW/ibw7400aW5mtZ5fs0sUsWcqV8w5/PFb4a3tY3dl37eZUHZ3PTLTxxqNr8QT4Z1Tw09tHJIyw3UTMxYDJDHjGCB26V6jGtyhSCHZ58pU5POwHrn3xWHod1CljZ2FxqcF3qFsvkyMjAt155+ldFqL2ts1uLRgxx8zK2SPx9a9nEzUpKMY2++z89TWKbWvX8CXUA1kdpO9nbLN6fhVO6nuUuC0W9rJVOdjchugIHpVPxQ12Ldk0RoftZCgPOciME/M3uQO1W9PDW+mQ2zSG5IADTyD5pD3J/wrnjG0FJ6lWdtCta6/dWN1EZ5JJbZj86nkgeorrrHUbLUAJbSeOQfXBH4GspIbeSwZnP7xX3AFeVzXE+OrXW0ltE8ORE+XKrTElQGTuM9jUulTxMuVe6/wM5K+p6ZqtkL6zZR/rACUPvXKzWN0FH2aEiVDlg47+npW/o10YrJVuMoqj5cnccfX2rVVhMmUIK+tcsKs6F47oSm46HnnxG8WXfh+w0GQQAvc3HlTREA5XHP4c9abp+ja1ofjafUI7jzPDdyC0yM+Qhxw2O2K7PWtC03V5bZ9Sto5jCcx7+3tj8BXL6j8QLFfFP8AwjlnC0kqOIJmK4VSew9a6aNRzp+zowu7Pm9L6fcQrvQ6KDVbPUEFxaSpdRL8u5GBHvWJfxzi7mm3eXl/lTvt9z6Vj6Vo9l4bS/eF3SKVmfHICc9B+fX2qlL4lKgCGZZB0C5zuWt6WGtJ+y1Xmax9xnbvbpJafaoceXKoV4wOh9RUCRuGMqM3nwriRc8utZug6tDcSG2dwj91z0/Ctm7jPltcwuA8AzuXkOtYSjKnLkkX5Mz/ABfoz6z4dmXTpgk+A+CSAT15xzXnnhLwg6ac3/CWWdvcXvnh4Zy5d0UdMt3GRnBr0eOe7hlQRlSz52jqAPpUN00ckEuI1WdiCB02+v4V0UKtSlH2aej69SPZK+pVW/8AMm8iI43A/d5ZvYmtaXSLebR5E/di7K+YpB4z6c9aoabp1vp4uLlgr3DIQMdOeuPfmtDSDFLfr57HOzdhuxWs6sktaey/EctnY87s5btdVeDWLZZLWY+W0TDp6Ee+a2IPCNrY6jBfxNIqkktE7bg+OnJ6da6jXV03UL9Ps95D9sjwxXd1FVz5hTzAvnGLJCHv68Vu8Q5pOPu33RnFJ6s0rma3i8PPNJcJBGEO9y2OfT61B4Q0+G7sIL+6AmPSAPz5aDp+J615v8Rry8m0hDpFjNduGVHWPny2/vEDp9a9M+G/2xPBumJqsK2995eWi74zwfyxXPiKMqGH5k9W/mQ97Glr9uDps7x5RgAW2D7wFZFjqSQwp554VNpPTvwa6a8kSK1leX/VqpzXCzW4uLEqvDOmQfeufCpTg4z2ub0kpRcWVvE3jazneXTdMvrZr+RGVYd4LMwGeg54HavCIvGdz4f1G6hOrXFrPOmGkhPylgTgE/p04q9rGh2Oma/d3tnLPHqsqMQ5IHlt3KDqSen41yjXj6tek3ulW0tldP5YcoBJC4HJOME89a+owuEpUoOKV46X23/r+tjNu2iRZttYv9Zu7nTbv7ZFcT5bfG33/wARgc+vSqGmtdRalLaHUrsQxZaSzvFO51HUL1BP0Newaboel+FNHhmunkFmqbpCp2mNjjlck8e1ZNtaaTqFxJereCZo5C8ay4dtnUDIrRYmDvyx0/UTVzH+Ga6Z4kn1CxNyz2nlsWtrhgGX/aAPX8K0LHw1baZJFO0zTz2znyJivzBM9D6itQ+ELW+1GTUtP09bbUbRPNd1YpvznnA4PFY+i6te6H4n/snxTbnaQZoXdeJFIOOeh+lZubm5OD9VpcFZbneX2lPY6bBe7I2hwXljUfdBHX3ryzWry88M+JY5mjnudGvnwkLL8yOcZ24/OvWri9vG0SWExK8IjHzZzsU+49KW70UjUdLjkKSeeD82MgMF/wAK5aVb2d1U1vcdjxvXJvEWn+Klmsra4vNPm6xBN2zsR7etejaR4YSy0qHVbG3hZJwJLhIV2sp9cd8c8V0+m6OLjSr6zvAI7yKYgMO/dSPYj+taWi2rWNhbNb7fIc5mj9GPcenPUVNbF3SUd1p6hdmbDBd2Nh/aVld+Z8uWhkHysvse1X4bm586J3hV/NA2vG2Rk+vfFJHpU5u7yyspHMLkuB2TPX8Pauk0Dw6un28JEzTFQCpccr7Vw1q8IK8nqU9FdlbSNHkhllnaFRNJJzxjjHWusjTaoBOT3NEa45yTn1rM13XLTSYGMsgM+MrEOpP9K8mc54idkrszu5mlLIkS5dsCvlb9ti9trq28JpbzxyPHJdb1VgSuRF1r17WNcvruMm5lKQt1ijGAPqetfO37UFvFDB4deDhXafj04SuipgvZUnOT1KdOyuzwOiiivPICiiigAooooAKKKKACvo79kmKZ7XxPJHO8cYe2V0A4kBEnHr618419MfsbmWX/AISW0SF3jme33uvRMCTqe3etsO+WomXC3NqfQWgW1ta3wVreEWk6N1QZGO+etZWozJYyTCDLW0pwm/gnvgZ9/wAa6bW7a0sLeBCTxkKoJ3MD1yahs7SSSMSmGEKp3IhjyT/kV6sKyf717M3SVuZbMy7oTteWcoCGCVNrjByW9u3FbMe2fXDaRhRBFbBpDnGGJ44rm1a50dtWvr0yyG0je5jiIy33cBAPrisf4Z219N4ck1LxGsianfXLSyKXKsI8YQY/hFazpc0HK+i0+b/yRDvpE7rV7cW1v9oSUEowU7T+hFYOraubC2W6lR2hkwPl5LH+grZ1qcvYiWOFms4ojKI1+8xAOR9eMVzfwv8AGc/jLRtRa+0RbZbeQIiE7lK/iOCO9ZUoyVJ1GrpPXXuNz5Ur7i6Lr9pq08kULMsiod0MxHHHBBHBFdZ4b+1W+nh02mE5cpnO32FJBp+i6koFtBbxXI3bdgAIHf8ACq0pvdLYmFF2D5TkfLUVJxqpwirPsxfGvMu6Rcahe3MtzNE21CQi8AL+HesvTvB1paa1d6msO+7nmaYmTkox649f6V0thMgtIHs/3iuv3DweO9WYG86Rj5g3YBKDtXK684OXJotjO5ialBvieO5hPlkY5HFee2HhmWS/YLCVsy5O/eDt4/zxXsL4kjKsQAOM+hrmU0yW3uLi3Eu8uhZCO5+n51vhcU4Ra2ZSamtTmbXw5HaX0d+jPPKoJHOAQeORXQWOoMJEVzmIcbCOCD1rnV8Y6TH4pg8NyLcNqTHBUJ8g4z16g1200Fu1iXkEiPGCw29VIrfESkre1W+3oUnHVFW9g+zXguLcBYsZO3kA/wBKq3ipLM0jsscRiBBbAC4PJJ71e0G8R2+zzFD5gyp/mKzr9LG5OpaZaXMdxLGMvHnmPPBUmsINqXLLp18hyk07dTORxcwrMk2+MEnKHIwO/wClc/JqElvc5+0/bLbO4sjEMw7j1BrotA8KjTdOVo9U273yuUzgn1rmfGGgvHqudOltv7WhAla1T5VmX6djXoUZ03NxTM+bS6MCZV0v4m2Nxa+H9UudOuTuWW2kMn3lx8wboB1xkfjXqtzItmcWb+ejLkHuG9KvaHKmqaXbnUIRb3AjGVBwUOOg9qytbsJDMsUc6qYjvV14z9fWsJ11WmoSVmlbe9wppK5DodrPbyveQKWuHfc0YHPA9PSn6T40sdXvoLC9iltrskqG4UBgegPUGprRJDPbAyoCDhn6Ke+DVmfwha32rQarLI0dwrrKfK4V2x19qzqypNt1fk0KpdWJr2C/y8c++VFyytk8j3Aqr9naOyeQoVXOFJ4rq1JUF2yV6nBJx6/hXP6s8sFj50zxeUw4Rh8x965qVVytGxVKWtjwL45aRPqLW91YRustu+d6g8k8cfiK8/1Czv5Tp13KwivY9oaLlWBB+8B78Zr1Xx/qiW1lJe3zT/ZonwqxqWO7OAceleZ3yXpd4tcMqRr8sc4XlM8g+49q+wwjfIovoKqvedj2vUdPh8ReB2tbmR/Jm4IXqh4I/pT9M8NW/h3Qbe2MYF1bYBYgEy885PfIrmvh9cagfBk6z/vRHIxVxg5Ud1PevQPC3im11W3WNtqzlgMOM/lXlVvaUk4x1SZMV1M6M3VmftNvKzAt5bQgceUTnP4f41f8Tw2+r3+mo8Mc0AdQxIBwM9M+9dlqUFhfywKHhjkYkZUYZvaqkGgTmNxGEQHAGR6dK4VioO05aMvQpadbQ2d5dWQVRBKu9EPI2ngrWXfXCw2vlAFZdMlDH1ZR0x7FTitPUrDUZHjbygk1sDyG+9n09a5+O1u11ac30KvI4BVyODV0kpe83f8Ar/IaSZsXt3BHc2l8HPk3CiNiD+Kn+lVke7lu72K3IFpMQwZj90nqB/nvXReGdHtWt2kmiR3B+UHkD8K1J9DhlkVgdqLjCgcCuaWJp05cnYm8UybRrFbO3D53SyKNzf0qvq+u2mkgIQZpjk+XGRkfX0qXXtSi0bSzIfvkbIl9W7V5zIkMlvHPCBJdAl5OxY9xWGGw/t26lTYUY82rOjbxTqF3LMltDFZhVDIZfmLDvXN+ILW484XFzM0y3Jw5I5U44x7VXutXtrtVhbZtQgkbsMmeORUE899NbyWlx0gAePjG9c8En9K9SlRVN3irFJ220KmqXMthpsov1ZlcEK4/iGPT1r58+OF7NdadoSSySSJG0uwvjoQnevfrnX7LUTGLqKSIKQpBG7GOwxXh37QwgVNIFspERlnZMrj5SEpY3/dpJrX/AIKCTutTxeiiivmzIKKKKACiiigAooooAK+kv2S7y7tNE8Xf2e6JM0tpjccZH7zIB9ea+ba+k/2Ryn9l+KlkQuWltQoB5ziWtsPb2sbq+pdNXlZn0JbyG8vFW83BwPnyefpXSm4lAAgSNiCMFuK5W5mL3wSVZIioyWaPDHHrj+dY3g/4iJc+Jbvw7rFlJp2pRE+RFK25bmPnDo3f6V6tXDzqx5oK9lsb1rJI768026muI5x5XnMMMRkBTj9RVPWtPMMRuAR5oGZCOhHTNRyahe+S6RO7SluOOoz0BrbE0E1qkd26oxQbtzY56EVyXqUmm9vIz5pRscwsjzW8EJJSNfl3496v2jf2ZNJFKiGG44WdVAz7kCua8KeKtI1TWb7RIrhZWiZlKDggg44z1roZT5kBtJWctG42sR29K6a0HGXJJW/4PU0k4yduhxGg2GvWPxql8qN20G5g8wSKPkQgYIz65H6161eWcN1E6OD+8GCVOK5pUvdKnzHmaMDKlckYPt2q7Fqs6XESXNuYWcjJOQCPXHrWeKc60ozhbRJadbdTN03e8WaNg7eaIZDukjQ8+2ehp0MWF3oPmPysM4KmsyfUfJ1MEx7tvBeM8Ffema9rE1jb/a9Ot/tUW/ZOqsAUPQGub2U20ktyJJrVm9E6C3HYEfxVhahcTw6lAZJY2i5KlV+ZR6Gk0rUv7bhhuomaGEErz13D+dW7vTrW+u7Np3kJhyyYOOehJ/wpwiqU2p+YJ21OZh0awh8XXGuJbJ/aRTb5jjJCnjK9uR3rpodNaeQTXLylSh/dBsDn+fFUNQtWs52EZ3xspUAn5gPr3roraVXgSQMCCBz2q8RVk4xkn0sOWmqM260SBbX/AESECZeU524ryvVFk0PxlbX8BYPdy7Z4Tx83AOPUH+de1McFjntXL+J9JtbrV9IvblG2xThgQOjDpn2NXgsS4ycZ6pp/8MK7krdTB8QXVzYRu9qS6K24Rsu9hjsK871W41W61463Yx+ZOzhphtwflAwB7dK9i1y126o86ShfkDmNgMP2IFVobrRtKiknkt0hbZskDLtDZ69eK7aOJUYJxhdv+tQmuZ6GPBeNPCH3qmOSuR8p64zmtC1ubtxELlQYmJEcnVunNcBaeBr2TWV1DRNTH9nyP5vkAg/KDznnn2r1P7bYzQWkcJQtAw3DHTsfpTxPJCyh736Fqprqjz3xfqk/h1p9RmNw1tGFDRwqGLAnGfQY9ak+H3xWTXWvILeynj+zDeVlGQVzjKt0/CtjxpaRupNs7CMZyGHY9RjuK88u/ES+F9MnE7ubfeu2NcDccZFdVOlTxNFJxu/66BVuvQ7TxD8T4o7ZmOLUK/Bb19D9a8Uv/Feu6j8Qn1yS4kl023VoxEj5jSEjlcepbBPuK43xp4gPiHW5PLby4XP7pR0I7Ej17GtLwRpGqRaps2MFuoHQLIu5WYDKn3BwK9GhgqWGg5Ja2M+ZdOh1vjLxcVH9kQwypfywRTq7kFNzjJQL9CPxrN0lNR1XR7e2aacrzHLZhBhxnhx79vbFZ1zpV/4i1IyajH9nurUA+YAVVlU8AemO30q3qPiC803XLHWdHdL+O0QLcxQEow4wSR3B/vDvW3Iox5I2vv8AMhyb1Z1/gvSdU8MRapbTXCNCkuyONn7EdeORnIrp9GjXTdRju4oFXzSPMMfQYx2rzPwprVx4i1i7W2SQq43RxSkl154XI69a9LtGuILGCe5gIMb7JlVhk89/yrkrxlzPn3Zcdj0uzvw7rcKkUyJwSzZOfY9jW1pOo3N5OY3RAF5JIIOK4bTbvS7m5y8uGlBIViODXXeEpJkF5BJJ5ioQUkY5OD2r5/FUoxi3bVFPY6CWSNP9bhVx949Khe0t5wV8tSOMtjmpLvBiCkZZjgDGalRRGgUdBXlp2V0ZjLeCO3TbEuBVTW9Vg0qyknlILgfJHnlz6CszxJ4nt9KKwQtHJdt2Y4VB6k/0rgbq8a9v2m1GUkyDespB2qB9Ogruw2ClV9+pt+LLUb6sffavNr91KLv5XAAjjAIAHtn+dVJ7pLa4h3CWC5jbDw/3l9R2x3qqmuxy+fYzFBcWoEkNyOS4zkEY+mCKfc6vNexW1/dWchjVxhgMKMcH3PI6V7Shy+6lZFXvsN8X2tg7QywKrNIwO5eDn3/LvVTX9Zn1SKOCOPyJowI2deTyece1a3iVNNvrFr1ljBV12+SeQMdSOorgdTv7exmaNrqS4ldPMVCvJGOvHWrox50tLtAa9kUs763tLlS6ytneB6cHOO9eV/tMIkT6JHEdyBpsNnrwldzo+uynTrLV74Qx26T7Wzktkdj7YzXlXx+v4NS163udLuRPpEm5oAp/1b4XepHY5xWOYU5KhO/T/NEyfQ8pooor5cgKKKKACiiigAooooAK+gf2U74W82s2wRmlmlt2U4yo27+v518/V9BfsnaAup3mt6i928IsDH+7Q48zcsg59hiunBuCrJz21/J2/EuDakrH15fQ/aVik8sFSo3AjOeelZup+FdJu9QtryW3VLuxzLBOByoxzVfQNVvp9XOm3dtm1EPmRXKk53Dgg/hXUQq5l3ORt2BduP51pN1MNKydvTswk3F8py1zbM1st1bXAljblWU4B5/nXL6/pGtXeo22p6XeuxhOJbOd8xSJnn/db36V6NqcMEGlTJDEqIDnCLgA5rm42MRCrIykqdgUAjPcGuvDV3Zyj+PY2g+eOpjr8NfD0niy18VWBuba+ik82SGJgFkbHcf4da7HU54BcW8qfvMMVdQMlfqKj0jzXuYleBkQAliRwSKs6lfW1m7+dtiUPlpW4XPuaxqValSaU25WVl6djOyjLQypRfJE0qKywSEnGOVH86R1vbxEVs3KLysijlT6Gunt7mG4QGNlO4ZwCDketYmqQTQxNJZytFvX94F45qadbmdmkmVGd+h57410DXPFU2mWena2NKjhnP2sEkGReMYx1IIwAeOan8VXureDrhbuC0kvNPYBHZOePcf1qv8AEDUdV8OeINBm0+3N3YTriRHyQ75/n0xXotuXv9GRLiEK7xgFeu2Qdfwr0Z1nThTlJJwd9Pnr5kykm9DN8H67a+INJims4ZLQHK+XKMYOOcHvXQxB4dRJdPkdQqsezelZ+hWksNm7yIFlK4VWGAQK1YbKLy1dQyyH5g2TkGvLrygpy5dvvE3YZqEX2mByq/vIzvQ+uO1ZDXSaYYXEiIsoB8lnGWJ9B+NZ2teMm8Nh11S1eRQxUTQp8vXjNcB4k0q98Y/2dq2gSuxxiLadpIDZ7+h/lXXhsJJr967Q79BbKx7nCFEYbBG4Z561T1i2W8tGhzhuqEdmHSoQ95bRWzzP56BVViAAxbGDnt1q074heRVbIPy98mvNScZKSYldWZ5h8S4PEGu+GLODQbwWmqJLhm37C4HbOP0qfxh4D1XxH4c06K+1eGzvowguJI1LJIduCSPrk1102nv5D7wPP5ZQOQ1XLGeHUbZ7W9VTKmAVbjIr0/rcqcY+ytaLb211/QucU1zIxvBPhDT/AA5oKWsF3LfYJ3SyEYZicnA7VhWvhifQvFVy8M4+yXqHAbpnOQCOlekQQwWkPlwxhI+u0e9cL8Q76+sbjTHt7VZrRJM3W3l1Q9CB7EZ4rPD16tatJXvzdzNeZL5tlqsX7mSOUodh8v7uQcH8RXm/xJ0Wyaz1C0uy6q0YlSQLkLtzyP8APeuvtNHk07Vpp7Fw1tPIWdVP3iedwFaHivSRqumGCZB5mw+U+OntxXoUaioVFZ6M2s5LlZ8ZzXFvp0ls9nb+ZKj7xLKMA+2K73whBqGrJey27SxzQhbxCGPXPKr+fT2qXxd4Untb67hDJHsQeXDGuSPp/j1rL8DXl34burnOorMhOzy4HD7WP8RB6Y56V9FOSnByhqYP3dzu/EaanqNhYtbXpt7gHzDE/wAoc45yKveCdC06LXbWW4iWK4aL98FP7tGbgmuW8QLeavJZ6hb3uZkBEbg8Mo68eo/WpdEvEW/kdi9vdg7CAcFwevy9MfjXK4SdKyf+f/DBFXRS1u6v9L8Wahoclo9tdq3+iGFjgHOQw45zXdyaqxsLd79lDLEvmbRgggctxweafPffaruDYoluPJCiXbl9p42g9R+FR6zoXmWdyJLeOCdE8xI8keavdc/T+dZSnGXKpKw46blLSIIbvWRf2GoWxbZtILfMc99teyeD0PniJ3Vtx3qQMHIH8q8Q8CwnS72Vf7LN1He/8e0wRcxsOqlvp/KvcPhxak+ddyQeU/K4LZIBxiuHM7QpvXToadGducGRQewyBVXWb5NO02a5kBbYPlQdWY9APxq04bcrLjAPINcb8SLz7NFZ4O5UJldB1wO/86+dw1L21WMDOKu7GBpsqytM2rwSI0pJYyrkc0unXUVreXEEhCRbA1u7dHUfw/UVNH4l0eSKKO4cgzDciyIRjjpmuP1mH7VNI9vI7wKxEaOSDz/d9K9+EHUbUlYtts6DxH4etYbW61G1VLe5IySThW45GPWuF1IXi2R0/Rr4JdeTvIlO7B65APSl17X49HsYV1W9eEk7CsuXdiMdAeKi+yX914MudY0lY/MmjMfnuDlSejDHtXVShKCXO766X2DZGXar4g1H4eavBHNIdb0+TzSY2G+W374x6GuFvNQ1ybRNN1Ca3Mj2spXey/M4znkenaus+DngnW7TxBNql3LIWjjZI03EiUt/e9QOuO9e0rpGkWlkLbUIgl7uBHyAh/fHTNb1MVChNxsnrfT01+Qcjep4JNb3yW91Z6kZDo11F9pCgDMMhwQVHr61578R9Nj0/wAOaE0STbZ5Z28yVdu/GzoPSvra40Ozkl+e1M7njaw6j6DivDP2sLd7SPwxBJbvCAs5XIwMfIMD6V5+YYtVMNKC62KlT5FdnzzRRRXy5iFFFFABRRRQAUUUUAFfSf7I5RdK8Ws7KAGtyQR2xJk57V82V9JfslWI1HQ/GlusgjkcQKM98iStsO0qsbmlL4kfS3hy73tvhaKTIAJVweD9O9bUdwzanJEzJt28evH/AOuvK/hv4KbwYl5NBczX+pXjKZIB8scSgk5BOcnBxmu71W6V7yOWE7SqqWB4IbPOfwr0cTQg6zVN3XcppylqrF/XJRhbS1XMk5y5HQD1NS2WnQW2yMIGlxlmPP8A+qobKILdRm5IkmZeAB0XrWoqHzJGPUjoOtcU5ckeRP8A4Im7KyJIhsyoUAdcis3W9JttVtJ7LUIhNaXKlHXv1zkVpK/y5IJ/CsXV9Ys9Pspbm/uGQCTylCKWIJ6AAd6ikpuV4bkIyvBuj3PhWwlsZpzcWa3BWzYtl44z0U/Q8cV0l9A81odg/eKMgf3vaoLkwz6UbnzfMhdQwYcZHH5Gsfw/4y03VtS1HRbSYnVrNirwvwTx94eo966JqpWbrWu1v/X5j2SaJre7g4hnkXzlyI1Yjc4HQjvx04q6ulyTl3lmaF34ZYycY/x9a80+Inh+y1FbG/1CO7N1bZVZoLho2TnJxjjOR3r0zSdYsb7TLaazuBLGyjdub5wR1De9bV6bpwjUp9d9NhttOyI5LS601YvsxkngU/NGDk8+lR3OtT4eOKHyZNuP3hzs9yK3EY5IHck5BrL1+3ikjilkfZIrYEg6gf4VzU5qckqiuOMk3aSOT1J3vdOl0/UIfNinXbIJBgN/teornL2DV9CnsW0GArZW6hPIjGR15IPeun8UajeeHTbTR6S2qabPhZZoSS8TZ647gj+VdGNEimhjkt5JYo3XeUzjqOOOxr0liFSim17rv6eenQuTpvyG2+pJcWuXDqWwWUjIHt7VOjTug3qwIGVUHt2yK4K4j8SaRqjXemL9stThJLWQ8D3BPSu0TUpXtFku4PLuFHzIrZJ+h9K5a1Dks4WaZNrdC1JK0yoZcCRCSMjH61mSnEiz7lPzYyvb0JqsurPcyMrxbVQfKAckj3NV5L8MjrIODwMcY96qFCUdLGsINrQv3/i610iwnutWjkiWBQS46bScceprK8G+NtK8Wazcm1ZfJhXYyvHgjPILZ7Hmm3jx3dusd0I3hI2sHQHcD6iszR9N0zQJb06HaRJ9uCpKQp529gO3U8etdEcNR9nLR8z27GUoNM6eW1h+3XkFtJGluBvU/wAIPcCkjuJY/ILSJ5S8bG53dqw9W1G7FvBLZCK6eLaJVdcBQDyo9609WBgiWQIUj2+aAew7g1Ps3opdS4tP3Wef/FW1MGsRPBjy5U3biBuQHgr9DXk+n+FZrTWryTTbK8mxkRM8eUUkclh39q9u+IejnX9GjKzOrovyyxfeAP8AOuTtNXsPDmmwXHk3L6qI2tJZg2AfRmHTj3r2cLVlGilHV7WMKsbPU8UvfEVzYanIkd7PKsWVjJQBUbvgfnWiniFINPt59QsvNmlcsJVfJwO+O1ReIbdId1/LKt08krZdo8uOepzwPzNVbK2XWrqG18145T80M7pgHvhvUeletyxtdmcW7HsXhme31DTLGaO2ecS5xJEcFCfunjpg1193o63+iRpLJM13GcZZyCPUGsbwVpt/oZEtpHFFGiYMLDIJx83HHfmu58N69DezyNeWsUkTyAFoz/qyOPxFeDiJyi24K6Rqcxo2lXaWMUCoiqsodcDBBHXivXtEsY7PS0S3OC43FsdzV2NIWUmJYyDwSoFOiARFjA+6AK8HFY14hWtYTldWFiPGM8jg15r8TbxRq8UMwYRrF94Lkc54P6V6YAMk45NeUfFFIrjXfLae4iZYl4jOAc9qrLEnXv5Dg7MxJdIsJoPIhu95bBX5sjP1/pTLt7rSLAs9oLto1zF5YwSR/Cc1gT2a2hW50+5eFkHzIByT689a0dO1+BtNe5v5BJHuKlsEZOO1fQcr33RV0zy7xd4mTxBBLaa3pM1ndxybo2CndH+B6j1r1zwJfY8MHw9NarPDERtlDcHI5yKy5NB/4SC8t7+dEEcKYQgcsPc+mK7ePTtN8OaAdU1C6itrUHa7lSfpyKrFVqbhGCXXbz8hxio6yNi3jSztYAdkcScqOOTjvWTr8JvUumj8s3JUSRyu+0qQeg9cjtXE+JfEFvDYRXzXTyaTNJ+6eImRXJ7DH411nhvW7KfToyAs0MhUq55JFcboTpr2m51VKcIx0ldv8DU0fXLHRdMjn1GZUWOL99LL91Tn19BXz1+1d4s0/wAUJ4d/sueOeG3a4/eIOG3bP04r6Wht7SSxu7m4W1WyBKTLKBtVMc7vXrXx38drPRba9t38PyFrZ7ibChcKAAuCvt1rir06U6VSpZ8yt6bnDLc8oooorxSQooooAKKKKACiiigAr6Z/Y4lkhtvFZj6ObdD7cSYNfM1fSX7Itx9nsvFDB9pMlsAPXiStqEeaokaUviR9V6TFGbBCEQNIu5z13NUZtIJV+Zs4XB5Hy57VS0jUT57wXGxUOWQg4GK0jFa+a1ygUMw+90BHet5qUJu45XizLsb1hceUyyNIp2ggZwOnNas2oxQ+UZcqzKdpbgN+NcRNo1/qHjTTntdWks9GiLu0cJxJM45Azz8tbusX09nDeacBFNchCbaSRNygkcbh7GuirQjKUVHVtXt26FNXlaxq20kl1OnlBjFnPnAfLwOgpsGlKk5je4V42JZkblifX2rg/htp3inQbfUJ/EmtPfzX0wlihGTHCOSQvp9AMCug8MeKNN8T3Fz9keQzR8lGG1iAeuOuKKuHnTcvZu8V1RKb9DpxpluCgc5iHCxdFz9K4qbwlp2j+MZPEkcDjUmiMcTq37vkYyR6gce9S65r2sx6xaDTdMtb7RVkVLmT7Rh1JOMgdBiuqkhguoPOi3GPAcIWwM/0qYurh0nJ6SVv+AwT6S1Rz/nyvdN9sjDbMO2V2jn1FRSGEu8toiwuv31Cj86t+JWnsBPdWls107AIYPX0INcD4p1HxPB4k0Sz0nSh5F0yve3Mo3LEufmXjocV14eHtbONl8/vNlUgtTqoxdQgzW7y5OS2CSPxp6ahLFPHcz7n8tThWHUfT1rpTFDZqn2dQ0MgAyWzkGqGu2SKY1iO2N3BQcfIen5Gso14zlaS3E6sZPYqeHfFdnqVzsh2kFgCj5DD3wa7C5YeTkEeua8x1bSfIinuYhGt1ACy4G3n6981zGieOvE9reKt7pt1dWZOMhAdmO9XPL1X9+g9ujM5LW56V4t8XaP4YsJpNYl2CRTsUfeY46D1rM8KeIIvE3g+31iHzfmYwmORMMCO3vxRregaL40EP9vQssafvYkZ8Y455H8qv6fpUGnWSWOmQR2+kW4+UEYG7qW5559TUqNGFJRs+e932t2QJOL8iCEFmDrGQu/GVI5NF5ZHzAo3o391iBn2zV+yj0zUXuTBMk00P9z5QDjg0tyxWL94qyLIw+b17Ype0alZblOXNsYmr208VstxbwSS26KSUXPzHHY1leCtV/tq73HT7yNLdiJIbuLBOeMqQcZ6Vvaz478PS3Q0lr1be65V1Y42n+79aq+GtUkmaa/sblZLIsUhJ5VlXgn8Wroi6nsXzws+hCm5K1zX1GwVZisMAQkbiuMjP0q9qZS604xXCqJsEDB4JPXHsahmjnu5ROsnlErgknr3/Krdr9mhiIu1Uz92b5uPb0rhlJ2i3q0U7uxytgkttM2nX0bGPjy5AmMqegJ9RXnHxb8J30crXMEkkUXJKr0OB3A716/qEo+2bfNLoMBSe3pUGpiPVLC6srtUd9pKucgnt+dd9DFTpzVRLff/ADCpB2Vz4+mvzd20dvFL5XkAlmb7r+7ADqOnOa2PCGlTa7rEcg1SGLyk3sYjkcfwAcD8KT4ieF9W0zU/JUSHBKxlU++CeFbHf61z3ha8Gjau2wsWyEliPT0bBr6hvnhen1OdKz1O2PxM1W4Mr6faObCFvKkdjubaemcd+Ca77wZdEwzWjwpFLMTIsrfLhfX8qxdF0zTLDUbqDw/HxcOvnRl9yqcZ2q3T8OetdvaaTpcrQLNEyurDz2I+6PTPavMryglaMbfmVG/U7vwnqFzDdvbyTRTWioDuAAIPqTXZwTRzxiSJw6HuK4jw9oFnbagsllJ5kbgkg9BXZWdv9n3KBhfSvlsb7NzvHf7hysWa8l+J8tyviNltZY4h5CbsgEkknr7V6ySFBLEADkk180fFK6Or+J0lilki8wnDqxwyA8CunJ6XPWb6JBE2Ha5s4JftRinE+MoBsK+49a4vQrG513xbqejwqY7F8OAnAUjHzfjz+VS2ut7dSazimlyYyFaQ7wW/w5rvfAelqb37NJv+0qN0gTjHtmvelJ0Iyb6r+mNK71Oo8P6fHa2kYc/Ip27WH38dfpVq7tdN1XTtR0LUj5dpOQIgDk+oOfatR9LtbGzhGQqGVd7ZP3Tx3rntetoJdQuIbb51tgpdgMkDHBNeRCarTum159rM1SjUdmYmgfDG30LT9Q068v1v7CVxLFbzJ8qMO/1IrS0bw9YwzoltCkcYGFj28Kc5zVi01+z1CJorPUrW8eIBXaOQEj64/KsiZr+01lLy3uojGT80LPyRXRzV583tJa/cEVyqzNyawgv7DU9K1JnjtbhNvmDONwIwf5V8ofHrw1c+HJdNjuJoZo5JJdjxtuzjb+XUV9jWd5Hd2sssnyZ5kJGVVQPTrXzr+2E1rJYeEpLMoyM1z8yEEH/V81xV6840Z02tHa/roZzfvO58z0UUV4xmFFFFABRRRQAUUUUAFfTn7GkEM9t4tS4xt/0Yr9R5mK+Y6+oP2NkuX0zxd9kiSR/NtclmxtGJeferpu01Z2Lh8R9GrZCW2bzCrAKTG445Bxj+VeeeIr/XdPu9OmsT5unrNtuoguWVSeo9BXpkr3D+F7z+ysf2gsEnk7hn97g7f1ryvwXB4g8c/Di5M8i6X4iguXgkmlgysyrwVdT0znkj0r28HKylOpblTS1876lOe6Z29hdxXUcJhlGyI5DIc5yeSCO1XPEWraJp2iz3N1KStunmOwQyOcfhk1y/w18L694etbqz1e5sJGK4gtrOLZFEvPTPc10ujWUMtteyXiY254btjrms60aUZtqV0u3W5otVzPQwfh/4ssfFFhBfLELVG81IojJllYMcZ9GwAce9dHpmk6PpN5PdW9tHDeXSMXlxy2ev0Oap2mkWTyzXKWcEMc4CqyoByMYPH061p2unSNceYGDsTgszZCj2FTXlByfI3FPp+hLimveZjf2jovhvRJbzUZFislJEofkE9QFXqSewFaHhPxVo3i7SDqGmLcwRq2wrNGYnBAB6dCCCDmq3iLwdp1/bINTtY7u3inW6VS5ADrnH169KilgmRg3EEa8k4xuP0puNGtG6b5u/T7uo1Dnd09Dpo1guEZp3Z9pO31xXF+O9J1uG6i1zQy7CJMT2ch3JKhPPHY+9db4aaSQFnjbbjIduMe1bH2hAG81lQDOdxwMVyRrSw9XRXM5aOxxmkXjXeiLOqOsZUMI24aNv7v4etV/HPiNfDotpJ45HjkUHLHAB+v8ASuq+wqrSeWsYgYkhgeMHqPpWXr+i2OraA+n69cQrYqQxdsKVweCGJraFak6ilJaX/MG9LnicXxH1XxL4yu9At9PQWDxsbS6VSHUou75j0IJGPbNei+GtJu/7Ge61GI217H1XGVkHoRWr4O0HRNBgH9kFbi0lYusobduPAOO3YVrGMo9yrzM0MjY2MOAfY1218XC/JRjypW+YoXWtxILa0FtBLAoVic7ipG0/jVmWNlLQS4madSvynsR15qWSLaAjgEbRsA6EVCunM7eazMCMMB2rzedPVsvR7lXRtLtNEM4AuEmbkvtyMdulGq3cbzEIhaNP7g+Y8da0LZRG5cy/OTjDHn8KqTwGOZpo2dt5yVxynbIqlPmnzTd2KyWxw8fhPwzc3z3l1pizak8/nefLIzEL14AOOvbFbNvpNp4fsGh0tj9lnYv5ZP3CWyQPSrrRqsqnyyj7ypDDnHrmp7uBbosZWBG7b8o9s5rslWlJrmk7etyoxXQmsdNefUJLy4lRYUYCFAT0A6mp9XW2EWRKodj8o6c+grO1GWCG0F9e6nHb2nMas7gYI7CuTguZNWuYLi2ngnghkMiSRPv5H5YPsazp0ZVXzt6L+rArQd0zpbHZHfkXTFYs+Wz57ntUqf6LqqlolkIbB38Aqec59RzVSO2ku4JvMVgZP3hDN09Af50QmVCqybWKqefatHFNvUttzbbOV/t+y8W6zqUKxoHhkKpFnDsg4LfyryTx94Xitbie/wBCVxqUUmSVUAEc/MP9r613ug+G518defCvkoJmkKlSA2c5APfIre1bQEvnuRp74ldDuTuM969anUhh5qMHpZf0znUXJanhXhTxe9rbW1ndWgM3mkCRcK4J7lf5mvY9F1w21nexahBKQ4EglUbg+exxXhWu+D9TsPE0st9azR24cyGUH74AzxnucV33w38Wfb7AW90YmUt9maOcjLIV+UKT0Ix19668TRjKPPFXJu47nuumQX9vpMd3FdZiWPzIxHgjGOlWZ9Z1G1uoY5bpf3qkksgGMDnFcloWjXPhnwVPY2muTzRl2lSORQ+xTz5YP171zHinxFqWrWlusv2a0mt8O7wkkODwRz0BFeLHDKrN7NXetvuLjJvdHbeIPEQutAa5vbv5CdoVPlX34HWvMPFl0tvo32+KSJoo3/dg/ewe2PTNa8utaRBBa2l9dQwgPvCMcluPXpya4zxjr1pqV4NGijDxFTumUbSDz19a9HC4flaUVpv8gctLGb8PHk1/xRBJcMCsbEyFR/Dn0+lfQ9/NbaHNca0Yyj3jgQQN8uQFAJPt3ry34O+GP7P0+e6kO64kkKLxgYGK9d1XTItYt7Ka5kcfZixK9Qcjv37VhmNWMqyX2dv6+Zo4Wgn1Y+41aHU7fToFkUG5UyPtPRuwrXigWN3hhgUvINsh/vcY+Y1zD6LbQ3Md1DPLmFAIYTkAE+nvXTaPMDa+XeSKkyknJyo+vua8muoxj+72M5aIxfDvgDR/DOpz3WmWVvG14p8xcbuM5xz2zWZ458Nx3MctrFeS2E0hDQzxLlfow+vvXbT3Qub1fKP3W2rn+IY5Oa8i1zxHqdn8abnSbrc9g8EaxowO0cAll+pJBrbByr1qjm5apX+4lLaL6nJaPr2u+G/Ga+G9Yu4dRVnCCdDjAIzyfp2NeUfHfxVa65qUGm2WlvYR6bPMm55SxkJ2gnGOPu5/Gvo7xl4J0i+vxeW87Wd7FOrSbH++vdsHuOma+ff2jrDUrLXLI3rxy2coY20gUBmACg5I69q6sdUpVsNKcVZ2XlrddNv8ipXsrnjtFFFfLkBRRRQAUUUUAFFFFABX1f8AsPuqWPjBnIA8y16/SWvlCvpf9ji9S0bxGsqbo5Ht/wAwJCKuEHUlyocVdn01He2tvq0xhl+Vid8YB+91yK0NJktpVlaFAhZtzDGOfevOfHFx4ig8YeHLjTIx/Yd05S8IUEqvXJPYHtjvVlPHFlYfFC48LCGYMbcTGcMCucZwRjIxXqSwcqkE4atq+/be5cmmd5cBbWb5lcpLz5gGSGHSsSytbi/ubhHOISw3vkj5uvA961pryOR0jhnDiZcgrztx3HvmqunyTx3IVhyHIYgfeAPX61z03KMW+pSukzZKRJEylEwRgKcAMPSvMfil4m1fwfocF/pcTSW0kzJI6jJjY/dH0Iz+Ndz4tiuJtNb7InmEfwg4PXt9Kk0tY7vTW8yINGxwY5FDAkH0NPDSjSSqzXMr6oz1aZBp95PqHgqyvr2Mx3EtvHNIjDGCcE8dqp3Ye91NFwCrYO1f4UqfUfEumf2uNCWbN/LGX8rbkbR1/KrWkNZ21xLEkkZkxy5PH0zTXNTTny2vqvRl03yx8zT2+REkUQCgggH0NNubeO4sHt7hd8bqUceoPXmqtjrmn3+q32m2s3m3dmAZ1CnCbugz0z7VfXJRM9MYPauNqUH72j3M73Oc8MeDoPD2oTT22qanPbyDC2s85eNPoKs+JdIstbgfTb6NmjYiVQpx8w6HPbB9af4k8R2Ogwwm7kJmmO2KGMbnc+w9PeobWe63C/ukG1xwAcEDtxXUnWk1Xk9ej80VCItjYXFnZx2tmkUMSH5QQGYnoT7VVvrSZLxfsrO86YON2cH19K1I7x7xlgt1ZN+d0p42jHYetWY4YrcsIuirljnk0vayjK8t3/WpopOJix3V2ZUeRQBGMFFB4q7FqCOW3s8J2/K2P1xTdNnWfzlbKPE+cE43CnX2paRJqlvpc11Ct867lhzhtv8AkU5WcuXl+4TlHqizpphmhBwsik4JKd/x6VDc2OPMkszslAyUGdrj0p+lKFNyUYKDIdozx6f0qKwEttctHcMxyx8th0JPUVnqpNpkN2ehgm+86DPkkSAnO7GQf5iuI8Y+Om0Wz1O4GnyS+QgSIMSu6QtjJHYD9cV2/iuGLSbSW9VSZDMqlQem44P4Cs++Sx8iFLsWpe54EM/Jl57Z6ivWw7p6Tcbr+mWve0TscDoGj6h4/wBE0LVNQk/s7TZZXURJnsSCy57N/jXqdxoVl4Y0cT6VF8kCf6rIG4Dqfc96kuLi3hsbd0iWOC3ChYoxwijg4Ht6Vuy26app5EkrCFxuBXHHvn0xWGJxc5NN6Qu9PmS04I4Twl4t0nxPFO+lOwZABLE42kc9R6j3rTlUxuGHzHr6jHpXJ+CvC9h4Ynv7i0JWa4lbALA4QHgKPT611JusfcyWbv6fSuitCEaj9l8PmdNGL5bsbdZWeG5CHgDaAe/rjtV7w5Y2c15fXUyt5pHO444+g+lUpZVeFoyyqeuccg0lrduL5S7fK67c4/WspRlKDS0FKk2iS7tbW5jeG5WOSNgQVZeR6de9eOeLvhk8vlpaTi2tEl3CSCMs6BupYDrjA5Fe46Vp6Xs0pLsCmM/41la7Hc6TewMkUk9u5ALL1HOM/hW2FxUqVTkg9TOai9HucB8UbcQeErLStE1A3UrxIkskeVZwAB+GcdK8cuPCnie6SC1hXUHWNckAP8p9OfQYr6stbRr99xgSUrxuKjI980umz6JeXJsoL6GW/tx+/WNywBB5DfhXTRzJ4eHKo3tq/wDg2MnTjHdnyLqeg60mp5nsL4lcbDLCwUL2Ndn4Q8JX+ratNdrAVt1wrSvwcke/pXsniDxboen+Oo/DuZDeSgFFK5TpkDPqQK6S80/7G8KhEjeXL7E6L0wK3qZnPkScbcy09BwhFu9zEtlsNENjZyTQRR7ljjDvtLHvj8a7Ke0WSMdFD/KxB+8D3ri/GPg2bX4XliwZfLAIHGCOhB9aTwRe3mkaKum+IAfMjygKtu246Zz+FeVUh7WCnCV5LdDlJzenQ614mggSONV8vjOOT1/+tXjkfxK1y08dto+sWMRtJLgxeWqYYAnhgep/rXsFvEzX63qSnymBOwdh6YqHUNJsF1GK8MEMk8GGjlaMfLz0BqcPVp0241I8119zIa1JbUxJN5kDqYSyuMNwM9R7VZurW1udWW6a3jllRNqsyAso9QfrXAeKPFun+DLNbnUlf7PcTbFMSbsHOenbiu38PahZ6rp8V9ptxHNBMu6N1z8w649j7VnXozppVNbPS5UtzP8AEPhyC5uIryNmWaIfM0ZxkehHf3r5t/avjCReHAOm+4C8dB8nFfXs0KSBSPlLAEgcZr5U/bGsWtIfC7k/JI9ztHpgR8VzyxDlRcJP+rkqXu2Z8z0UUV55IUUUUAFFFFABRRRQAV6z8B/FsXhm6u4riPdDeTwozA8rgNyPzryau9+G2hz6rBc3EEkSLaXETP5jAcEMQRn3H616OUqMsXFT21/Jid+h9q6dqsd9o0e8fabSRP3fbac/zql/ZemyeIrPU7i2U6nA21Lg/e2kYIPqPY1wfwVubq70S5ileTFu7Kivjk9TXpP2pblYbu3B3R/uZVYYxIByK9WvS+r1JQj5/j/mdMHGcbW1Z0Ol2MLTXzLhFB2qRxg1m6RqkF/B9ptJ0kLSPE75wAy5B/l3rf0aJzpe4hfMlJY5HWuI8DeH5fDx8QQXTJPbNeNMinptfJK/rXmw5ZKo5PVWt59GRzNtncrcxrEwlkHAzknk/wD16zNMnjiikBfy5CWbIB2nPI/GqeuvbafpTahct5aKMCNeiiuW8LeLrvXvC4AhUXCyyxeayYiwG4Yfhj8adLCudNyjtezGloT2fhyNNc1HX7yUXWrvG8Efl/KqBhwAO3bJqHwN4dvvDmi7NXuTd3LS+cXPRW9BmrOjWcehWr6nJw54nuGYlZSe2Dx9MV0dpdW+o2aeQ6SwyoWAbncfT3rrq1ppOKd46fh08gVky14WttMs1upbRVWe6k8y4cnLSPk8n8+1XdTmcgxwMSD8pwP0FUdO0+EwQuiFQRgxrkACrr2cnnH5i0ZHyqGxivMny+0cm7+orRTObsfDIfXmv5ZDLdDGwyDIQew9v60uoa2y+J5NFOSkUaOCq/eHp9a6W1haG4DkqQcjBPIrMS3tF1w35CG5mkCFivRR0reNbnk3PWy09Qe9ylretQeHvs73uDezkmKGPqB0zn8a6OyCXtm0kbECXDHI56dMVzfirwbYa74gttWuryWM2qBTGOnBz61qXGsPbwyRwxAygfKo4JHY/SonGNSEfZ/F18vIi7Y5ruC2Ja4kEbgFRsXuK5iHTtIfxNJrFtaXF5qspG1rh8JEcAAgd6xviF4vm8J2uk3GqW7TT3xZWWEhQqjHc9+a6Pwzr9pewmeW1eyEkYaFXXBOO+O3411qhUpUvapNqV1o/P7yrxZp20V/DfywzTGF5TuBVQyH8anlmvraTdLNFMsXcjFc5cXniG71+3S3sEGnhcFhnDZOScnvmugvfNuNNe0nj8uZ42Qg8dQcEetYTg01zW19A5mzj/GXivTZPElhoswkFxfAPHGY8gbedxPboQKm8Y+A4vFtxpEsWoTWa2h5wu7PuORWXZeHLOWayutQDzXloNyOSTtI6YFbKSXMmr2cLzsmn7mMpHG70Brva9ly+wlZxTKcHZ3M3SNe0bUdd1PTbS4xOrGHyZWwZGXq4FdVBeNZ6PFp63KyiNSrSjgkegzU1voOj3MCailnBFqUSOkd2IwHGeuD3Bpmn3NssLRz26MZOPtAwR+Fc1WpCp8KeltH37jppNWau0eb+HdRjk8bakkY8uEIwwBy7D7zfpXT/C/Xo9c1W/imjRJYG3RAjnZnH51o6Z4YtbO8uJ9Nj3yuSCzkDAJycVs6BYWln5twtvFCScs6IO3bPatMViaU4SSWtkidVDcq+Kry0tYLi6lWGKKJ/LMmRudz2xWRFcRX0AmspFOw5+hrTurC31lrvzIRJaS5DRv/ADPofSsWDT30WOS1sbMtaSHGN5Yqe3XnAqaCio8t/eRvDmTsdD4dn/4mG3nEidAenNay32n6otwlpPFcCP5H8s5KEHpXKMzWtyrRsFMZBBA/i71P4asNP0vX9V1Ox8yKTUtsk1vx5auAcsp9zzj1rGtRi71OttP+D8jKrB35kb2gKbaaWAopRyWWTpnHaqmmeGtH0G61G60u28m4vZAZuS2fUKOw5NGpXf8AZFlqOpwQyXs0UJeOBCcu2Og9OetYHwa8Ta34p03Ub3xFpq6c6T+XAoRkDKB833uTg96zcKjpzrRfu6J67v0MpNORR+LWl6VpkD+MoNPtptW02P8AdOyngk4BI74z+FL4N8Uy+LrC11C+jW2kiVo5FVsh2B6r+B7+ldz4otIdQ0a6trqOOa2fCyRno3PSuKGl2+ieTZaTBtt7ddqqx3Dkkn+ddWGqwq0FCXxLZ9lbYqmrs6dtWt7NC0pLYG4BVyfxrlLzxNoGoPDavewpqUhJSEMCxAPIYjj8K6y0hjSxkMjpIvknzkbHHvivLPCnw+0y3vNQ1SzPmyNK8mXAO3k5C1WFhR96Um00C0loWNW+I2meGvEFvo947iadVaJ2RjGdxwOe2fWvQNM87UGT7QzGAkl0HTgdK5VdCsp5ohqtjbagIMPaTTRgtFjnFdvpEBjhe53r5TAgD+dPFypxinBa9/8AIGmtzy34sXOmx6rpuh6nZwtpOqEB2OQY3VsAqR064/Gu90HR7Xw7pVnp2mIVt4Pubzk4POCfWvP/AIs2kXiG70tw6wtbXHyZX7wJHT8q9U1mzuL/AEuIadOtvcDYwL/dI7g1WIly0aUW7Xvf9H9wneOrLH29p5YGWJ0UY4JGef6V84ftsXCyxeFI1I+Rrk49MiKvoWPTLlYUFxMBcLz5kX3SfSvmH9rhHQeHg+f9Zccn6R15dSnBwbi9v8xWTV0fOdFFFcJIUUUUAFFFFABRRRQAV7t+zjotvrOgeLIrsOYFNuWCnB6SH+leE19A/svmVNK8TyKoMCSWxlPpxJjj6114FtYiLi7MEdXp/ixdC1rT9P0qD7RC1yYLqXyyGWQkLgDvxya9Y026uSt9JII2sbrZNAR1R1BVx+JGc18/+P8AQ7vSjqF9Z3coS6uVmnjiYqwzk5yPc16r8LtXk1HwOkkyb5LJ3j29yB83PvzX1WMoxlTVSPo/z/Mul8dj2vSI5I7WL5y6lQfm7cdBWTrv2uTQ9cuLFEWXynEQPJZlB5/PtW3FODZRzRqCrqGHOOMVg+Kte07wl4Zl1DWpvItCfLZgM/M54wPrXytLmlU0V22tBKXU4ww3viLwjptrqZ23LJE07MNrDAyRgd81leLY5LOTRtD0W3YRyzAskYxvycY9u5JrY8Gy6knhonVnSW7d5AJAB88ZY7GH1XBro5VtbWC2uXRRMkZCueq5HzV7LqeyqWSuruyW1zVu8VFFbxhClzoun6XBtPkupdlPygAEfzNSW0CabptvHH8sa4Tg8jHWuP1n4j6LoiR/L57tJtXYOcev4Vxnin4qyfYLyHTADdsgMAxuTDdz6nHOKulgq84qFtL/AHmfNCB9DeHrkSWkgRy4VyqqTzjtXnejWGuaL408Ta/rmps+mzHybZUkLYTdkYU8AjpXmHhf4jXdmv2DVZ1XUGRT5gPyhjzt44BwRXovjDxPHYeCXubuLfKTGscAPzSuTxt9T9KSwFShUcVqp2Xyv0Ji1LU7Czvo7uzM1rLKHJKlHGGJ+npVqOzae0R5mxIHO457HtTLMTLZ6d50f2We5jVpFYfMhOOD7jNcnH4qvbvxRd6VptlPPBA/ltL2TtuJ6DNccacqjfs9Lf8ADGvPax2bWU7wsgkVlboxPAPYZ79q5SLwJrMOqf2r/aGboSAqoJbj8+ntWrrb6bq2gtpesOyoME4fawZTkNmsPR/GWgeD7L+z0uJBCGJUTOWY+p5PH0q6Ua6g/Zq77W3Xr/wCZt9TpdQsHmcf2jBFMFbIDpwOP4c5xWBqHjPQ9O8V2mkXbtDqUm0xER/KS2cAseM+nFGlfErStVunj+0oYZPuCQ5yP6e1UfF/hHQ/E95aXM4fzLfAjmtpcHGcgH6GtKVLlly4lNK3QqLclaJZ0HR/G+meOraf+2ZNR8O3DObgTSBvK44AHUHOOnFdt4vv7PTtPnu9RlWGC3TeZH4Cj1qGzsZF0qKWzZxMpGH3ZJx6+tcB4ugT4madf+HUvprVoSN8jLkMVb8MjPbNYpfWaqnOyUdG0rfN2I5eXVGrp2qQ6vplrfWZ22tyPMjkZcEjPeszxH440Tw7rtvYax5zSOo+ZFykeehatXQvCkPh3SLeGwleS1ijETpITlioxkehzk4p2paB4Y12cXHiG0heS3jwJWYg7c8BvXB/nXTGdDnbabjrtuaSbcbnQT31tf2kkKTeUZI8IyHHB749P8azLK3Swthz5hUk88r9fx60WeoeHbljbW0odoMjCnBAHAx+lSadCs08vmSSLalRtHfcT39q50uSLWqXmFJpO5eh1K5kjaCExrJKNoIXkeh/CuH8GeOdUn8YX2g6nZneoY/NGU3beo9+Oc10vjK70XwuIJb3WYrB5D8qyk8+4xyKuRarcT2sNw1tC8hQMl35YJaNhwQfcYpwUfZuShdS2vpr+vyLlGNRr2f3E+nzrbytJGjLC7YXceM+la2nXSXUb4j+8TweRnvzXHeLvCEXi7SLSS3v5dO1bTD+4dX+QMcckd8+vWrXgyLW9O0uG31y6ivNRDMxkj6MucAkkDLYrGpTpzpual73b9fMmXvSasKiCK/Ntcn7zFOvU9au6dZ7dRureYNmJAVKn34/SuG+Kt3d6RrHh2/ty2xb1fPU85Q/5NepauAgh1SDb+7A8zj7yH/DrWte8YQafxp/egnNt2GTNLa3USMwEUj48zbt2tjv9fWoovEFrNrD6MrH7WM5V4yARjJ571wOj+FPGcXi+S+1LXIrnS5ZSTD5rPvXJK4TGFxxW3468WXvhLw7HqlnpyXr+cIpVkfAjz6d+cYrJ4WMpKnBqbfZ21+Zg22rnT6oWTS5y8YJSNvnViOaz7C4s1jQNKGkYBzjkk1i6Z4sXxT4PttQjs3tZbvcDG7527Dg/XmrHhOykW3QrC3ntksW42jtzTVB06clU0aZpHa5duNLiIkmuF2My/3uevT6VkvZPY6oVhJht5jlFUfKxPGK6QsXlP2kqqg7TnnFQSTxrFMolzllCseccUU6s1o9QMO7tLqz1WBDsIcHGTjJ9xWlGhjT5ZfvDPlHofpW0baCa3t3A82S34Rs9Sf515bofxJtdb+JFzokFnLAts7ReZKdpZ14Y4/hHpWlNzxEW4r4VqJTTdjZ8V+GF8QXdpNHcm3hs3GYQvMhJ4Ge3NbyXt9bO8csBkiiAUbu/utK9wsmqmOJVO+RXC/7o9fet/UYzPa7srHgfwc4/Gs6lZpRhNXX5BJWshg1m1+zksHWUDO1l5zXyn+1zM88fhx34JkuePwjr6NicIz7D5rE457V84ftavmDw4u3BEtzn34jrGpSjTpSt5BypJnznRRRXmmYUUUUAFFFFABRRRQAV9E/spxXV5pfi6ytDGgm+z73fsB5nA+tfO1fQ/7KFvJLB4meGZonQ24JDYBB39a6MJ/GiHodT8UYlXwuYj+7ulnEa7TyT36dsUz4CaokdzceH5keK4eMzxybsq7d1I7HGMGt3xhpSpAb2WQnaxBI5wD/ABY/rXD/AAJt7S31nU7ydpjeWpMcJ3gIQx6nuemK+y5lPDSj/VxNtNNH014dnnm0x7O6O6eCTahJ5ZM5BP8AKs34q+FYPHHg7+xmkWJ3uEZJCPuMpOSB34zVu5c2V3b3oIQSIpAzjeccioZru2NpLc3sh8xnIij3bRHnvXzUYyVVVqemt/mbOKbutjGuLJNL0GO1SQpFFEsMLN1KqoGf0rzr4neOho+k2tnFF9ommXyyWbjB7kium8ZeKrOKzfzZD5Ece1XK52nPTA7V4/4Vgk1W7uL25uLe5sWYgxuu4Fuw2nocfnXu4Sh7vtKvTUic+iF0rSYPGVpDy9i0I+8CCe/Jz1yaZ468K3cerpcW1rttxCkTKrACMqMbm7YIGc9K7eKzEQARAsndFXbjC54x6dK5Txw95c6pBp5myb2Jkz1XHXnn6V20qsnU93bXcyskjk9P0S11bV4k0+4821iKpM2MbmHOF9c44r6e+H2itNZC51KxikeEgxNMmWj+ma8p+H2g2vhLw1Lf624kLv8AaFjUYJ2jjB/OpPFPxa1bUtPsxaxfY7GR3AMeVLKMDn8658ZGti37OlstLlRtFXZ7HrviKy01JJr6+jWaFsIvmAkf/rry7UviI9r4kTSvC9isjXJ3zc5LMR1FecaVb3njC8miMiBkdXDuOMYPB969J8A+FLbR9chbebjUJGU/aHGFRVByoHvkflULB0cLB8/vO23QbqN7aHFalaeJL2K61S+jura4WQBFyRkZ+Y/gKxrXwnr/AIpUzxEN5fyF5WIOAf1r3XxVcSC3a1+zEgSkI6nIOB+n0rndMubyAMiRiKBxvHGOfYVvTxc+S8Ul/kRY8N8SaJqvh/UJo3EnlRsMSL93NevfBPxLcXNk9rc/vSjjBJ++p6j6jNSanp6a07LMrPG3zyxg88dT9aztK0tfC1qk1n5zmYkq7pztPHFVVqqtS5J7jXuu6PedKluI7WWFJXVTwpHOKfbjT9GjnYR4h3bpW2DOe5z3rE8L3w1TRra5gkV/lCMQ/Q+h96b4yvrvR/DWp3tlbfa54IfMSA5ILdO3JA6474r550nKo6fd+h2aNXKenePNGv5k+w3UmZWZUVkI5XOeD/Oq9hqkGvyajp17aNbJIu1jkHcmfvg9j0rK+F0c3iLw7Lreq6Vb2EsTmJBHFsSXp8yqeR7+tdZpPg3TtE1y7vrfLzXiAs0hyAPSuqr7ChKUPtL56rzK92UFZ6mNpfgO38OXL3mmtLdSzLkyyvlseg7V0UIltncT8OuGPO4j0/CprFUkuLfFxIFjkKvD1HPTr0GRnNSQ/v5pVdhl3KbyN3TpWFStOf8AEdzOKcXYk8S+FvD3jCK0XX1SfyMMNsuwMPRv8K5fxloviS412wuNBuoTp8DBTGrhCiDjGOhGO1cRqvjjxKniWKHT7QxwRyGBrcoHL4OCTnk5/SvbLa6WcpIgDQxQgyY42tx29qc6dfBKLburOy3t/lcwWuqKWjZl1JEjAiZV2yKx+9j1rdvFh+VsETH5VPcVixPFBrsQaRGjz8rr0O7kZNbeoMPMVVPzNxgHkV59fWafkbVHdpnPeMdIs9Yg0+3voi8JYPwcMCvv+NXxfW8HhyVdQuIbdY2NvJJKcA9h+JGMVZurN7qAo4bCKXTOQcnsa8w8daBqPirTkstJkUXaSBzFI2FkABGCfUZ4NdGHhGuownKyT37EtXhdbo9V8O3ENxp1vKrq8mwZYd/xrD1SXT5tRvLLV4YprSY4dG5Xp3Fc58NJr+30ZrLWLSSwuLYtCVORnH3T+Io1GGQypIoJ3J1PI/z1q4YVRrTTfp/wGNRvr3Ni7ihmAh0mFYLGztwkaKMADPYVr6TKFgIiJyVGceuetUdIRV0R5EB86T5WX+VZfhvxTYyz3Nh5gS5EhAGPvYPQUpwlOMoxV+UuVuXlOp1FBgnYS7cY/ve2O9ZqMkcnzKFV+o28D05rgfjN4/1Xwbc6UljBbu9yjSu8q7gFBxtHp712Ph/UG1vw7a6nPbmzkniE0sR6LxzimsNUp0Y1JfDIwUi/p2o/ZzLbzALErYWROQPbNZd5pemv4i/tSzsoBfSReTLcGMb3+p749azH1C2kYLbzoWEm0xq33lx3rfBEBJK7QoGAMHjrVun7N8y3ZoktzPim8q98wkkpwfX061oadrthqDXEEN2hkgbbIgPKelUzENjrI21nfaABz8xFedeDtB1HSPjD4ieSOZ7AI67iCBIGI289K1VGnVjJydnFXXn/AFcdR6pHptoyO1wk5OwE5IHbvXzV+1oizXugXyO22UTRhOwAKEH9a94vtQi0zSby4nBCxAjH446181fHrXo9e0bw/KilWjluFJ7EYjxWOJpONCc1tovyJm1seM0UUV4RkFFFFABRRRQAUV9Y+JdA0x/gvFu0m0tl/wCEMsr6O/m0+FYPtIALKs4xIbhxgBcleh7nPydQAV77+y9cJBB4gBiMkkkluo9AMSZrwKvTfgpp+u32oyHw75gnjni3MucDhuv5Gu/LIKeJjGTstfyYm7ao+h/G001rpkyCJWtwDIZd2No/utn3718/+Ery4g8RRTz3LKgmBzuzn5hXuviLQrqbQtYgvd6S3Ic725GQc/hXg/hnT4LrxRbW4llWLzQCSM5we1fZYLlUXqEttD7G8SRvq2haXDZxsZY7iJyAf4R1Oa8x8e+LDp7i3mH2e1EjYAHznnr+fau78Fa6dTtZIbmyls50LGASHImiGBuBHfpx15ry740Pa/8ACQWVpqds5hulIS4jONmPX15NePgqfLV9lJbXZo/hdjLsILfxPeq322S40wA+aixlW3EdGrpPCHhpE0u5tNMhWNPNMokfj1xmq3gvw5N4d0yGG6KrFdyhzKowCewzW1qd2kn2g2gaIrhPkkwvHGfeu+rO7cIPQxitDC1C6hsbK5+2SeRIhYSNn8MDHr0rF8OKdV1C3T7Hmyi3edcSDlVPI288Djk0fEWT/SLCxjsZmknxtcKVR8H+HPWusXR44/A95plqzx3Nzb+W7IpcpjufXpV6QppveX4eY0rs47xXr8H9tII7hb7SnhCoY2ym3kEfXtWjH4RttQ8OxJb+eEiYyK27lQ3JrkvhzY6bJ4ihs75Xu4YGaXKqQJTxxtPOBXu0t1apbNcW4jELrt8pR0x2Hv7U68/YuMIXuJO7ucppvhuHw9pv2fTVdpCfMeWRsn6ZHt0rWtbmCz1K2vrORpIsANH3Vm4/Wq9vdXq2U9pbwsV3LumIz5QPrWndfYdOjKRRblnCkSIQw8xTng981yzk5O0tWxl7VJFvd6x7mmLKsUG35mkY4H/167V/ClmdKVJdyyrGc+UvGcdgayLKa1lvIJcD7RAp3D+JOnB96u+I9eVbSBkllUrIGxEfvjoQ3tXlVpVZyjCloUed+I9MbSbrzYI3eHqxbqvtXP8AxB8Tvb6KTZbPPJ224PLICOT9etdlo2oCXUL23vYFZZMtGWb5RntzXlfjjQVt/FNreT3UcFvJtUo5wQFOPx49K9jDJSmo1en4kyLvwxuJ/C9i1zq1zIIrk+aLUNg4PO4+hNehaT4rvdT+IraTbWUqaGbVbhp5Vwq4UnOT25Arm5PCkt9qMTrdhrO8uAxlHJEIUZOD044FdZ4x1mxvtNfQ7aRIIp4/s4VPvBR1/OssRKNad+W7kt+3n6lxukbGp3lzC1ktqIm0Z1ZMwfNtbrk47HPWtq2kN5I5Rd8cUQHXAJ6CvPfhTcJoD3uk3d1EbcuPJRnyQOhH16GvUfD7QwzSwgAh2yH/AA4FeZi17G8Ur22ff/gm0Ze4Yd1buk37ggnYRMM8gdiK19TvNKstDW4up4Le3iAG9mC5b0HvVnWDFaXcUibEkKEZI7e/tXm9/pnhjXta+3atcRXMVl/rYYpNyAjnOBzWdJKulKV0l23FKT5bpmwniOMa+lsdPBBXcsxQZZSMg5x05revJIpoo4bND5zn94c8fnXBy+K4daE6aAjPa2kmwybMOR6KfQcV09isjaZE0xHnbRznpmuirQ5LSas+3+YU9dTa0izguFmR418+Fh16e38q07mdEkiSdI98nQ5+Xg9qwdFuDaSB8ny2YCQdaxfinN45sb23u/CNha6hpkce6eB8byc9AMgkY9K5PYurX5HJK+13YdXSXkdp9oYSyF5SSNwC55wfSuYcvp18JVY7lx/9etezuHEkIntkjaSNJB3Ckj5hn1FV9TtFWYFWGxuDuOcH6f1oo2hJxezLppXs+ompXi3N0GK4/ckZX+I9c1xWs/ELSNL1KDRLyK5HlkIly+AoY9c98e9dHygMb/dAIGKnPgnw94qMF/qunLJMnG5WKhgP7wFdMHRoq9VNx8u5NVOKXKLHKyxW0LEBpn3sU5AXtj1rjbLQ7bT/ABiwZpI3kmO1CMgsOQwPpzXoOqQLJfPHAoQWsQ2YHC/3cVh6gL19ZtbyWziazRQyyx9UX+LP4/zqqFXR20uv+GE3ezN29sbTULSE6pZQ3O1co00YkVPzHFU9T1CysdPeGaW1WSVGiiUsBvZhgcfj29K2o2aFNsBDx8EBj2615f448Aw+OPGOmai149nDZOHkiUckhgeD26da58Oozlao7RWplq9jD8J+Er631651W+eIO4C7UORkcZA7DivTIFJsiF9duD1+tct8Tp9S8OXVpc6bb3E9uWbcsalsE8/MB2PrXMTfESTTvFlpp82mzx2swTzJpCQVL9MD0GcV6bhUxcVUj/ViotRR6hE5gwJU+ZCCWJ9+taGmTLdao3m48tVwGNYaXSzTDzQWj5IA71U8La1Bqgu/smQIZDHk9SRkfzrjnRbi3/WprJL5nOfFZJP+EXu47PmacsUXqS27gV88/FPTbiy8DeFZb62NtczT3W6M9cDy+T6V9bz26vIFdQSsfQ88+tfP/wC1cY/7N8LqBtkElzuXGB0jwRTxdd/VHSXe5nNbs+dKKKK+eMgooooAKKKKACiiigAr3b9mnW/7AsfEt6xyiCJtij5iQHxivCa9r/Z10i51W3177KQBG0O8nsCHrswCi68VPbX8hrc9N0DxRd+J9Knj8SXEmy9uwI9gC+VGeDz3H+FQXnwm1vRfiHDfaH5J0G2ZZUfzBu29wynkn36Va1PQLIX9nHJePbso+ZQuQ/8AhXpumyNrFuIQ8iuoEYQEnp0LH04r6ivVdF89LSLvdW0Dl1sal/bWAu0vIoFjuUjK7l4XJxzj1xxmvDfidpnjC9tL29tLAPYx6ootmAWR/LKhSVHJA3dfrXt2rwGOCQIei4z6nFHg/wAPyx6Kzag80bXWT5XZOeD7GvNoYhYaHtb32Wv6HVKjFUrt6nmEVxe6drk2havcwTQW8qiJVxuXKbsEDnjpk1laLrFve+PE0O2twY5Gbz3dfmUqMkD06V2eo/BfTW1z/hIbbVNQguxL57qZBhmB4O7BIzWXN8ONQ0u9udZ0q6gvNXleSR4pRhcsc5T+WDXfTxOGmtJatW2tqcipy2Ry3hrQ9ZvvFupDxLHct5MheNnyUVg2QVPTBXjjsa2fiJqd9YarpS6b+5RkKvtO0M24YJP+eteteFrWW68CudSH+lsHZ2dNrAjtj9K8J+LE2lTRLbmYxTxbWTYxYEk8jA+vWqw1b61XcWvh0027XBpKLsXdL0WK38SyapZxOHfOIgcLuPUj8e1d5pNwj6ZPp7abNJeEMzCQKQ2Tw2e1cr4dgurfwzbyNNHJahlAKghwRXVfb4bvVhJHczWUvlAFyuMjuCMGlXTnpvb9BLXUr20iabazLHOsF8hCywsvyuO2ffBNVddjmsms7KT7K1pC4fcBhgGz29K1dADXX22za4RoCzHzJF/eSZ6nn/PFSJpNhaXklvqTfaRsxGZMZ2d/xFY8yjN33C1zDM507UJYhK88U6K+8tnJ6EZ9K3L54r3RmW0IIClg2fu/WsK6trKwW7lecRpAGaNmbOUPQfX2rzjxXr2ow20Umj3rC2OfMwME56V1U8O60lZg9D1uwhtru23XsRDInzsTtYevI7968dvm/wCE98YwWFlJOtjZlgJWHyMM8uT2yBVn4barrfiHUJNPmmle0kwXJ42+oz6Edq7nxJc6J4FgWxsYULXp2uYhz6Ek+g/rWsYSw9VwWsnt5eYRSau9kafxB1qXwt4Fs00u2E8RxB9objn6dcHFcDovkaze2WqPMEk2bJI1zhWz/Kum1Lwrb7NYAvbi6bVY4zHayZKRMuCHB7fTtmue0rw7f6Y6WMcfmbeZJFB4yev0qKMYRptRet99r3/qwpXb8ite2eqaJq008gZ7VpMpLnOBknB9Otet+EvEsd1ZoIXNxNgbyB0OK4jx1omqavon/EtYsFILKBjcMY61x0Lap4cstO0+3aWO7upWlldODgYCp+uaqdCOKp6tXGm4O59E/azdmd7lTLlNirnoK4jTPD+k+GJ7zULq+jt4pJvlMnAAbsT3PauxsIGWKN5QWkZF8wDghsc1w/xO8Mal4oFhY2CotqkhkldjyD0Ax6YzXl4Xl5/Z83LF7/I65QvHmSLXibTJ9e0NovCmqR2Er/NBcQfKh9QSOxrH8M2HiTw74Pub/wARal/aF0k26OKB/NZUAxgn3PPtXovhnT7LQ9GtdPdAriIKiqMg+p9smp2jihuEE9rHJbEDcq8FjR9bavTSvG/ld/MmVPqtzzD4YeKte8Q3t/bSWRe3RTIkgGBHhumfp0+le02WotJp7JJgSrxknAI7Gst9b0fwratNfTW1hZXEmyFpgIizkfdI706V0liUo6MuRtOeDnv9K5cVJYiXMocsen6ihC65W9ixqt7HPbsISGmiO7YDjnOMGsyVrl2kM8fl4/hHp65o1a0KxRf8992Nx4JHofaoUkaaN4jK2AhIG7jPelThGMVymkYOLuQmZOIxlmY4FaWk3FzZOwtypgkBIDdCR1x6VShtUzDucCVslUDfMQO+PSrFtayyFYVkO0biN3QZ64/KrqcjTXQuS5m0ZR8S6YniZtJm1GIau6h3tgxDOOox2J9q1kmVbZ7QSPiQgKp6LzXJeI/hdB4i8W6dql/busaL5jXME3lyoynKgcc111zZTSyfaLcophJILdT3wac3RfLyPpr6mMU3e5oQ20luxiTMu7kbRgA98VHbrD59xIzSrMeFQLgHFc74Z8X3+r6xNbQaOVt4s+fN56kAjpiuvtozJApaPl8lsHkE/wD165qsZ0m1U3+RnvqjLvJrqR/OUqR3HoKq3mi2F5EpvYluJYG/duR+OPf6Vt3pSCZ1eNi2MKxHX1rnTHrEU1s1lAspJ3OSM7BnoAf51dJuS912Ks7XLunaWZYpHUIJE+6WGMY56VW8B6Jb6dZXEsabjJcO7sP4mJ7j0rqEUx2E8kfybvTkdOteM+M9I8bnUdOvPCFxPNa7gZbaKTZskJ6kHqCMZrShfE80HNRXmTJyabPQtRH/ABNLllXBR8ccYGK+bP2s7i3efw9DEQsyCYtHnkKdmD+PNfRsEeoy6Yl1qsIguycThfmCsBg8ivnH9q3SY7dfDuqbSJ7kzwsx6sqbNv8A6Eeazr8qoSTfZfkOSdj58ooorxjIKKKKACiiigAooooAK1dF8Q6xoazDRtUvLATY8wW8zR78ZxnB56n86KKabWqAst4w8RvKJX13UmkHRjcMT/OrVv8AEDxfbZ+z+JtYizwdl24/rRRVOpN6NsBzfEPxi33vFGsnnPN4/wDjU3/CzvHO3b/wl2u7fT7dJ/jRRUtt7sbbYh+JfjdlKnxbrhUjBBvZOR+dMHxI8aggjxVrYIGAftkn+NFFF2Ih/wCE+8Xbpj/wk2sgzEGTF5J859TzzWVca1qlzIZLjULqRzj5nlJNFFXGtUj8MmvmBdh8YeI4Ikjh13UkjRtyqtwwAPrjNWR4+8WiaSUeJNW81/vP9qfLfU5oopOrN7tgRy+OfFUrlpPEOqs55JN0+f50yXxp4mlIMuv6o5HTdcuf60UU/azX2mBHceLfENwHE+t6jIHGGDXDHI9+arJr2rISU1K7BPXEpoop+3qLaT+8C9b+NPE1sALbXtThA6eXcMv8jVa48T65czrPcavfyzKCFd52JHOeuaKKSrVFrzP7wLSeN/FCABPEOqrjgYun/wAacPHXiobseItWG7r/AKU/P60UUe1n3YDk8feLVj8tfEurhMY2i7fGPzqpL4s8QTPE8utag7RHchadiVPqOaKKFVmtpP7wNBPiJ4yT7ninWl+l4/8AjSr8R/GikFfFWtgjpi8k4/Wiip5n3HdjT8RPGTNuPijWS3qbx/8AGl/4WL4z3hv+Ep1rcOh+2ScfrRRRzPuF2UdZ8XeIdbhSLWNb1G+iRt6rcXDOFb1AJ61Yt/Hfiy2t0gt/EerxwxgKiLduAoHQAZooqvaTty3dhXsTSfEXxnJ/rPFOtN9byQ/1qtb+NvFFu5eDxDqsbMMErdOCf1oopKpJKyY7sjfxf4je9F42u6mboYxMbl9wx05zV0fEXxmCCPFOtAjpi8k/xooodSb3YXZKfib45KlT4u10g9vt0n+NRH4i+MypX/hKdaweo+2Sf40UVKbWwXZX0/xx4p04OLDxDqtsHOW8q6dd31watr8SvG6/d8Wa4OMcXsn+NFFNzlLVsQSfEvxvKAJPFmuOB0BvZD/WkX4j+NU+74r1sfS9k/xoopXY7gPiT42CFB4r1zaeo+2yYP60sXxJ8bRDEXivW07fLeyD+tFFF2FxrfEbxoyMjeKtbKs25gb2TBPr1rL13xNrniBIE1zVr7UEgJMS3M7SBM4zjJ4zgflRRRdsRj0UUUgCiiigD//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    At low power (upper panel), the lamina propria of the surface/foveolar zone is expanded by a cellular infiltrate. The epithelium is normal. At high power (lower panel), the infiltrate consists of cells with small central benign nuclei and copious faintly basophilic cytoplasm. On immunostaining, these cells are CD68-positive, thus defining them as macrophages. The cytoplasm contains phagocytized lipid material. The appearance is typical of a gastric xanthoma. Similar endoscopic findings are seen in granular cell tumors and muciphages. Gastric xanthomas are sessile, yellow nodules, usually diminutive (&lt;5 mm) in size, confined to the mucosa. This represents accumulation of lipid in macrophages. Gastric xanthomas have no malignant potential.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Heather Crowley, MD and Donald Antonioli, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_11_36022=[""].join("\n");
var outline_f35_11_36022=null;
var title_f35_11_36023="Classification and clinical features of diabetic retinopathy";
var content_f35_11_36023=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Classification and clinical features of diabetic retinopathy",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/11/36023/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/11/36023/contributors\">",
"     Claire E Fraser, MD, PhD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/11/36023/contributors\">",
"     Donald J D'Amico, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/11/36023/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/11/36023/contributors\">",
"     David M Nathan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/11/36023/contributors\">",
"     Jonathan Trobe, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/11/36023/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/11/36023/contributors\">",
"     Jean E Mulder, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/11/36023/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 18, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic retinopathy (DR) is one of the most important causes of visual loss worldwide, and is the principal cause of impaired vision in patients between 25 and 74 years of age. Visual loss from diabetic retinopathy may be secondary to macular edema (retinal thickening and edema involving the macula), hemorrhage from new vessels, retinal detachment, or neovascular glaucoma.",
"   </p>",
"   <p>",
"    The vast majority of patients who develop diabetic retinopathy have no symptoms until the very late stages (by which time it may be too late for effective treatment). Because the rate of progression may be rapid, and therapy can be beneficial for both symptom amelioration and reduction in the rate of disease progression, it is important to screen patients with diabetes regularly for the development of retinal disease.",
"   </p>",
"   <p>",
"    The classification, clinical features, and natural history of diabetic retinopathy will be reviewed here. The pathogenesis, screening, and treatment of diabetic retinopathy are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/45/30422?source=see_link\">",
"     \"Pathogenesis of diabetic retinopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42501?source=see_link\">",
"     \"Screening for diabetic retinopathy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/38/32362?source=see_link\">",
"     \"Prevention and treatment of diabetic retinopathy\"",
"    </a>",
"    .) Cataracts associated with diabetes are also a major cause of visual impairment, especially in type 2 diabetes. Cataracts are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?2/19/2362?source=see_link\">",
"     \"Cataract in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diabetic retinopathy (DR) is divided into two major forms: nonproliferative and proliferative, named for the absence or presence of abnormal new blood vessels emanating from the retina. DR can be further classified by severity (",
"    <a class=\"graphic graphic_table graphicRef50486 \" href=\"mobipreview.htm?38/22/39276\">",
"     table 1",
"    </a>",
"    ). These stratifications have been useful for analysis of treatment efficacy in the literature and general indicators for treatment strategies. However, each patient with diabetic retinopathy has a unique combination of findings, symptoms, and rate of progression, which necessarily requires an individualized approach to treatment in the effort to preserve vision.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Nonproliferative retinopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nonproliferative retinopathy (NPDR) consists of a variable display of nerve-fiber layer infarcts (cotton wool spots), intraretinal hemorrhages, and hard exudates, and microvascular abnormalities (including microaneurysms, occluded vessels, and dilated or tortuous vessels) primarily in the macula and posterior retina (",
"    <a class=\"graphic graphic_picture graphicRef56138 \" href=\"mobipreview.htm?5/16/5376\">",
"     picture 1",
"    </a>",
"    ). Visual loss in nonproliferative retinopathy is primarily through the development of macular edema (ME). (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Macular edema'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    NPDR can be further classified into mild, moderate, severe and very severe categories (",
"    <a class=\"graphic graphic_table graphicRef50486 \" href=\"mobipreview.htm?38/22/39276\">",
"     table 1",
"    </a>",
"    ). This stratification primarily impacts the risk of progression to proliferative retinopathy, which influences follow-up intervals and treatment strategies. Whereas the one-year risks of progression to proliferative retinopathy for mild and moderate nonproliferative retinopathy are 5 and 15 percent, respectively, the severe and very severe categories have respective one-year risks of 52 and 75 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36023/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Proliferative retinopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Proliferative diabetic retinopathy (PDR) is marked by the presence of neovascularization arising from the disc",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    retinal vessels (",
"    <a class=\"graphic graphic_picture graphicRef56334 \" href=\"mobipreview.htm?17/3/17456\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef70167 \" href=\"mobipreview.htm?43/19/44336\">",
"     picture 3",
"    </a>",
"    ) and the consequences of this neovascularization, including preretinal and vitreous hemorrhage (",
"    <a class=\"graphic graphic_picture graphicRef74536 \" href=\"mobipreview.htm?27/51/28479\">",
"     picture 4",
"    </a>",
"    ), subsequent fibrosis, and traction retinal detachment (",
"    <a class=\"graphic graphic_picture graphicRef82420 \" href=\"mobipreview.htm?3/14/3296\">",
"     picture 5",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef59002 \" href=\"mobipreview.htm?20/47/21232\">",
"     picture 6",
"    </a>",
"    ). PDR may develop in the setting of prior or coexisting severe nonproliferative changes, or may arise without substantial nonproliferative retinopathy.",
"   </p>",
"   <p>",
"    Visual loss in PDR may occur acutely if bleeding from the abnormal vessels into the vitreous blocks the light path to the retina; however, the blood is often reabsorbed and vision clears spontaneously. More permanent loss of vision may occur through retinal detachment, ischemia of the macula, or combinations of these factors.",
"   </p>",
"   <p>",
"    The severity of proliferative retinopathy can be classified as early, high risk, and severe (",
"    <a class=\"graphic graphic_table graphicRef50486 \" href=\"mobipreview.htm?38/22/39276\">",
"     table 1",
"    </a>",
"    ). In early PDR, new vessels are present as fine loops or networks, but they do not meet the criteria for the high risk category. There is a 75 percent five-year risk of progression from early to high risk stages.",
"   </p>",
"   <p>",
"    High risk PDR is defined by moderate to severe neovascularization of the optic disc (greater than",
"    <span class=\"nowrap\">",
"     1/3",
"    </span>",
"    to",
"    <span class=\"nowrap\">",
"     1/2",
"    </span>",
"    disc area), any neovascularization of the optic disc if vitreous or preretinal hemorrhage is present, or moderate to severe neovascularization elsewhere on the retina (at least",
"    <span class=\"nowrap\">",
"     1/2",
"    </span>",
"    disc area) if vitreous or preretinal hemorrhage is present (",
"    <a class=\"graphic graphic_table graphicRef50486 \" href=\"mobipreview.htm?38/22/39276\">",
"     table 1",
"    </a>",
"    ). Untreated high risk proliferative retinopathy results in a 60 percent risk of severe vision loss at five years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36023/abstract/1\">",
"     1",
"    </a>",
"    ]. Macular edema can be present with any degree of proliferative retinopathy and should be addressed as part of the overall treatment strategy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Macular edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Macular edema (ME) can occur at any stage of diabetic retinopathy. It is defined as retinal thickening and edema involving the macula, and it may be visualized by specialized fundus exam with stereoscopic viewing,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    angiography, and most directly by optical coherence tomography (OCT; a non-invasive low energy laser imaging technology) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef88023 \" href=\"mobipreview.htm?29/33/30224\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Clinically significant macular edema (CSME) is defined as retinal thickening within 500 microns of the fovea, hard exudates within 500 microns of the fovea if associated with adjacent retinal thickening, or one or more areas of retinal thickening at least 1500 microns in diameter that is within one disc diameter (1500 microns) of the fovea (",
"    <a class=\"graphic graphic_table graphicRef50486 \" href=\"mobipreview.htm?38/22/39276\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The ophthalmologic features of macular edema are discussed in more detail below. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Retinal thickening and edema'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The vast majority of patients who develop diabetic retinopathy have no symptoms until the very late stages (by which time it may be too late for effective treatment). Because the rate of progression may be rapid, and therapy can be beneficial for both symptom amelioration and reduction in the rate of disease progression, it is important to screen patients with diabetes regularly for the development of retinal disease (",
"    <a class=\"graphic graphic_table graphicRef61833 \" href=\"mobipreview.htm?17/18/17707\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42501?source=see_link\">",
"     \"Screening for diabetic retinopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Patients may have some symptoms depending upon the type of eye problem (eg, a curtain falling with a vitreous bleed, floaters during the resolution of vitreous bleeds, and decreased visual acuity that cannot be corrected with refraction in the setting of macular edema).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Ophthalmologic features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The development of clinical DR is complex and is the result of many interrelated factors, which cause two basic changes within the retinal vessels, namely: abnormal permeability and vascular occlusion with ischemia and subsequent neovascularization. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/45/30422?source=see_link\">",
"     \"Pathogenesis of diabetic retinopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The retina is one of the most metabolically active organs in the body and is particularly susceptible to substrate imbalance or ischemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36023/abstract/2\">",
"     2",
"    </a>",
"    ]. Retinal pericytes and microvascular endothelial cells are lost at a very early stage of diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36023/abstract/3\">",
"     3",
"    </a>",
"    ]. Thickening of the retinal basement membrane is another early change in DR, a finding similar to that seen in glomeruli.",
"   </p>",
"   <p>",
"    Death of retinal pericytes and microvascular cells and impairment of basement membrane function are associated with the formation of retinal capillary microaneurysms and excessive vascular permeability. Microaneurysms (hypercellular outpouchings of retinal capillaries with weakened walls owing in part to pericyte loss) and the leakage of lipid and proteinaceous material (\"hard\" exudates) are the initial clinical signs of diabetic retinopathy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Neovascularization",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial stage of cell death and increased capillary permeability may be followed by cycles of renewal and further cell death, leading to progressive microvascular obliteration, and ischemic injury with the subsequent release of vasoproliferative factors (such as vascular endothelial growth factor (VEGF), erythropoietin, and many others) in the ischemic retinal area [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36023/abstract/3\">",
"     3",
"    </a>",
"    ]. These diffusible factors incite the development of new vessels (neovascularization) from the adjacent retinal vessels, in an abortive attempt to revascularize the diseased tissue. This process is associated with the following clinical changes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The intraluminal proliferation of cells, as well as changes in platelet function, erythrocyte aggregation, and high plasma fibrinogen concentrations, results in vascular occlusion and rupture. This can cause small flame-shaped and blot hemorrhages proximal to the occlusion (",
"      <a class=\"graphic graphic_picture graphicRef75988 \" href=\"mobipreview.htm?13/20/13647\">",
"       picture 7",
"      </a>",
"      ) and intraretinal infarcts (\"cotton wool\" or \"soft exudates\") distal to the occlusion (",
"      <a class=\"graphic graphic_picture graphicRef67621 \" href=\"mobipreview.htm?13/42/13999\">",
"       picture 8",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Proliferation of the endothelial cells of retinal veins results in marked changes in the caliber of the veins, with formation of tortuous loops (",
"      <a class=\"graphic graphic_picture graphicRef82311 \" href=\"mobipreview.htm?38/30/39407\">",
"       picture 9",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      More severe ischemia results in vasoproliferation, with formation of new vessels (neovascularization or proliferative diabetic retinopathy) (",
"      <a class=\"graphic graphic_picture graphicRef70167 \" href=\"mobipreview.htm?43/19/44336\">",
"       picture 3",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/11/36023/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although PDR can be diagnosed by fundus examination,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    angiography (a photographic study in which the transit of intravenously-injected fluorescein dye is recorded by photography with a special camera) is useful to document capillary nonperfusion and leakage from new blood vessels (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef80102 \" href=\"mobipreview.htm?42/38/43617\">",
"     image 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    New vessels are categorized by four variables: presence, location, severity, and associated hemorrhagic activity. In PDR, the vessels initially grow along the plane of the retina, under the posterior hyaloid or outermost layer of the vitreous body, but as the vitreous gradually pulls away and detaches from the retina, the new vessels grow out from the retina plane and into the vitreous cavity.",
"   </p>",
"   <p>",
"    The consequences of neovascularization are extremely severe, because the fragile new vessels invariably rupture with the development of intraocular (usually vitreous) hemorrhage (",
"    <a class=\"graphic graphic_picture graphicRef74536 \" href=\"mobipreview.htm?27/51/28479\">",
"     picture 4",
"    </a>",
"    ). Alternatively, they can create a fibrovascular overgrowth of the retina that can cause distortion of the retina and retinal detachment, especially if forward growing vessels have attached to the posterior pole of the vitreous body and pull the retina anteriorly when they contract (",
"    <a class=\"graphic graphic_picture graphicRef71858 \" href=\"mobipreview.htm?39/54/40800\">",
"     picture 10",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef50023 \" href=\"mobipreview.htm?42/30/43503\">",
"     picture 11",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    New vessel proliferation can also occur on the surface of the iris (rubeosis) and in the anterior chamber. The latter change can block the outflow path for aqueous humor in the eye, leading to acute glaucoma.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Retinal thickening and edema",
"    </span>",
"    &nbsp;&mdash;&nbsp;Capillary leakage is associated with retinal thickening and edema. If treatment is not initiated, loss of visual acuity can ensue if this occurs near the macula (macular edema) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36023/abstract/4\">",
"     4",
"    </a>",
"    ]. Macular edema can develop at all stages of retinopathy. It typically presents with the gradual onset of blurring of near and distant vision in patients who have other evidence of microvascular eye disease, such as peri-macular microaneurysms.",
"   </p>",
"   <p>",
"    The yellow exudates typically seen in association with macular edema in diabetic retinopathy represent a residuum of more copious leakage that has been principally reabsorbed leaving behind the least soluble lipid components. This \"circinate\" exudate (",
"    <a class=\"graphic graphic_picture graphicRef79466 \" href=\"mobipreview.htm?9/19/9520\">",
"     picture 12",
"    </a>",
"    ) has an arc-like appearance because of demarcation of areas of damaged retinal vessels from those adjacent more normal areas that are capable of reabsorbing the edema.",
"   </p>",
"   <p>",
"    In advanced ME, widespread or diffuse leakage is present, and the macula becomes generally thickened and even cystic without the presence of visible yellow exudates, given that no normal vessels remain to resorb the leaked fluid. Patients with diffuse or cystoid edema will typically have the most profound visual decrease, yet the fundus exam may appear unremarkable unless specialized techniques (",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?28/27/29108?source=see_link\">",
"     fluorescein",
"    </a>",
"    angiography and optical coherence tomography) are used (",
"    <a class=\"graphic graphic_picture graphicRef57041 \" href=\"mobipreview.htm?20/30/20960\">",
"     picture 13",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef88023 \" href=\"mobipreview.htm?29/33/30224\">",
"     image 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     NATURAL HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Wisconsin Epidemiologic Study of Diabetic Retinopathy is one of the most comprehensive studies documenting the natural history of retinal disease in diabetic patients. Ninety-nine percent of clinicians in an 11-county area of southern Wisconsin participated in a series of studies involving over 10,000 diabetic patients starting in the early 1980s [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36023/abstract/4\">",
"     4",
"    </a>",
"    ]. The following data, largely representing retinopathy incidence and prevalence prior to \"tight\" blood glucose management, were noted:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The prevalence of retinopathy increased progressively in patients with both type 1 and type 2 diabetes with increasing duration of disease.",
"     </li>",
"     <li>",
"      DR began to occur in patients with type 1 diabetes three to five years after diagnosis and almost all patients were affected at 15 to 20 years (",
"      <a class=\"graphic graphic_figure graphicRef70042 \" href=\"mobipreview.htm?24/45/25309\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The incidence of DR in patients with type 2 diabetes was 50 to 80 percent at 20 years. Some had retinopathy at the time of diagnosis; extrapolating backward suggested that their retinopathy began four to seven years before the clinical diagnosis of diabetes (",
"      <a class=\"graphic graphic_figure graphicRef58736 \" href=\"mobipreview.htm?2/16/2318\">",
"       figure 2",
"      </a>",
"      ). This observation is primarily a reflection of the typically insidious onset of hyperglycemia and delayed diagnosis of type 2 diabetes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These older studies included patients treated predominantly with conventional therapy. The DCCT found that glycemic control is a major determinant of the rate of development and progression of diabetic retinopathy in patients with type 1 diabetes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36023/abstract/5\">",
"     5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/34/11817?source=see_link&amp;anchor=H4#H4\">",
"     \"Glycemic control and vascular complications in type 1 diabetes mellitus\", section on 'Retinopathy'",
"    </a>",
"    .) The United Kingdom study indicated that glycemic control is important for preventing retinopathy in patients with type 2 diabetes as well [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36023/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of DR has significantly decreased as intensive insulin therapy for the management of type 1 diabetes has become more widespread [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36023/abstract/7\">",
"     7",
"    </a>",
"    ]. Prevalence rates for retinopathy at 8 to 10 years duration of type 1 diabetes vary between 32 and 59 percent in reports from Finland, Sweden, and a follow-up cohort from Wisconsin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36023/abstract/8\">",
"     8",
"    </a>",
"    ]. The severity of DR has decreased as well, with only 18 percent of retinopathy patients found to have vision-threatening levels of retinopathy at 20 years follow-up, compared with 43 percent at 20 years in the earlier Wisconsin study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36023/abstract/9\">",
"     9",
"    </a>",
"    ]. Similarly, in studies from the US and UK, rates of diabetic retinopathy and the proportion of patients with type 2 diabetes requiring laser therapy have decreased over a six-year interval [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36023/abstract/10,11\">",
"     10,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to the degree of glycemic control, the incidence of severe visual loss is influenced by other forms of therapy including photocoagulation and control of hypertension [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36023/abstract/12\">",
"     12",
"    </a>",
"    ]. These issues are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/38/32362?source=see_link\">",
"     \"Prevention and treatment of diabetic retinopathy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Transient worsening with intensive insulin therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Another observation from DCCT and other trials is that intensive insulin therapy is often associated with worsening of retinopathy during the first year (",
"    <a class=\"graphic graphic_figure graphicRef61305 \" href=\"mobipreview.htm?28/32/29197\">",
"     figure 3",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36023/abstract/5,13\">",
"     5,13",
"    </a>",
"    ]. The deterioration is associated with an increased number of soft exudates (due to retinal infarcts in the superficial layers) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36023/abstract/13\">",
"     13",
"    </a>",
"    ]. This probably represents the closure of small retinal blood vessels that were narrowed but patent. Correction of hyperglycemia lowers the plasma volume which can put marginal vessels at risk. As noted above, increased IGF-1 levels also may contribute to the exacerbation of the retinopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36023/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Worsening during pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of pregnancy on the natural history of diabetic retinopathy has been addressed in several studies; progression has been observed in 16 to 85 percent of patients, and the rate of progression may be accelerated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36023/abstract/15-19\">",
"     15-19",
"    </a>",
"    ]. In a report from the DCCT, as an example, the likelihood of worsening retinopathy was significantly greater during pregnancy and in the first year postpartum in the 180 women who became pregnant during the course of the study, compared with 500 women who did not become pregnant [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36023/abstract/19\">",
"     19",
"    </a>",
"    ]. The risk was higher in women who were receiving conventional therapy before pregnancy than in those receiving intensive therapy (odds ratio 2.5 versus 1.6), even though the conventional therapy group women were advised to initiate intensive therapy when planning for pregnancy.",
"   </p>",
"   <p>",
"    A substantial number of pregnant women had a greater than three-step progression in retinopathy, including a small number who required laser photocoagulation during pregnancy. Despite these short-term risks, however, the long-term risk of progression (over an average of 6.5 years of follow-up) was not different among the women who did or did not become pregnant.",
"   </p>",
"   <p>",
"    The Diabetes in Early Pregnancy (DIEP) study found that the likelihood of progression is related in part to the severity of retinal involvement before pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36023/abstract/18\">",
"     18",
"    </a>",
"    ]. Among 140 women who did not have proliferative retinopathy at the time of conception, retinopathy appeared in 10 percent of those who had no baseline retinopathy, and it worsened in 21 percent of those with mild background retinopathy and 55 percent of those with severe nonproliferative retinopathy.",
"   </p>",
"   <p>",
"    The importance of glycemic control as a contributing factor was also confirmed in the DIEP study [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36023/abstract/18\">",
"     18",
"    </a>",
"    ]. The risk for progression of DR during pregnancy was increased in those with the highest initial A1C values and in those with the greatest reduction in A1C values. The rate of worsening retinopathy was significantly higher than that during the first two years on intensive therapy in the DCCT, suggesting that factors other than improved glycemic control contribute to the acceleration of retinopathy in pregnant women.",
"   </p>",
"   <p>",
"    Retinal blood flow may also be important. In one study retinal venous diameter and retinal volumetric blood flow decreased during the third trimester of pregnancy significantly more in diabetic than nondiabetic mothers [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36023/abstract/20\">",
"     20",
"    </a>",
"    ]. This lower retinal blood flow may exacerbate retinal ischemia and hypoxia, thereby causing progression of retinopathy. Changes in hormones, growth factors, and systemic hemodynamics (such as a fall in systemic blood pressure) during pregnancy also play a contributory role. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/32/24072?source=see_link\">",
"     \"Renal and urinary tract physiology in normal pregnancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Regardless of the mechanism, the modest increase in risk of worsening DR during pregnancy is sufficient to recommend counseling on the risk of development",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    progression of retinopathy and more frequent retinal evaluations during pregnancy and for one year postpartum (",
"    <a class=\"graphic graphic_table graphicRef61833 \" href=\"mobipreview.htm?17/18/17707\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36023/abstract/19\">",
"     19",
"    </a>",
"    ]. However, women can be reassured that over time their long-term risk of retinopathy progression is not altered by pregnancy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36023/abstract/19\">",
"     19",
"    </a>",
"    ]. In addition, women who develop gestational diabetes should be reassured that they are not at increased risk for developing DR.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Morbidity and mortality",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence of DR appears to be a marker of excess morbidity and mortality risk (primarily cardiovascular) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36023/abstract/21-26\">",
"     21-26",
"    </a>",
"    ], as illustrated by a prospective study of 2013 patients with type 2 diabetes, free of known cardiovascular disease at baseline [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36023/abstract/25\">",
"     25",
"    </a>",
"    ]. Patients with NPDR or PDR had a greater risk of incident CVD events, including MI, stroke, revascularization, and CVD death, compared with those without retinopathy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36023/abstract/25\">",
"     25",
"    </a>",
"    ]. Although the presence of other cardiovascular risk factors may explain the association, the risk of CVD events remained twofold higher in individuals with PDR, but not in those with NPDR, after adjustment for hypertension and nephropathy.",
"   </p>",
"   <p>",
"    The topic of diabetes mellitus and cardiovascular disease is discussed in detail elsewhere (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?26/37/27226?source=see_link\">",
"     \"Prevalence of and risk factors for coronary heart disease in diabetes mellitus\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Diabetic retinopathy (DR) is divided into two major forms: nonproliferative and proliferative, named for the absence or presence of abnormal new blood vessels emanating from the retina. DR can be further classified by severity (",
"      <a class=\"graphic graphic_table graphicRef50486 \" href=\"mobipreview.htm?38/22/39276\">",
"       table 1",
"      </a>",
"      ). Macular edema (retinal thickening and edema involving the macula) can occur at any stage of diabetic retinopathy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Classification'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      These stratifications have been useful for analysis of treatment efficacy in the literature and general indicators for treatment strategies. However, each patient with diabetic retinopathy has a unique combination of findings, symptoms, and rate of progression, which necessarily requires an individualized approach to treatment in the effort to preserve vision.",
"     </li>",
"     <li>",
"      The development of clinical DR is complex and is the result of many interrelated factors, which cause two basic changes within the retinal vessels, namely abnormal permeability and vascular occlusion with ischemia and subsequent neovascularization. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Ophthalmologic features'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The prevalence of DR increases progressively in patients with both type 1 and type 2 diabetes with increasing duration of disease. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Some patients with type 2 diabetes have retinopathy at the time of diagnosis; this observation is a reflection of the typically insidious onset of hyperglycemia in type 2 diabetes many years before the diagnosis is established. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Natural history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Because the majority of patients who develop diabetic retinopathy have no symptoms and the rate of progression may be rapid, it is important to screen patients with diabetes regularly for the development of retinal disease (",
"      <a class=\"graphic graphic_table graphicRef61833 \" href=\"mobipreview.htm?17/18/17707\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42501?source=see_link\">",
"       \"Screening for diabetic retinopathy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Data from the DCCT and other trials suggests that intensive insulin therapy may be associated with worsening of DR during the first year (",
"      <a class=\"graphic graphic_figure graphicRef61305 \" href=\"mobipreview.htm?28/32/29197\">",
"       figure 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Transient worsening with intensive insulin therapy'",
"      </a>",
"      above.) However, the prevalence and severity of DR has significantly decreased as intensive insulin therapy for the management of type 1 diabetes has become more widespread.",
"     </li>",
"     <li>",
"      The modest increase in risk of worsening DR during pregnancy is sufficient to recommend more frequent retinal evaluations during this time and for one year postpartum. However, women can be reassured that over time their long-term risk of retinopathy progression is not altered by pregnancy. In addition, women who develop gestational diabetes should be reassured that they are not at increased risk for developing DR. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Worsening during pregnancy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36023/abstract/1\">",
"      Aiello LM. Perspectives on diabetic retinopathy. Am J Ophthalmol 2003; 136:122.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36023/abstract/2\">",
"      Frank RN. Diabetic retinopathy. N Engl J Med 2004; 350:48.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36023/abstract/3\">",
"      Mizutani M, Kern TS, Lorenzi M. Accelerated death of retinal microvascular cells in human and experimental diabetic retinopathy. J Clin Invest 1996; 97:2883.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36023/abstract/4\">",
"      Klein R, Klein BE, Moss SE, et al. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984; 102:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36023/abstract/5\">",
"      The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329:977.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36023/abstract/6\">",
"      Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352:837.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36023/abstract/7\">",
"      Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Research Group, Nathan DM, Zinman B, et al. Modern-day clinical course of type 1 diabetes mellitus after 30 years' duration: the diabetes control and complications trial/epidemiology of diabetes interventions and complications and Pittsburgh epidemiology of diabetes complications experience (1983-2005). Arch Intern Med 2009; 169:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36023/abstract/8\">",
"      Lecaire T, Palta M, Zhang H, et al. Lower-than-expected prevalence and severity of retinopathy in an incident cohort followed during the first 4-14 years of type 1 diabetes: the Wisconsin Diabetes Registry Study. Am J Epidemiol 2006; 164:143.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36023/abstract/9\">",
"      Lecaire TJ, Palta M, Klein R, et al. Assessing Progress in Retinopathy Outcomes in Type 1 Diabetes: Comparing findings from the Wisconsin Diabetes Registry Study and the Wisconsin Epidemiologic Study of Diabetic Retinopathy. Diabetes Care 2013; 36:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36023/abstract/10\">",
"      Sloan FA, Belsky D, Ruiz D Jr, Lee P. Changes in incidence of diabetes mellitus-related eye disease among US elderly persons, 1994-2005. Arch Ophthalmol 2008; 126:1548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36023/abstract/11\">",
"      Vallance JH, Wilson PJ, Leese GP, et al. Diabetic retinopathy: more patients, less laser: a longitudinal population-based study in Tayside, Scotland. Diabetes Care 2008; 31:1126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36023/abstract/12\">",
"      Leske MC, Wu SY, Hennis A, et al. Hyperglycemia, blood pressure, and the 9-year incidence of diabetic retinopathy: the Barbados Eye Studies. Ophthalmology 2005; 112:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36023/abstract/13\">",
"      Early worsening of diabetic retinopathy in the Diabetes Control and Complications Trial. Arch Ophthalmol 1998; 116:874.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36023/abstract/14\">",
"      Smith LE, Shen W, Perruzzi C, et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med 1999; 5:1390.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36023/abstract/15\">",
"      Jervell J, Moe N, Skjaeraasen J, et al. Diabetes mellitus and pregnancy--management and results at Rikshospitalet, Oslo, 1970-1977. Diabetologia 1979; 16:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36023/abstract/16\">",
"      Moloney JB, Drury MI. The effect of pregnancy on the natural course of diabetic retinopathy. Am J Ophthalmol 1982; 93:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36023/abstract/17\">",
"      Klein BE, Moss SE, Klein R. Effect of pregnancy on progression of diabetic retinopathy. Diabetes Care 1990; 13:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36023/abstract/18\">",
"      Chew EY, Mills JL, Metzger BE, et al. Metabolic control and progression of retinopathy. The Diabetes in Early Pregnancy Study. National Institute of Child Health and Human Development Diabetes in Early Pregnancy Study. Diabetes Care 1995; 18:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36023/abstract/19\">",
"      Diabetes Control and Complications Trial Research Group. Effect of pregnancy on microvascular complications in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group. Diabetes Care 2000; 23:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36023/abstract/20\">",
"      Schocket LS, Grunwald JE, Tsang AF, DuPont J. The effect of pregnancy on retinal hemodynamics in diabetic versus nondiabetic mothers. Am J Ophthalmol 1999; 128:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36023/abstract/21\">",
"      Rajala U, Pajunp&auml;&auml; H, Koskela P, Kein&auml;nen-Kiukaanniemi S. High cardiovascular disease mortality in subjects with visual impairment caused by diabetic retinopathy. Diabetes Care 2000; 23:957.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36023/abstract/22\">",
"      Chew EY, Ferris FL 3rd, Csaky KG, et al. The long-term effects of laser photocoagulation treatment in patients with diabetic retinopathy: the early treatment diabetic retinopathy follow-up study. Ophthalmology 2003; 110:1683.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36023/abstract/23\">",
"      Klein BE, Klein R, McBride PE, et al. Cardiovascular disease, mortality, and retinal microvascular characteristics in type 1 diabetes: Wisconsin epidemiologic study of diabetic retinopathy. Arch Intern Med 2004; 164:1917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36023/abstract/24\">",
"      van Hecke MV, Dekker JM, Stehouwer CD, et al. Diabetic retinopathy is associated with mortality and cardiovascular disease incidence: the EURODIAB prospective complications study. Diabetes Care 2005; 28:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36023/abstract/25\">",
"      Targher G, Bertolini L, Zenari L, et al. Diabetic retinopathy is associated with an increased incidence of cardiovascular events in Type 2 diabetic patients. Diabet Med 2008; 25:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36023/abstract/26\">",
"      Kramer CK, Rodrigues TC, Canani LH, et al. Diabetic retinopathy predicts all-cause mortality and cardiovascular events in both type 1 and 2 diabetes: meta-analysis of observational studies. Diabetes Care 2011; 34:1238.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1783 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-A392849A5D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_11_36023=[""].join("\n");
var outline_f35_11_36023=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H14\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Nonproliferative retinopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Proliferative retinopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Macular edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Ophthalmologic features",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Neovascularization",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Retinal thickening and edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      NATURAL HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Transient worsening with intensive insulin therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Worsening during pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Morbidity and mortality",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ENDO/1783\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1783|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?29/33/30224\" title=\"diagnostic image 1\">",
"      Diabetic macular edema",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?42/38/43617\" title=\"diagnostic image 2\">",
"      Fluorescein angiogram",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1783|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/45/25309\" title=\"figure 1\">",
"      Retinopathy and duration of DM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?2/16/2318\" title=\"figure 2\">",
"      Retinopathy onset in NIDDM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?28/32/29197\" title=\"figure 3\">",
"      Strict glycemic control slows progression of retinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1783|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?5/16/5376\" title=\"picture 1\">",
"      Nonproliferative diabetic retinopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?17/3/17456\" title=\"picture 2\">",
"      PDR neovascularization disc",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?43/19/44336\" title=\"picture 3\">",
"      PDR neovascularization retin vessels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/51/28479\" title=\"picture 4\">",
"      Vitreous hemorrhage",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?3/14/3296\" title=\"picture 5\">",
"      PDR traction retinal detachment 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/47/21232\" title=\"picture 6\">",
"      PDR traction retinal detachment 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/20/13647\" title=\"picture 7\">",
"      Retinal blot hemorrhages",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?13/42/13999\" title=\"picture 8\">",
"      Cotton wool spots",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?38/30/39407\" title=\"picture 9\">",
"      Retinal neovascularization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/54/40800\" title=\"picture 10\">",
"      Traction retinal detachment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/30/43503\" title=\"picture 11\">",
"      Severe neovascularization traction detachment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/19/9520\" title=\"picture 12\">",
"      Circinate exudate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?20/30/20960\" title=\"picture 13\">",
"      Diffuse macular edema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ENDO/1783|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?38/22/39276\" title=\"table 1\">",
"      Classification of DR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/18/17707\" title=\"table 2\">",
"      ADA opthalmologic exam schedule",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?2/19/2362?source=related_link\">",
"      Cataract in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/34/11817?source=related_link\">",
"      Glycemic control and vascular complications in type 1 diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/45/30422?source=related_link\">",
"      Pathogenesis of diabetic retinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?26/37/27226?source=related_link\">",
"      Prevalence of and risk factors for coronary heart disease in diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/38/32362?source=related_link\">",
"      Prevention and treatment of diabetic retinopathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/32/24072?source=related_link\">",
"      Renal and urinary tract physiology in normal pregnancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/32/42501?source=related_link\">",
"      Screening for diabetic retinopathy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_11_36024="Placement of femoral venous catheters";
var content_f35_11_36024=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Placement of femoral venous catheters",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/11/36024/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/11/36024/contributors\">",
"     Mark P Androes, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/11/36024/contributors\">",
"     Alan C Heffner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/11/36024/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/11/36024/contributors\">",
"     Joseph L Mills, Sr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/11/36024/contributors\">",
"     John F Eidt, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/11/36024/contributors\">",
"     Allan B Wolfson, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/11/36024/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/11/36024/contributors\">",
"     Kathryn A Collins, MD, PhD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/11/36024/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 31, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H3099774\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central catheters provide dependable intravenous access and enable hemodynamic monitoring and blood sampling [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36024/abstract/1-4\">",
"     1-4",
"    </a>",
"    ]. Although femoral vein cannulation is often considered less desirable due to higher complication rates, the femoral veins remain a reliable central venous access site, particularly under urgent or emergent circumstances [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36024/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. The femoral site is increasingly used for the introduction of venous devices (eg, inferior vena cava, iliac venous stent).",
"   </p>",
"   <p>",
"    Femoral venous cannulation and catheter placement will be reviewed here. General considerations for venous access and issues related to other access sites are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44553?source=see_link\">",
"     \"Overview of central venous access\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/1/29?source=see_link\">",
"     \"Complications of central venous catheters and their prevention\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/14/3306?source=see_link\">",
"     \"Placement of jugular venous catheters\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?1/27/1466?source=see_link\">",
"     \"Placement of subclavian venous catheters\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3099781\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The femoral veins are commonly viewed as an alternative access site for central venous access due to higher incidence of infection and catheter-related deep vein thrombosis compared with jugular or subclavian access (",
"    <a class=\"graphic graphic_table graphicRef71716 \" href=\"mobipreview.htm?1/53/1885\">",
"     table 1",
"    </a>",
"    ). With contemporary skin preparation and proper routine catheter maintenance, infection rates appear to be comparable to other sites [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36024/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. However, short-term use does not completely eliminate the risk of deep vein thrombosis, which can occur within one day of cannulation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36024/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H58340727\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The femoral veins are frequently preferred when other access sites are exhausted or there is increased risk for complications such as with emergency access, coagulopathy, and in the uncooperative patient [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36024/abstract/12\">",
"     12",
"    </a>",
"    ]. The femoral veins are generally easier to cannulate and provide dependable access for less-experienced operators, or when there is concern for arterial injury at upper extremity sites because of altered local anatomy. Caution is needed when this approach is used in pulseless patients because chest compressions can produce femoral venous pulsations that may be misinterpreted as arterial. Catheter misplacement at the femoral site occurs in up to 30 percent of cardiac arrest resuscitations [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36024/abstract/13,14\">",
"     13,14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Femoral venous access is also used for the delivery of most inferior vena cava filters, and for lower extremity venous intervention. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/28/16840?source=see_link\">",
"     \"Placement of inferior vena cava filters and their complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3099788\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Coagulopathy is a relative contraindication to central cannulation. Compared with subclavian and jugular access sites, the femoral veins may be preferred in the face of coagulopathy due to the ability to provide direct pressure at this access site. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44553?source=see_link&amp;anchor=H1382365406#H1382365406\">",
"     \"Overview of central venous access\", section on 'Femoral access versus other sites'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3099795\">",
"    <span class=\"h1\">",
"     FEMORAL VEIN ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The femoral vein is the major deep vein of the lower extremity. The vessel traverses the thigh and takes a superficial course at the femoral triangle before passing beneath the inguinal ligament into the pelvis as the external iliac vein (",
"    <a class=\"graphic graphic_figure graphicRef51298 graphicRef65123 \" href=\"mobipreview.htm?18/18/18729\">",
"     figure 1A-B",
"    </a>",
"    ). The hip joint and psoas muscle lie directly beneath the femoral neurovascular bundle at the level of the inguinal ligament.",
"   </p>",
"   <p>",
"    Within the femoral triangle, the common femoral vein is enclosed within the femoral sheath where it lies medial to the femoral artery. The common femoral vein receives several tributaries within this region, including the great saphenous and anterior saphenous veins (",
"    <a class=\"graphic graphic_figure graphicRef55019 \" href=\"mobipreview.htm?35/46/36579\">",
"     figure 2",
"    </a>",
"    ). These veins can be inadvertently cannulated during the procedure and initially misinterpreted as femoral vein cannulation. Lower extremity venous anatomy is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/29/11735?source=see_link&amp;anchor=H21#H21\">",
"     \"Classification of lower extremity chronic venous disorders\", section on 'Anatomy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The femoral artery provides a useful landmark to guide needle access (",
"    <a class=\"graphic graphic_picture graphicRef56646 \" href=\"mobipreview.htm?9/12/9409\">",
"     picture 1",
"    </a>",
"    ). The midinguinal point lying half-way between the anterior superior iliac spine and pubic tubercle marks a location just lateral to the femoral artery and provides an important reference point during cardiac arrest or in the absence of a palpable femoral pulse (",
"    <a class=\"graphic graphic_picture graphicRef66432 \" href=\"mobipreview.htm?26/23/26993\">",
"     picture 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3099802\">",
"    <span class=\"h1\">",
"     GENERAL PREPARATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;General considerations for patient preparation, including catheter and access site selection, monitoring and sedation, measures to control infection, and consent, are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44553?source=see_link&amp;anchor=H3104738#H3104738\">",
"     \"Overview of central venous access\", section on 'Preparation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3099809\">",
"    <span class=\"h2\">",
"     Equipment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Femoral venous catheters and other femoral devices are usually placed using a modified Seldinger technique in a series of defined steps, usually using a kit that contains all the materials needed for their placement. Typical supplies are given in the table (",
"    <a class=\"graphic graphic_table graphicRef54646 \" href=\"mobipreview.htm?26/30/27115\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36024/abstract/15\">",
"     15",
"    </a>",
"    ]. For non-tunneled catheters, the steps for central venous catheterization are given in the table (",
"    <a class=\"graphic graphic_table graphicRef68138 \" href=\"mobipreview.htm?43/26/44459\">",
"     table 3",
"    </a>",
"    ). For tunneled catheters and other devices, the steps are similar except that a sheath is placed over the guidewire, and the catheter (or other device such as pacemaker leads, filter) is placed through the sheath, which is then removed.",
"   </p>",
"   <p>",
"    Prior to the placement of femoral venous catheters, assemble the following equipment:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Ultrasound machine (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/47/3833?source=see_link&amp;anchor=H16#H16\">",
"       \"Principles of ultrasound-guided venous access\", section on 'Ultrasound machine preparation'",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Sterile ultrasound transducer gel",
"     </li>",
"     <li>",
"      Central line kit with intravenous catheter (size and length based upon diameter and depth of vein)",
"     </li>",
"     <li>",
"      Sterile drapes, gloves, gown, surgical mask, and cap",
"     </li>",
"     <li>",
"      Topical antiseptic (eg,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?12/36/12870?source=see_link\">",
"       chlorhexidine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/0/32768?source=see_link\">",
"       povidone iodine",
"      </a>",
"      ) (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10805?source=see_link\">",
"       \"Controversies in control measures to prevent surgical site infection\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Local anesthetic (see",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/50/43817?source=see_link\">",
"       \"Topical anesthetics in children\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33689?source=see_link\">",
"       \"Infiltration of local anesthetics\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Isotonic saline",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?39/34/40489?source=see_link\">",
"       heparin",
"      </a>",
"      for flushing the catheter",
"     </li>",
"     <li>",
"      Transparent adhesive dressing, tape",
"     </li>",
"     <li>",
"      Intravenous tubing and connectors (eg, needleless Luer connector, three-way stopcock)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although any length central venous catheter can be used at the femoral site, longer (20 to 24 cm) catheters are needed for hemodialysis to achieve placement in the inferior vena cava to provide adequate flow during hemodialysis.",
"   </p>",
"   <p>",
"    The proper functioning of any fluoroscopic equipment should be verified. Fluoroscopy is rarely needed for femoral venous access to place implanted catheters, but is necessary for placing inferior vena cava filters or other venous devices (eg, venous stents), and may be useful when altered venous anatomy is encountered. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H662980389\">",
"    <span class=\"h2\">",
"     Skin preparation",
"    </span>",
"    &nbsp;&mdash;&nbsp;For femoral venous access, a wide skin preparation encompasses the anterior and medial surfaces of the proximal thigh and extends superior to the inguinal ligament.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58340216\">",
"    <span class=\"h2\">",
"     Positioning",
"    </span>",
"    &nbsp;&mdash;&nbsp;Correct positioning facilitates vein cannulation.",
"   </p>",
"   <p>",
"    The clinician should position the patient&rsquo;s bed or procedure table at a comfortable height. The procedure is generally performed while standing on the same side as the access site. Alternatively, some operators reach across the patient to cannulate the contralateral femoral vein (eg, right-handed operator cannulating the left femoral vein from the patient's right side).",
"   </p>",
"   <p>",
"    The patient should be positioned supine. The target leg can be abducted and externally rotated 15 degrees to open the femoral triangle. Elevation of the buttock with rolled sheets or a firm pillow facilitates exposure in some patients.",
"   </p>",
"   <p>",
"    Most patients can be safely positioned supine [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36024/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. However, critically ill and obese patients may develop respiratory compromise in the supine position and require close monitoring. Head-up positioning (ie, reverse Trendelenburg) may augment the cross-sectional area of the femoral vein, but the effect is not universal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36024/abstract/18,19\">",
"     18,19",
"    </a>",
"    ]. Reverse Trendelenburg may be contraindicated in patients with volume depletion. Some patients may require anesthesia with a controlled airway for safe placement of central venous catheters and devices. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/41/35482?source=see_link&amp;anchor=H708418#H708418\">",
"     \"Anesthesia for the obese patient undergoing non-cardiac surgery\", section on 'Positioning'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58340713\">",
"    <span class=\"h1\">",
"     FEMORAL VEIN CANNULATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The femoral vein is generally cannulated with ultrasound guidance. Following cannulation, femoral catheters are placed using an orderly sequence of steps (",
"    <a class=\"graphic graphic_table graphicRef68138 \" href=\"mobipreview.htm?43/26/44459\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85546193\">",
"    <span class=\"h2\">",
"     Needle access",
"    </span>",
"    &nbsp;&mdash;&nbsp;When equipment and expertise are available, children and adults undergoing cannulation of the femoral vein should have the procedure guided by ultrasound rather than using anatomic landmarks alone. Ultrasound increases success rates and reduces the rate of inadvertent arterial puncture. The basic principles of ultrasound for guiding venous access are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/47/3833?source=see_link&amp;anchor=H1232393340#H1232393340\">",
"     \"Principles of ultrasound-guided venous access\", section on 'Femoral vein'",
"    </a>",
"    and",
"    <a class=\"local\" href=\"#H85547079\">",
"     'Dynamic ultrasound-guided femoral access'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85546259\">",
"    <span class=\"h3\">",
"     General techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;The femoral vein can be cannulated using the access needle with or without the aid of a finder needle or using an angiocatheter (catheter over needle combination). The general technique for each of these is described below. Isolated arterial needle puncture is one of the most common complications of venous access, but is typically uneventful if recognized [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36024/abstract/20\">",
"     20",
"    </a>",
"    ]. Confirmation that the needle or angiocatheter is in the vein is essential prior to dilating the subcutaneous tissue and vein. (See",
"    <a class=\"local\" href=\"#H662985603\">",
"     'Venous confirmation'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    There is a learning curve for central venous access procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36024/abstract/21\">",
"     21",
"    </a>",
"    ]. Experienced operators enjoy greater success rates with fewer complications. Among both experienced and inexperienced operators, an increased number of introducer needle passes correlates with increased complication rates, which are significantly higher after two to three unsuccessful passes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36024/abstract/3\">",
"     3",
"    </a>",
"    ]. If two attempts have been made, the needle should be completely removed the landmarks reassessed, a new access site chosen, or assistance obtained from a more experienced clinician [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36024/abstract/3,22,23\">",
"     3,22,23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85546457\">",
"    <span class=\"h4\">",
"     Access with introducer needle",
"    </span>",
"    &nbsp;&mdash;&nbsp;To access the femoral vein with the introducer needle:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Insert the introducer needle (18 gauge) into the skin and apply continuous negative pressure by pulling back on the plunger of the syringe. It is helpful to have a small amount of saline in the syringe to minimize the formation of thrombus. Penetration into the vein will go unrecognized unless negative pressure is applied, but only a small amount of continuous negative pressure is needed (about 1 cc of a 10 cc syringe) during forward advancement of the needle.",
"     </li>",
"     <li>",
"      Always advance and withdraw the needle in the same vector. Lateral movement of an inserted needle can lacerate vessels and should",
"      <strong>",
"       not",
"      </strong>",
"      be done. Prior to any redirection of the needle, it should be withdrawn to the skin surface.",
"     </li>",
"     <li>",
"      Anticipate that venous backflow into the introducer needle will be sudden, and steady the position of your hand to avoid losing access when it occurs.",
"     </li>",
"     <li>",
"      The introducer needle may compress the anterior wall, puncturing both walls simultaneously without entering the lumen. Failure to aspirate blood during needle advancement is common. In this circumstance, withdraw the needle slowly while maintaining continuous negative pressure.",
"     </li>",
"     <li>",
"      Once access is achieved, stabilize the hub of the needle and carefully remove the syringe to avoid dislodging the introducer needle from the vessel.",
"     </li>",
"     <li>",
"      Cover the hub of the needle between manipulations and coordinate hub exposure with the patient&rsquo;s exhalation to avoid air entry during femoral access. Encourage the patient to hum or perform Valsalva maneuvers to augment central venous pressure [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/11/36024/abstract/1,24\">",
"       1,24",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85546464\">",
"    <span class=\"h4\">",
"     Using finder needle",
"    </span>",
"    &nbsp;&mdash;&nbsp;A small caliber (21 to 22 gauge) exploratory, finder or seeker needle, 3.5 cm in length, can be useful for initially locating the femoral vein (",
"    <a class=\"graphic graphic_picture graphicRef55560 \" href=\"mobipreview.htm?6/60/7105\">",
"     picture 3",
"    </a>",
"    ). This technique minimizes injury in the event of inadvertent arterial puncture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36024/abstract/22,25\">",
"     22,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    To use a finder needle to aid introducer needle placement:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      As described above for large-bore needle access, insert the finder needle while applying negative suction on the plunger of the syringe; more suction will be required (about 2 to 3 cc of a 10 cc syringe). Steady, unimpeded blood return confirms intraluminal venous placement.",
"     </li>",
"     <li>",
"      Once the needle enters the femoral vein, withdraw the finder needle noting the angle and depth needed to reach the vein. Alternatively, remove the syringe leaving the finder needle in place to anchor the vessel and provide a guide for venous access by the introducer needle. While applying negative pressure to the syringe, advance the introducer needle in the same vector, or alongside the preceding finder needle, into the vein.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85546471\">",
"    <span class=\"h4\">",
"     Using an angiocatheter",
"    </span>",
"    &nbsp;&mdash;&nbsp;An angiocatheter, which consists of an 18 gauge plastic catheter mounted on a 20 gauge needle, can also be used for initial femoral access. The needle tip is exposed and extends 2 mm distal to the catheter tip. The angiocatheter (not the needle) accommodates a standard 0.035&rdquo; guidewire.",
"   </p>",
"   <p>",
"    To use an angiocatheter for femoral venous access:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Attach the catheter-over-needle unit to the syringe and advance it into the target vessel as described above.",
"     </li>",
"     <li>",
"      Once blood is aspirated, advance the needle another 2 to 3 mm to ensure intraluminal positioning of the tip of the catheter, then advance the catheter over the needle and into the vessel.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H662986351\">",
"    <span class=\"h3\">",
"     Approach to the femoral vein",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palpation of the common femoral artery aids in anatomic localization of the vein. The target venipuncture site is just inferior to the inguinal ligament where the common femoral vein lies superficial and medial to the artery. Compression should be minimized or released prior to attempted venipuncture. Cooperative patients can also be asked to hum or perform a Valsalva maneuver to augment venous diameter.",
"   </p>",
"   <p>",
"    The target venipuncture site is just inferior to the inguinal ligament where the common femoral vein lies superficial and medial to the artery. Orient the needle with the bevel up and introduce it angled 20 to 30 degrees to the skin. Insert the needle (finder needle, 18 gauge needle) 1 to 2 cm inferior to the inguinal ligament and just medial to the femoral artery. The vessel is normally reached within 2 to 4 cm, but may be deeper in obese or edematous patients. If unsuccessful, perform systematic needle passes medial to lateral (while maintaining continuous negative pressure) until the common femoral vein is located. We prefer to use a finder needle under this circumstance.",
"   </p>",
"   <p>",
"    Take care not to push the needle into the periosteum of the pubic tubercle as a tissue or bone plug can occlude the lumen of the needle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85547079\">",
"    <span class=\"h3\">",
"     Dynamic ultrasound-guided femoral access",
"    </span>",
"    &nbsp;&mdash;&nbsp;The basic principles of ultrasound-guided venous access, including ultrasound modes, types of probes, and equipment preparation, are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?3/47/3833?source=see_link\">",
"     \"Principles of ultrasound-guided venous access\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    When using ultrasound to guide femoral venous access, the following steps should be performed (",
"    <a class=\"graphic graphic_table graphicRef68138 \" href=\"mobipreview.htm?43/26/44459\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Prepare the site with antiseptic cleansing and a sterile drape (central line). (See",
"      <a class=\"local\" href=\"#H3099802\">",
"       'General preparation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Place the ultrasound gel and probe into a sterile sheath.",
"     </li>",
"     <li>",
"      Apply sterile ultrasound conduction medium (eg, water soluble lubricant) to the external probe cover.",
"     </li>",
"     <li>",
"      Identify the femoral vein and center the image on the ultrasound screen (transverse view) (",
"      <a class=\"graphic graphic_picture graphicRef54501 \" href=\"mobipreview.htm?2/3/2096\">",
"       picture 4",
"      </a>",
"      ) or obtain a longitudinal view using care to distinguish veins from arteries (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef61917 \" href=\"mobipreview.htm?4/58/5029\">",
"       image 1",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/47/3833?source=see_link&amp;anchor=H10#H10\">",
"       \"Principles of ultrasound-guided venous access\", section on 'Ultrasound anatomy'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/47/3833?source=see_link&amp;anchor=H13563724#H13563724\">",
"       \"Principles of ultrasound-guided venous access\", section on 'Probe orientation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Infiltrate the skin at the intended puncture site with 1 percent",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      .",
"     </li>",
"     <li>",
"      Insert the needle (preferably echogenic needle), which has been placed onto a syringe, into the skin and advance it slowly toward the vein. (See",
"      <a class=\"local\" href=\"#H85546259\">",
"       'General techniques'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      If the needle tip is difficult to see using the transverse view, gently jiggle the needle up and down in the tissues to help identify the needle. In the transverse view, it is important to adjust the ultrasound beam to focus on the tip of the needle rather than the shaft. Failure to do so can lead to inadvertent puncture of deeper structures.",
"     </li>",
"     <li>",
"      If using the longitudinal view, directly observe the needle penetrate the vein on the ultrasound monitor (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef50251 \" href=\"mobipreview.htm?11/34/11811\">",
"       image 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      While maintaining negative pressure on the syringe, advance the needle slowly until a free flow of blood return occurs. Although the tip of the needle may not be visualized, the depth of the vessel is shown on the US monitor and should guide the depth of needle placement",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Remove the transducer and complete cannulation in standard fashion as described below (",
"      <a class=\"graphic graphic_table graphicRef68138 \" href=\"mobipreview.htm?43/26/44459\">",
"       table 3",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H662985603\">",
"    <span class=\"h2\">",
"     Venous confirmation",
"    </span>",
"    &nbsp;&mdash;&nbsp;An intraluminal position of the needle can be confirmed by observation of the needle entering the vein with ultrasound-guided access coupled with a steady flow of dark blood into the syringe. Bright red and high-pressure pulsatile bleeding are important but imperfect clues to arterial puncture [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36024/abstract/26\">",
"     26",
"    </a>",
"    ], which can occur, although less frequently, with ultrasound-guided access. Moreover, the absence of these signs is not perfectly reliable for excluding inadvertent arterial puncture. Dark, nonpulsatile backflow of blood may be seen with arterial puncture in the face of oxygen desaturation, hypotension, or needle malposition. If there is any doubt, the needle&rsquo;s location can be confirmed by pressure transduction. As an alternative, a blood gas can be drawn from the accessed venous site and compared with an arterial sample; however, blood gas analysis is more time consuming.",
"   </p>",
"   <p>",
"    To transduce the blood pressure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Attach the needle directly to the pressure tubing system",
"     </li>",
"     <li>",
"      Alternatively, replace the needle over a guidewire with a 6 cm, 18-gauge single-lumen transduction catheter (without any intervening dilation). Connect the transduction catheter to a pressure line and transducer and evaluate the pressure and waveform tracings on the monitor. Typical venous waveforms should be seen.",
"     </li>",
"     <li>",
"      If a pressure transduction system is not available, attach a short length of saline-filled intravenous tubing to the needle and extended it vertically to measure the pressure, which should be &lt;10 cm in height, and should demonstrate respiratory variation.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    If the femoral artery has inadvertently been punctured, which is not uncommon, withdraw the needle and apply pressure over the site for 5 to 10 minutes after which venous access can be re-attempted. Inadvertent dilation and cannulation of the femoral artery with a standard catheter does not usually pose a significant problem. However, larger bore catheters, such as dialysis catheters, may be associated with bleeding or vascular complications such as arterial thrombosis and embolization. If arterial catheterization with a large bore catheter is confirmed, the catheter should be left in place and a vascular consultation obtained. This should also be considered in patients with standard catheters inadvertently placed into the femoral artery of coagulopathic patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H662981202\">",
"    <span class=\"h1\">",
"     CATHETER PLACEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most catheters and other central venous devices are placed using the Seldinger method, which refers to the use of a guidewire placed into a vessel to provide a conduit for intravascular device placement [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36024/abstract/15\">",
"     15",
"    </a>",
"    ]. Seldinger first described the guidewire technique for arterial cannulation in 1953, and it was subsequently adopted for venous access procedures [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36024/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H662981333\">",
"    <span class=\"h2\">",
"     Guidewire handling",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the femoral vein has been successfully accessed, a guidewire is advanced through the needle or angiocatheter.",
"   </p>",
"   <p>",
"    Multiple types of wires are available to assist with venous access procedures. The most commonly used wire for initial venous access is a flexible J-tip guidewire, favored because it negotiates curvatures and avoids vessel trauma during passage (",
"    <a class=\"graphic graphic_picture graphicRef82419 \" href=\"mobipreview.htm?39/24/40320\">",
"     picture 5",
"    </a>",
"    ). Longer guidewires are used to place inferior vena cava filters and other venous devices (eg, stents), and, at times, more specialized wires (eg, hydrophilic) may be needed.",
"   </p>",
"   <p>",
"    The guidewire should always pass smoothly and easily thorough the needle, dilator, or catheter without resistance. Methods to address resistance to guidewire advancement or withdrawal are discussed below.",
"   </p>",
"   <p>",
"    To place the guidewire:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Position the tapered plastic introducer to straighten the distal J-tip (",
"      <a class=\"graphic graphic_picture graphicRef72306 \" href=\"mobipreview.htm?42/22/43360\">",
"       picture 6",
"      </a>",
"      ). The orientation of the bevel tip of the introducer needle and the J-tip of the wire can help facilitate the direction of wire placement.",
"     </li>",
"     <li>",
"      Maintain the residual length of guidewire (50 cm standard length) under constant manual control to maintain sterility and avoid its loss off the operating field.",
"     </li>",
"     <li>",
"      Advance the guidewire only as far as needed to allow passage of the catheter over the wire.",
"     </li>",
"     <li>",
"      Never forcefully advance the guidewire, as this can kink and permanently deform the wire, and risk vessel injury. The guidewire should always pass smoothly and easily thorough the needle, dilator, or catheter without resistance. Resistance to guidewire passage can be due to needle dislodgement, compression of the guidewire against the vessel wall, or anatomic obstruction. Rotating the needle",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      guidewire to reorient the bevel or J-tip may relieve impingement of the guidewire on the posterior vessel wall.",
"     </li>",
"     <li>",
"      If resistance persists, remove the guidewire and aspirate blood to confirm intraluminal needle position. Reducing the angle of the needle against the skin may facilitate guidewire passage. Once the guidewire is positioned, hold it firmly in place, and remove the needle.",
"     </li>",
"     <li>",
"      Resistance during guidewire withdrawal can be managed by simultaneously removing the needle and indwelling wire. Continued resistance may indicate entrapment and warrants diagnostic radiography to evaluate the wire appearance and position. A guidewire that resists removal (eg, kinked) should",
"      <strong>",
"       never",
"      </strong>",
"      be withdrawn through the needle because the wire can be sheared off by the needle, allowing the wire to embolize [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/11/36024/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H527628095\">",
"    <span class=\"h2\">",
"     Tract dilation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Central venous catheters are substantially larger caliber than the needle and guidewire used for venous access. Dilation of the subcutaneous tissue tract is required for catheter insertion and is accomplished by threading a single stiff tapered dilator or series of dilators over the wire to expand the subcutaneous tissue and vein. The skin and fascia catheter tract should be dilated carefully with gentle pressure. Only the soft tissue and vein wall need to be dilated. Overzealous efforts and guidewire kinking (especially with stiff dilators) risk traumatic vein injury.",
"   </p>",
"   <p>",
"    Many indwelling tunneled femoral catheters are placed through a peel-away sheath. To place these devices, a dilator-sheath combination is placed over the wire after the tract has been dilated. The dilator is removed and the catheter is placed through the sheath. Once the catheter is in place, the sheath is peeled away from the catheter and discarded. &nbsp;",
"   </p>",
"   <p>",
"    The dilator-sheath combination for large-bore tunneled catheters is stiff and placement is facilitated with fluoroscopy, which allows imaging of the tip of the dilator and sheath, ensuring that it is placed no further into the vein than is necessary. (See",
"    <a class=\"local\" href=\"#H3099809\">",
"     'Equipment'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    To place the dilator:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Once the guidewire is in place, make a controlled 3 mm stab incision made in the skin at the entry site with a #11 blade to prevent the dilator from catching.",
"     </li>",
"     <li>",
"      Thread the stiff tapered dilator over the wire, making certain the guidewire does not advance and is not pulled out at the skin exit site. The guidewire and dilator should",
"      <strong>",
"       never",
"      </strong>",
"      be advanced as a single unit, to avoid venous injury. The wire should serve as an immobile monorail over which the dilator (or catheter) is passed. Redundant tissue at the femoral site may require slight caudad skin traction to avoid kinking the wire during dilator advancement.",
"     </li>",
"     <li>",
"      Hold the wire just above the dilator hub, grasp the dilator just above its tip, and push it over the guidewire with a firm corkscrew motion (",
"      <a class=\"graphic graphic_picture graphicRef77656 \" href=\"mobipreview.htm?35/50/36640\">",
"       picture 7",
"      </a>",
"      ). Mild resistance is normal. Excessive resistance may represent an inadequate skin incision, a malpositioned guidewire, or guidewire or dilator deformation. Kinking of the guidewire against the dilator is associated with vessel trauma and puncture [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/11/36024/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      As described above with needle placement, the opening of the dilator (or",
"      <span class=\"nowrap\">",
"       dilator/sheath",
"      </span>",
"      combination) should be covered and the patient encouraged to Valsalva to prevent entry of air.",
"     </li>",
"     <li>",
"      Advance the dilator only to the anticipated depth of the femoral vein,",
"      <strong>",
"       not",
"      </strong>",
"      the entire length of the dilator. Withdraw the dilator while maintaining the guidewire position within the vessel. Apply direct pressure to the exit site to maintain hemostasis prior to catheter insertion.",
"     </li>",
"     <li>",
"      Steady traction on the wire during soft-tissue dilatation helps prevent wire kinking. Rotating the dilator during advancement often facilitates tract dilatation (round dilators only). If resistance is met, it may be related to a kink in the wire which can be remedied by advancing the wire deeper or withdrawing the kink into the dilator. Overzealous efforts and guidewire kinking (especially with stiff dilators) risks traumatic vein injury.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H662984425\">",
"    <span class=\"h2\">",
"     Positioning the catheter",
"    </span>",
"    &nbsp;&mdash;&nbsp;After the subcutaneous tissues and vein have been dilated, the catheter is placed over the wire and positioned (",
"    <a class=\"graphic graphic_picture graphicRef70002 \" href=\"mobipreview.htm?27/56/28559\">",
"     picture 8",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    To place and position the catheter:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Thread the guidewire back through the end-hole of the catheter until it emerges from the distal port, and advance the catheter over the wire into the vessel (",
"      <a class=\"graphic graphic_picture graphicRef51314 \" href=\"mobipreview.htm?33/50/34593\">",
"       picture 9",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Resistance to catheter advancement can be overcome by simultaneously advancing the catheter and wire together, but only for a short distance, otherwise vein laceration can result. Withdrawal of the catheter and redilation of the tract is preferred.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Femoral venous catheters should be placed between 20 and 30 cm deep for correct positioning of the tip of the catheter in the inferior vena cava, but the depth depends upon the size of the patient. For hemodialysis catheters, flow rate through the catheter is the most important factor. Good flow rates can often be achieved with a femoral catheter tip that resides in the common iliac vein. Standard length (15 to 20 cm) non-tunneled hemodialysis catheters will extend to that level from the femoral position of most patients. However, when placing tunneled femoral catheters for longer-term use (eg, Permacath), flow rates are often better maintained with catheters extending more centrally into the inferior vena cava. Longer catheters (up to 45 cm) are available for this purpose.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H85547786\">",
"    <span class=\"h2\">",
"     Catheter flushing and fixation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once the catheter is in place, the proper function of the catheter should be confirmed by aspirating blood and subsequently flushing each port with saline (",
"    <a class=\"graphic graphic_picture graphicRef56646 \" href=\"mobipreview.htm?9/12/9409\">",
"     picture 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36024/abstract/22,29\">",
"     22,29",
"    </a>",
"    ]. The catheter should then be sutured into place.",
"   </p>",
"   <p>",
"    The catheter should then be secured using 2-0 or 3-0 nylon or silk sutures (",
"    <a class=\"graphic graphic_picture graphicRef58552 \" href=\"mobipreview.htm?21/30/21984\">",
"     picture 10",
"    </a>",
"    ). If more than 2 cm of catheter remains exposed, it can be sutured to the skin or to a separate catheter anchor that is often included in the catheter kit. A transparent dressing should be placed over the catheter exit site to protect it from contamination.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H662983898\">",
"    <span class=\"h1\">",
"     CONFIRMATION OF FEMORAL CATHETER POSITION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Unlike subclavian and jugular venous catheters, femoral venous catheters (non-tunneled and tunneled) can be used immediately. A postprocedure abdominal film can be performed to confirm the correct catheter course and tip position if the catheter is not functioning properly. Although it may be acceptable to have the tip of the catheter residing in the iliac vein for short-term use, the distal tip of femoral catheters should generally be located above the confluence of the iliac veins. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44553?source=see_link&amp;anchor=H1232392311#H1232392311\">",
"     \"Overview of central venous access\", section on 'Confirmation of catheter tip positioning'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    If a femoral catheter tip is positioned too proximally (eg, into a renal vein), it can be repositioned at the bedside using sterile technique. The sutures are removed and the catheter withdrawn and resutured into place. If a catheter is not in far enough or is misplaced into the contralateral iliac vein, it should be replaced over a guidewire under sterile conditions when convenient. Although this placement may not be deemed as ideal, the catheter can remain in the contralateral iliac vein for short-term use if the catheter is functioning well. It is important to remember that the portion of a catheter left out of the body is unsterile and should never be advanced into the patient, not even if it is under a sterile dressing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58343377\">",
"    <span class=\"h1\">",
"     CATHETER MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of central catheters is discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31578?source=see_link&amp;anchor=H17#H17\">",
"     \"Prevention of intravascular catheter-related infections\", section on 'Site care'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31578?source=see_link&amp;anchor=H25#H25\">",
"     \"Prevention of intravascular catheter-related infections\", section on 'Catheter care'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58340727\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The complications associated with femoral venous access are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?0/1/29?source=see_link\">",
"     \"Complications of central venous catheters and their prevention\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H58340734\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Central catheters provide dependable intravenous access and enable hemodynamic monitoring and blood sampling. Although femoral site cannulation is often recommended as a secondary site due to higher rates of delayed complications, the femoral veins remain a dependable venous access site. (See",
"      <a class=\"local\" href=\"#H3099774\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For femoral venous cannulation, the patient should be positioned supine with the target leg abducted and externally rotated. Elevation of the buttock may facilitate exposure in some patients. (See",
"      <a class=\"local\" href=\"#H58340216\">",
"       'Positioning'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      When equipment and expertise are available, children and adults undergoing femoral line placement should have the procedure guided by ultrasonography rather than using landmark techniques alone. Ultrasound guidance improves initial cannulation success. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/47/3833?source=see_link&amp;anchor=H1232393340#H1232393340\">",
"       \"Principles of ultrasound-guided venous access\", section on 'Femoral vein'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Femoral artery puncture during attempted femoral vein localization is not uncommon and can be managed by withdrawing the needle and applying pressure over the site for 5 to 10 minutes, after which venous access can be re-attempted. Inadvertent dilation and cannulation of the femoral artery with a standard catheter does not usually pose significant problems. However, larger bore catheters, such as dialysis catheters, may be associated with bleeding or vascular complications such as arterial thrombosis and embolization. If arterial catheterization with a large bore catheter is confirmed, the catheter should be left in place and a vascular surgery consult obtained. This should also be considered in patients with standard catheters inadvertently placed into the femoral artery of coagulopathic patients. (See",
"      <a class=\"local\" href=\"#H662985603\">",
"       'Venous confirmation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Femoral catheters can be used immediately. A postprocedure abdominal film can be performed to confirm the correct catheter course and tip position if there is catheter malfunction. The distal tip of femoral catheters should generally be positioned above the confluence of the iliac veins. (See",
"      <a class=\"local\" href=\"#H662983898\">",
"       'Confirmation of femoral catheter position'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H662984425\">",
"       'Positioning the catheter'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a femoral catheter tip is positioned too proximally, it can be withdrawn at the bedside using sterile technique. If a catheter is not in far enough, it should be replaced over a guidewire under sterile conditions. The portion of a catheter left out of the body is unsterile and should never be advanced into the patient. (See",
"      <a class=\"local\" href=\"#H662983898\">",
"       'Confirmation of femoral catheter position'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36024/abstract/1\">",
"      Beddy P, Geoghegan T, Ramesh N, et al. Valsalva and gravitational variability of the internal jugular vein and common femoral vein: ultrasound assessment. Eur J Radiol 2006; 58:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36024/abstract/2\">",
"      Ruesch S, Walder B, Tram&egrave;r MR. Complications of central venous catheters: internal jugular versus subclavian access--a systematic review. Crit Care Med 2002; 30:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36024/abstract/3\">",
"      McGee DC, Gould MK. Preventing complications of central venous catheterization. N Engl J Med 2003; 348:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36024/abstract/4\">",
"      DUFFY BJ Jr. The clinical use of polyethylene tubing for intravenous therapy; a report on 72 cases. Ann Surg 1949; 130:929.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36024/abstract/5\">",
"      Merrer J, De Jonghe B, Golliot F, et al. Complications of femoral and subclavian venous catheterization in critically ill patients: a randomized controlled trial. JAMA 2001; 286:700.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36024/abstract/6\">",
"      Trottier SJ, Veremakis C, O'Brien J, Auer AI. Femoral deep vein thrombosis associated with central venous catheterization: results from a prospective, randomized trial. Crit Care Med 1995; 23:52.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36024/abstract/7\">",
"      Parienti JJ, Thirion M, M&eacute;garbane B, et al. Femoral vs jugular venous catheterization and risk of nosocomial events in adults requiring acute renal replacement therapy: a randomized controlled trial. JAMA 2008; 299:2413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36024/abstract/8\">",
"      Hamilton HC, Foxcroft DR. Central venous access sites for the prevention of venous thrombosis, stenosis and infection in patients requiring long-term intravenous therapy. Cochrane Database Syst Rev 2007; :CD004084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36024/abstract/9\">",
"      Deshpande KS, Hatem C, Ulrich HL, et al. The incidence of infectious complications of central venous catheters at the subclavian, internal jugular, and femoral sites in an intensive care unit population. Crit Care Med 2005; 33:13.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36024/abstract/10\">",
"      Botha R, van Schoor AN, Boon JM, et al. Anatomical considerations of the anterior approach for central venous catheter placement. Clin Anat 2006; 19:101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36024/abstract/11\">",
"      Meredith JW, Young JS, O'Neil EA, et al. Femoral catheters and deep venous thrombosis: a prospective evaluation with venous duplex sonography. J Trauma 1993; 35:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36024/abstract/12\">",
"      Kuhn GJ, White BC, Swetnam RE, et al. Peripheral vs central circulation times during CPR: a pilot study. Ann Emerg Med 1981; 10:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36024/abstract/13\">",
"      Emerman CL, Bellon EM, Lukens TW, et al. A prospective study of femoral versus subclavian vein catheterization during cardiac arrest. Ann Emerg Med 1990; 19:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36024/abstract/14\">",
"      Jastremski MS, Matthias HD, Randell PA. Femoral venous catheterization during cardiopulmonary resuscitation: a critical appraisal. J Emerg Med 1984; 1:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36024/abstract/15\">",
"      SELDINGER SI. Catheter replacement of the needle in percutaneous arteriography; a new technique. Acta radiol 1953; 39:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36024/abstract/16\">",
"      Ely EW, Hite RD, Baker AM, et al. Venous air embolism from central venous catheterization: a need for increased physician awareness. Crit Care Med 1999; 27:2113.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36024/abstract/17\">",
"      Mirski MA, Lele AV, Fitzsimmons L, Toung TJ. Diagnosis and treatment of vascular air embolism. Anesthesiology 2007; 106:164.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36024/abstract/18\">",
"      Bannon MP, Heller SF, Rivera M. Anatomic considerations for central venous cannulation. Risk Manag Healthc Policy 2011; 4:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36024/abstract/19\">",
"      Stone MB, Price DD, Anderson BS. Ultrasonographic investigation of the effect of reverse Trendelenburg on the cross-sectional area of the femoral vein. J Emerg Med 2006; 30:211.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36024/abstract/20\">",
"      Guilbert MC, Elkouri S, Bracco D, et al. Arterial trauma during central venous catheter insertion: Case series, review and proposed algorithm. J Vasc Surg 2008; 48:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36024/abstract/21\">",
"      Sznajder JI, Zveibil FR, Bitterman H, et al. Central vein catheterization. Failure and complication rates by three percutaneous approaches. Arch Intern Med 1986; 146:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36024/abstract/22\">",
"      Polderman KH, Girbes AJ. Central venous catheter use. Part 1: mechanical complications. Intensive Care Med 2002; 28:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36024/abstract/23\">",
"      Boyd R, Saxe A, Phillips E. Effect of patient position upon success in placing central venous catheters. Am J Surg 1996; 172:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36024/abstract/24\">",
"      Fronek A, Criqui MH, Denenberg J, Langer RD. Common femoral vein dimensions and hemodynamics including Valsalva response as a function of sex, age, and ethnicity in a population study. J Vasc Surg 2001; 33:1050.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36024/abstract/25\">",
"      Albuquerque J&uacute;nior FC, Vasconcelos PR. Technical aspects of central venous catheterization. Curr Opin Clin Nutr Metab Care 1998; 1:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36024/abstract/26\">",
"      Ezaru CS, Mangione MP, Oravitz TM, et al. Eliminating arterial injury during central venous catheterization using manometry. Anesth Analg 2009; 109:130.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36024/abstract/27\">",
"      Propp DA, Cline D, Hennenfent BR. Catheter embolism. J Emerg Med 1988; 6:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36024/abstract/28\">",
"      Robinson JF, Robinson WA, Cohn A, et al. Perforation of the great vessels during central venous line placement. Arch Intern Med 1995; 155:1225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36024/abstract/29\">",
"      Chalkiadis GA, Goucke CR. Depth of central venous catheter insertion in adults: an audit and assessment of a technique to improve tip position. Anaesth Intensive Care 1998; 26:61.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15196 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1103-201.65.114.212-C0B5FDA9AB-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_11_36024=[""].join("\n");
var outline_f35_11_36024=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H58340734\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3099774\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3099781\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3099788\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3099795\">",
"      FEMORAL VEIN ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3099802\">",
"      GENERAL PREPARATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3099809\">",
"      Equipment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H662980389\">",
"      Skin preparation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H58340216\">",
"      Positioning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H58340713\">",
"      FEMORAL VEIN CANNULATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H85546193\">",
"      Needle access",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H85546259\">",
"      - General techniques",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H85546457\">",
"      Access with introducer needle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H85546464\">",
"      Using finder needle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H85546471\">",
"      Using an angiocatheter",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H662986351\">",
"      - Approach to the femoral vein",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H85547079\">",
"      - Dynamic ultrasound-guided femoral access",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H662985603\">",
"      Venous confirmation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H662981202\">",
"      CATHETER PLACEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H662981333\">",
"      Guidewire handling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H527628095\">",
"      Tract dilation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H662984425\">",
"      Positioning the catheter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H85547786\">",
"      Catheter flushing and fixation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H662983898\">",
"      CONFIRMATION OF FEMORAL CATHETER POSITION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H58343377\">",
"      CATHETER MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H58340727\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H58340734\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/15196\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15196|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?4/58/5029\" title=\"diagnostic image 1\">",
"      Ultrasound femoral vessels",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?11/34/11811\" title=\"diagnostic image 2\">",
"      Ultrasound view needle",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15196|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/43/39605\" title=\"figure 1A\">",
"      Anatomy common femoral artery",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?27/39/28275\" title=\"figure 1B\">",
"      Central L femoral anatomy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?35/46/36579\" title=\"figure 2\">",
"      Superficial veins of leg anterior view",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15196|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?9/12/9409\" title=\"picture 1\">",
"      Aspiration following central venous catheter placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?26/23/26993\" title=\"picture 2\">",
"      Central line fem needle",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?6/60/7105\" title=\"picture 3\">",
"      Central line IJ finder",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?2/3/2096\" title=\"picture 4\">",
"      Direct US IV placement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?39/24/40320\" title=\"picture 5\">",
"      Central line J wire",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?42/22/43360\" title=\"picture 6\">",
"      Central line wire",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?35/50/36640\" title=\"picture 7\">",
"      Central line dilator",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?27/56/28559\" title=\"picture 8\">",
"      Central line catheter wire",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?33/50/34593\" title=\"picture 9\">",
"      Central line catheter insertion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?21/30/21984\" title=\"picture 10\">",
"      Central line suture",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/15196|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?1/53/1885\" title=\"table 1\">",
"      Advantages and disadvantages of central vein approaches",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?26/30/27115\" title=\"table 2\">",
"      Central line equipment",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?43/26/44459\" title=\"table 3\">",
"      Technique of central venous catheterization",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/41/35482?source=related_link\">",
"      Anesthesia for the obese patient undergoing non-cardiac surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/29/11735?source=related_link\">",
"      Classification of lower extremity chronic venous disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/1/29?source=related_link\">",
"      Complications of central venous catheters and their prevention",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?10/35/10805?source=related_link\">",
"      Controversies in control measures to prevent surgical site infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?32/57/33689?source=related_link\">",
"      Infiltration of local anesthetics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?43/32/44553?source=related_link\">",
"      Overview of central venous access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/28/16840?source=related_link\">",
"      Placement of inferior vena cava filters and their complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/14/3306?source=related_link\">",
"      Placement of jugular venous catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?1/27/1466?source=related_link\">",
"      Placement of subclavian venous catheters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/53/31578?source=related_link\">",
"      Prevention of intravascular catheter-related infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/47/3833?source=related_link\">",
"      Principles of ultrasound-guided venous access",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/50/43817?source=related_link\">",
"      Topical anesthetics in children",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_11_36025="Pathophysiology of alpha thalassemia";
var content_f35_11_36025=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pathophysiology of alpha thalassemia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/11/36025/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/11/36025/contributors\">",
"     Stanley L Schrier, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/11/36025/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/11/36025/contributors\">",
"     William C Mentzer, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/11/36025/contributors\">",
"     Donald H Mahoney, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?35/11/36025/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?35/11/36025/contributors\">",
"     Stephen A Landaw, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?35/11/36025/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The major hemoglobin in adults is hemoglobin A, which is a tetramer consisting of two pairs of globin polypeptide chains: one pair of alpha chains and one pair of beta chains. In normal subjects, globin chain synthesis is very tightly controlled so that the ratio of production of alpha to non-alpha chains is 1.00 &plusmn; 0.05. There are two copies of the alpha globin gene on chromosome 16. A single beta globin gene resides on chromosome 11 adjacent to genes encoding the beta-like globin chains, delta and gamma (",
"    <a class=\"graphic graphic_figure graphicRef65642 \" href=\"mobipreview.htm?6/32/6656\">",
"     figure 1",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/29/23001?source=see_link\">",
"     \"Structure and function of normal human hemoglobins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thalassemia refers to a spectrum of diseases characterized by reduced or absent production usually of one of the globin chains. Alpha thalassemia is due to impaired production of alpha globin chains, which leads to a relative excess of gamma globin chains in the fetus and newborn, and beta globin chains in children and adults. In alpha thalassemia, the excess beta globin chains are capable of forming soluble tetramers (beta-4, or HbH); however, they are unstable and some precipitate within the cell, leading to a variety of clinical manifestations. Since all normal hemoglobins of postnatal life contain alpha chains, homozygous alpha (0) thalassemia is incompatible with extrauterine life, leading to hydrops fetalis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    death shortly after delivery.",
"   </p>",
"   <p>",
"    Beta thalassemia, in comparison, is due to impaired production of beta globin chains, which leads to a variable excess of alpha globin chains. Alpha globin chains cannot form soluble tetramers and thus precipitate. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8058?source=see_link\">",
"     \"Pathophysiology of beta thalassemia\"",
"    </a>",
"    .) The excess alpha globin chains in beta thalassemia therefore begin aggregating as soon as they accumulate in erythroid precursors. For this reason and because of the unique biochemical composition of aggregates of alpha globin, the clinical manifestations are generally less severe in alpha compared with beta thalassemia of comparable genetic severity, except for homozygous alpha (0) thalassemia [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The net loss of alpha globin synthesis reflects not only the number of alpha globin genes affected by the mutation(s), but also which of the two alpha globin loci is affected, whether the mutation(s) involved are deletional or nondeletional, and whether the nondeletional mutation(s) partially or fully block gene expression. In addition, defects in alpha globin synthesis in alpha thalassemia can ameliorate beta thalassemia severity by rebalancing the alpha to beta globin chain ratio. Thus, understanding the basis for the broad spectrum of clinical severity (phenotypes) in individual patients with alpha thalassemia requires a detailed knowledge of the underlying genetic defect(s) and the impact of these defects on the overall levels and balance of globin chain synthesis.",
"   </p>",
"   <p>",
"    The pathophysiology of the anemia in alpha thalassemia will be reviewed here. This discussion will focus on the mechanisms by which excess unmatched beta globin chain synthesis leads to hemolysis of red cells in the peripheral circulation. Less importantly than in beta thalassemia, the accumulation of excess beta chains in erythroid precursors within the bone marrow and in extramedullary sites, such as the liver and spleen, also leads to certain amount of ineffective erythropoiesis. The molecular pathology of the thalassemias is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/58/9129?source=see_link\">",
"     \"Molecular pathology of the thalassemic syndromes\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DEFINITIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;While the thalassemias are profoundly heterogeneous from a genetic standpoint, certain clinical terms are available to describe the phenotypic expression of the alpha thalassemias. Because the alpha gene locus is duplicated in humans, each individual normally carries four alpha chain genes (ie,",
"    <span class=\"nowrap\">",
"     aa/aa).",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Alpha (0) thalassemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alpha",
"    (0) thalassemia refers to the more than 20 different genetic mutations of the alpha globin locus which result in the deletion of both alpha chain loci (ie,",
"    <span class=\"nowrap\">",
"     aa/--)",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef65642 \" href=\"mobipreview.htm?6/32/6656\">",
"     figure 1",
"    </a>",
"    ) on one chromosome 16. Patients who carry alpha (0) gene mutations on both chromosomes (ie,",
"    <span class=\"nowrap\">",
"     --/--)",
"    </span>",
"    cannot make alpha chains and are therefore unable to make any hemoglobin A, F, or A2. This condition is incompatible with extrauterine life (see",
"    <a class=\"local\" href=\"#H25\">",
"     'Hydrops fetalis and hemoglobin Bart's'",
"    </a>",
"    below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Alpha (+) thalassemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Alpha (+) thalassemia refers to the more than 15 different genetic mutations which result in decreased production of alpha globin, usually due to deletion of one of the two alpha chain loci in the affected chromosome. As a result, there are three general forms of alpha (+) thalassemia based upon the number of inherited alpha genes:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Inheritance of three normal alpha genes",
"      <span class=\"nowrap\">",
"       (aa/a-)",
"      </span>",
"      has been termed alpha thalassemia minima, silent carrier of alpha thalassemia, alpha thalassemia-2 trait, or heterozygosity for alpha (+) thalassemia. Affected subjects are clinically normal and may also be hematologically normal; the diagnosis can be reliably made only via DNA analysis.",
"     </li>",
"     <li>",
"      Inheritance of two normal alpha genes has been termed alpha thalassemia minor or alpha thalassemia-1 trait, and is due either to heterozygosity for alpha (0) thalassemia",
"      <span class=\"nowrap\">",
"       (aa/--)",
"      </span>",
"      or homozygosity for alpha (+) thalassemia",
"      <span class=\"nowrap\">",
"       (a-/a-).",
"      </span>",
"      These subjects are clinically normal but may have minimal anemia along with reductions in mean corpuscular volume (MCV) and mean corpuscular hemoglobin (MCH).",
"     </li>",
"     <li>",
"      Inheritance of one normal alpha gene",
"      <span class=\"nowrap\">",
"       (a-/--)",
"      </span>",
"      is termed hemoglobin H (HbH) disease, because of the formation of HbH, which is composed of tetramers of the resulting excess beta chains (beta 4). These patients have moderate to severe degrees of lifelong hemolytic anemia, very modest degrees of ineffective erythropoiesis, splenomegaly, and variable bony changes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/2\">",
"       2",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/13/38106?source=see_link&amp;anchor=H33#H33\">",
"       \"Clinical manifestations and diagnosis of the thalassemias\", section on 'Hemoglobin H disease'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      As mentioned above, inheritance of no alpha genes",
"      <span class=\"nowrap\">",
"       (--/--)",
"      </span>",
"      is incompatible with extrauterine life, since the affected fetus will be unable to make any of the hemoglobins normally produced after birth (eg, hemoglobins A, F, and A2), all of which require the ability to produce alpha globin chains (see",
"      <a class=\"local\" href=\"#H25\">",
"       'Hydrops fetalis and hemoglobin Bart's'",
"      </a>",
"      below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8671883\">",
"    <span class=\"h2\">",
"     Complex alpha thalassemia variants",
"    </span>",
"    &nbsp;&mdash;&nbsp;The above definitions are useful as a starting point but the classification of the alpha thalassemias can become extremely complex. For example, two general forms of HbH disease have been recognized, the deletional and non-deletional forms. In the former, the patient has inherited only a single alpha globin gene (ie,",
"    <span class=\"nowrap\">",
"     a-/--).",
"    </span>",
"    In the non-deletional form, the patient has inherited two alpha globin genes from one parent, but one of these carries a non-deletional defect, such as a point mutation (ie,",
"    <span class=\"nowrap\">",
"     aa*/--,",
"    </span>",
"    where a* represents the mutated alpha chain, such as hemoglobin Constant Spring). HbH disease tends to be more severe in patients with the non-deletional form [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/3\">",
"     3",
"    </a>",
"    ], due, at least in part, to interference with transcription of the normal alpha chain gene by the abnormal one [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/13/38106?source=see_link&amp;anchor=H33#H33\">",
"     \"Clinical manifestations and diagnosis of the thalassemias\", section on 'Hemoglobin H disease'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?37/13/38106?source=see_link&amp;anchor=H38#H38\">",
"     \"Clinical manifestations and diagnosis of the thalassemias\", section on 'Hemoglobin Constant Spring'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As another example of the potential complexity of these disorders, individual patients may have combinations of alpha and beta globin gene mutations of varying nature and severity (eg, combinations or variants of alpha (0) from one parent and alpha (+) from the other with one or more beta chain abnormalities).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Anemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anemia in the alpha thalassemic syndromes has at least four components:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Underproduction of hemoglobin HbA",
"     </li>",
"     <li>",
"      Production of two nonfunctional hemoglobins because of insufficient numbers of alpha globin chains: HbBart's (gamma globin tetramers) in newborns before the switch to beta globin production and HbH (beta globin tetramers) at all ages",
"     </li>",
"     <li>",
"      Intracorpuscular hemolysis caused by the accumulation within red blood cells (RBCs) of excess unmatched non-alpha globin chains",
"     </li>",
"     <li>",
"      Ineffective erythropoiesis, or intramedullary hemolysis, also resulting from the globin chain imbalance",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Protection against severe malaria",
"    </span>",
"    &nbsp;&mdash;&nbsp;The alpha thalassemia genes affect up to 90 percent of some populations and appear to offer a selection advantage by protecting against severe malaria (due to Plasmodium falciparum) and perhaps other infections [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/5-8\">",
"     5-8",
"    </a>",
"    ]. In Papua New Guinea, for example, there is intense malaria transmission and alpha thalassemia is present in more than 90 percent of the population. In one study, the relative risk of severe malaria, compared with normal children, was 0.40 in homozygotes and 0.66 in heterozygotes; similar values were seen for hospitalization for infections other than malaria [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/8\">",
"     8",
"    </a>",
"    ]. Similar finding were also reported from Ghana, where heterozygosity for alpha (+) thalassemia was noted in 32.6 percent of controls but in only 26.2 percent of cases of P. Falciparum infection (odds ratio 0.74) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The protection against severe malaria may be mediated by increased susceptibility to infection with the nonlethal P. vivax, particularly in young children, thereby inducing limited cross-species protection against subsequent P. falciparum infection [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/5,7\">",
"     5,7",
"    </a>",
"    ]. In addition, thalassemic red cells may remain susceptible to P. falciparum invasion but are associated with significantly reduced parasite multiplication [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?20/23/20858?source=see_link&amp;anchor=H23#H23\">",
"     \"Protection against malaria in the hemoglobinopathies\", section on 'Alpha thalassemia'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     HISTORICAL PERSPECTIVE",
"    </span>",
"    &nbsp;&mdash;&nbsp;In 1955, two groups of investigators virtually simultaneously described the syndrome of HbH disease [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. Affected patients had a hypochromic microcytic anemia of variable severity, target cells on peripheral smear, reticulocytosis, inclusions in a few RBCs, many more of which could be produced by incubating RBC with mild oxidant dyes like brilliant cresyl blue, resistance to lysis by hypotonic solutions, and signs of hemolysis, including a shortened 51Cr RBC survival, splenomegaly, and elevated indirect reacting bilirubin. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36326?source=see_link\">",
"     \"Red blood cell survival: Normal values and measurement\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/3/18489?source=see_link\">",
"     \"Approach to the diagnosis of hemolytic anemia in the adult\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A key finding was an abnormal hemoglobin, accounting for up to 40 percent of the total hemoglobin, which had more rapid electrophoretic mobility at pH 8.6 than HbA. When this hemoglobin, now called HbH, was allowed to stand it turned brown and precipitated, forming aggregates that looked somewhat like the RBC inclusions. This phenomenon was accentuated by addition of mild oxidants.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Consequences of impaired alpha globin synthesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Subsequent studies identified this disorder as a moderately severe form of alpha thalassemia with the deletion or inactivation of three of the four alpha genes, leading to a clinically significant unbalanced globin chain synthesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/13\">",
"     13",
"    </a>",
"    ]. The",
"    <span class=\"nowrap\">",
"     alpha/beta",
"    </span>",
"    synthesis ratio was found to range from 0.3 to 0.6 (normal: 1.0 &plusmn; 0.05) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The reduced synthesis of alpha globin chains leads to an accumulation of otherwise normal beta globin chains in adults and gamma chains in the fetus. Instead of forming",
"    <span class=\"nowrap\">",
"     alpha/beta",
"    </span>",
"    dimers which then form normal HbA tetramers (a2b2), the excess beta globin chains assemble into beta-4 tetramers, called HbH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. In the neonatal period, before beta globin chain synthesis reaches adult levels, excess unmatched gamma globin chains accumulate and form gamma-4 tetramers, called HbBart's [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/17\">",
"     17",
"    </a>",
"    ]. These two homotetramers are susceptible to oxidant injury [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/15,18\">",
"     15,18",
"    </a>",
"    ], and are functionally useless as oxygen delivery pigments because their affinity for oxygen is at least 10 times greater than HbA. They demonstrate no Bohr effect, and the oxyhemoglobin dissociation curve is not sigmoidal because there is no heme-heme interaction. The oxyhemoglobin dissociation curves for HbH and HbBart's resemble that of myoglobin, a compound that holds but cannot deliver oxygen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/19\">",
"     19",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?22/29/23001?source=see_link\">",
"     \"Structure and function of normal human hemoglobins\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A critical factor underlying the difference in pathophysiology between alpha and beta thalassemia is that, in the alpha thalassemias, the excess beta or gamma globin chains can form partially soluble but ineffective hemoglobin homotetramers. These homotetramers do not precipitate extensively until they are exposed to damaging effects, mostly oxidant in nature, in the circulation. In contrast, in the beta thalassemias the excess unmatched alpha chains that accumulate cannot form alpha-4 tetramers; instead, they produce insoluble alpha aggregates even in very early marrow erythroid precursors, affecting membrane assembly and accelerating programmed cell death. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8058?source=see_link\">",
"     \"Pathophysiology of beta thalassemia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MORPHOLOGY OF ALPHA THALASSEMIC RED BLOOD CELLS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The RBCs in alpha thalassemia are hypochromic and microcytic. The hypochromia is due both to less hemoglobin per cell and to hyperhydration of the cell.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Red blood cell size and shape",
"    </span>",
"    &nbsp;&mdash;&nbsp;The unbalanced globin chain synthesis leads to a deficiency in the amount of hemoglobin per cell (low MCH) and, since hemoglobin accounts for 30 to 35 percent of the RBC content, the RBC volume (MCV) will be low, producing the well known hypochromic target cells and microcytosis. However, in addition to these well characterized morphologic findings, there are frequently fragmented RBCs and bizarre shapes.",
"   </p>",
"   <p>",
"    The introduction of sophisticated technology such as the Technicon Bayer H* Analyzer has allowed more precise identification of RBC indices. The MCH tracings show that, as a consequence of time in the circulation, RBC fragmentation occurs in HbH and the alpha thalassemia variant,",
"    <span class=\"nowrap\">",
"     HbH/Constant",
"    </span>",
"    Spring",
"    <span class=\"nowrap\">",
"     (HbH/CS),",
"    </span>",
"    producing populations of tiny hemoglobin-containing fragments. It is highly likely these fragments have shortened survival time in the circulation. Both the intact RBCs and the cell fragments with a markedly reduced surface area-to-volume ratio have great difficulty in undergoing the elongated elliptical deformation that normally allows 7 to 8 micron diameter RBCs to pass through 3 micron diameter capillaries and 2 to 3 micron slits in reticuloendothelial sinusoids. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36326?source=see_link&amp;anchor=H3#H3\">",
"     \"Red blood cell survival: Normal values and measurement\", section on 'Senescence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several early observations noted that while both beta- and alpha-thalassemic RBCs were hypochromic and microcytic, the decrease in hemoglobin concentration within the RBC (ie, reduced MCHC) was more prominent in the Constant Spring thalassemic variants [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/20\">",
"     20",
"    </a>",
"    ]. These observations lead to further studies of RBC hydration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Red blood cell hydration",
"    </span>",
"    &nbsp;&mdash;&nbsp;One approach to assessing the extent of RBC hydration is to perform density gradient analyses on peripheral blood. In patients with severe alpha thalassemia, the RBC (not only the reticulocytes and younger RBC) are uniformly of lower than normal density, are found at the top of a discontinuous Stractan gradient, and are hyperhydrated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/21\">",
"     21",
"    </a>",
"    ]. This contrasts with the RBCs of comparably anemic patients with beta thalassemia in which a few of the younger RBCs are light, but other populations are found throughout the gradient, including populations of RBCs as dense and dehydrated as those seen in severe sickle cell anemia (MCHC &gt;45) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/21\">",
"     21",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8058?source=see_link&amp;anchor=H19#H19\">",
"     \"Pathophysiology of beta thalassemia\", section on 'Red blood cell dehydration'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The Technicon Bayer H*3 Analyzer allows one to make quantitative assessments of the levels of hydration. As an example, the percent of RBCs with MCHC levels below 28, (ie, definite hypochromia) is approximately 50, 70, and 20 for HbH disease,",
"    <span class=\"nowrap\">",
"     HbH/CS,",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     HbCS/CS,",
"    </span>",
"    respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. The use of this instrument also showed that reticulocytes, as they left the marrow, were already well hydrated (increased MCV and decreased MCHC).",
"   </p>",
"   <p>",
"    The cause of the hyperhydration in alpha thalassemic RBCs is not clear. The K-Cl cotransporter is a pH and volume activated transporter that functions in the normal remodeling of reticulocytes to mature RBC. This transporter controls the loss of KCl and water, leading to a reduction in the MCV. It closes down in normal RBC but stays open in beta thalassemic and sickle cell RBCs in which it is partly responsible for the RBC dehydration in these disorders. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37224?source=see_link&amp;anchor=H10#H10\">",
"     \"Control of red blood cell hydration\", section on 'K-Cl cotransport'",
"    </a>",
"    .) It is an unproven hypothesis that, in alpha thalassemia, the K-Cl cotransporter closes down very early, thereby preventing the usual loss of K-Cl and water that is part of the remodeling process.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     HEMOLYTIC ANEMIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Studies with 51Cr-labeled RBCs in HbH disease have shown a shortened survival halftime (12 to 19 days versus 28 to 37 days in normals) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/11,16,18,20,24\">",
"     11,16,18,20,24",
"    </a>",
"    ] and evidence for increased splenic sequestration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/18,24,25\">",
"     18,24,25",
"    </a>",
"    ]. A potential error with this technique is that HbH binds more 51Cr than HbA and has a higher rate of label elution [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/20,24\">",
"     20,24",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36326?source=see_link\">",
"     \"Red blood cell survival: Normal values and measurement\"",
"    </a>",
"    .) However, studies using the noneluting cohort label glycine-2-14C showed that RBC survival in HbH disease was one-third of normal [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are other signs of uncompensated hemolysis. Patients are mildly jaundiced with indirect reacting hyperbilirubinemia and palpable splenomegaly. These results are consistent with the presence of an intracorpuscular abnormality, leading to extravascular RBC destruction by the macrophages of the reticuloendothelial system. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?18/3/18489?source=see_link\">",
"     \"Approach to the diagnosis of hemolytic anemia in the adult\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/60/43977?source=see_link\">",
"     \"Overview of hemolytic anemias in children\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The response to the anemia is evidenced by the presence of marrow erythroid hyperplasia and reticulocytosis (2.5 to 16 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/11,12,25\">",
"     11,12,25",
"    </a>",
"    ]. In addition, serum erythropoietin (EPO) values are increased, as are levels of soluble transferrin receptor (sTfR), an indicator of increased erythroid activity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/26,27\">",
"     26,27",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?25/39/26234?source=see_link\">",
"     \"Causes and diagnosis of anemia due to iron deficiency\"",
"    </a>",
"    .) The increases in EPO and sTfR are directly related to the HbH concentration which, in turn, reflects the globin chain imbalance [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following section will review the multiple factors that contribute to the enhanced extravascular removal of alpha thalassemic RBCs. Although our understanding of these processes has increased, a number of questions have been raised concerning the pathogenesis of anemia in HbH disease that will be discussed in the following sections:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      How does decreased alpha globin chain synthesis produce abnormalities in the affected RBCs that are recognized in the microvasculature and by the macrophages of the reticuloendothelial organs, leading to removal of these RBCs?",
"     </li>",
"     <li>",
"      Why are patients with HbH disease anemic, since a rate of hemolysis three times normal falls easily within the normal marrow's five- to seven-fold compensatory activity? In fact, ferrokinetic studies show an increase in erythropoiesis up to six times normal in some but not all patients [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/25\">",
"       25",
"      </a>",
"      ]. This discrepancy is thought to reflect ineffective erythropoiesis (see",
"      <a class=\"local\" href=\"#H24\">",
"       'Ineffective erythropoiesis'",
"      </a>",
"      below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     REMOVAL OF ALPHA THALASSEMIC RED BLOOD CELLS BY SPLEEN AND MACROPHAGES",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the final common pathway of extravascular destruction of circulating RBCs, abnormalities in RBC deformability slow the passage of affected RBC in the microvasculature, allowing the macrophages of the reticuloendothelial organs to carefully scrutinize these RBCs and detect any cell surface signals that could alert the macrophages to retard, bind and engulf the defective RBC.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     RBC deformability",
"    </span>",
"    &nbsp;&mdash;&nbsp;As mentioned above, the 7 to 8 micron diameter RBCs must undergo a remarkable elliptical elongation to allow passage through 3 micron diameter capillaries and even smaller slits in the sinusoids of the reticuloendothelial system. Any increase in rigidity will hold up passage through the microvascular bed and delay transit through the reticuloendothelial organs, such as the spleen. There are three major factors that control RBC deformability: the ratio of surface area to volume, internal viscosity as measured by the MCHC, and membrane features. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/41/17046?source=see_link\">",
"     \"Red blood cell mechanics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Erythrocyte deformability measurements made via osmotic gradient ektacytometry have shown that HbH RBCs are very rigid [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/21\">",
"     21",
"    </a>",
"    ]. The increase in RBC rigidity was more apparent when populations of defined MCHCs were compared in normal and HbH RBCs. The RBCs in",
"    <span class=\"nowrap\">",
"     HbH/CS",
"    </span>",
"    are even more rigid than in HbH [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/22\">",
"     22",
"    </a>",
"    ], and are most rigid in",
"    <span class=\"nowrap\">",
"     HbCS/CS",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/28\">",
"     28",
"    </a>",
"    ]. This extreme rigidity could lead to the observed RBC fragmentation in parts of the vasculature in which there is elevated shear stress. These undeformable fragments are subject to rapid removal, while the rigidity of the intact RBC impairs passage through RE organ sinusoids.",
"   </p>",
"   <p>",
"    The reduction in deformability (ie, increase in rigidity) was an unexpected finding, since two of the three factors (the third being membrane features) that determine RBC deformability would be expected to increase the deformability of RBCs in HbH disease:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Measurements of osmotic fragility, which are an index of surface area to volume",
"      <span class=\"nowrap\">",
"       (SA/V)",
"      </span>",
"      ratios, showed resistance to osmotic lysis [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/11\">",
"       11",
"      </a>",
"      ], indicating a",
"      <span class=\"nowrap\">",
"       SA/V",
"      </span>",
"      ratio higher than normal.",
"     </li>",
"     <li>",
"      The MCHC is very low in HbH RBCs, indicating that increased intracellular viscosity due to elevated hemoglobin concentrations would not be a factor contributing to reduced RBC deformability [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/21\">",
"       21",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     Membrane features",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preceding findings suggested that membrane features must play an important role in the increased rigidity of HbH RBCs. Two features have been evaluated: deformability and stability.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Deformability &mdash; Membranes from HbH RBCs are two to three times more rigid than normal [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/21,28\">",
"       21,28",
"      </a>",
"      ]. Membranes from patients with",
"      <span class=\"nowrap\">",
"       HbH/CS",
"      </span>",
"      are even more rigid, and the least deformable membranes are seen in",
"      <span class=\"nowrap\">",
"       HbCS/CS",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/28\">",
"       28",
"      </a>",
"      ]. Ektacytometric studies suggested that an interaction of the excess beta globin chains in HbH RBCs with the cytosolic face of the membrane played an important role in the membrane rigidity (see",
"      <a class=\"local\" href=\"#H21\">",
"       'Membrane bound beta globin chains'",
"      </a>",
"      below)&nbsp;[",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/21\">",
"       21",
"      </a>",
"      ]. The further increase in rigidity in the HbCS variants appears to be caused by the combination membrane-bound beta globin chains and oxidized alpha CS globin chains [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Stability &mdash; Membrane stability is a technical term used to describe the ability of isolated RBC membranes to resist fragmentation under an intense elliptically deforming shear stress [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/21\">",
"       21",
"      </a>",
"      ]. Membrane stability is generally thought to be a function of the RBC membrane skeleton and the interaction of the skeleton with the major transmembrane protein, band 3. The same gradation noted above for membrane rigidity was noted for membrane stability: increased in HbH, more stable in",
"      <span class=\"nowrap\">",
"       HbH/CS,",
"      </span>",
"      and maximally stable in",
"      <span class=\"nowrap\">",
"       HbCS/CS",
"      </span>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/28\">",
"       28",
"      </a>",
"      ]. These changes are thought to be due to the membrane bound beta globin and alpha CS globin chains (see",
"      <a class=\"local\" href=\"#H22\">",
"       'Role of oxidant injury'",
"      </a>",
"      below). They are in marked contrast to the highly unstable RBC membranes in beta thalassemia, a change induced by partially oxidized alpha globin chains. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8058?source=see_link&amp;anchor=H17#H17\">",
"       \"Pathophysiology of beta thalassemia\", section on 'Membrane instability'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The combined consequences of increased RBC rigidity and increased membrane stability are likely to be slowed flow in the vasculature of the reticuloendothelial organs, giving macrophages ample opportunity to look for signals indicating RBC membrane senescence",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    damage, including bound IgG and complement components, or altered membrane phospholipid bilayer asymmetry (see below).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Red blood cell inclusions",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial descriptions of HbH disease identified inclusions that occurred spontaneously in some RBCs, were much more common in splenectomized subjects, and could be induced by incubating RBCs with mild oxidants such as brilliant cresyl blue or new",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/11,12,18,22\">",
"     11,12,18,22",
"    </a>",
"    ]. At the time of splenectomy, inclusion rich RBCs can be found in the spleen, providing a reason for the increased number of inclusion-containing RBCs in HbH patients following splenectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/18\">",
"     18",
"    </a>",
"    ]. These inclusions were thought to be aggregates of beta chain tetramers (ie, beta-4 or HbH).",
"   </p>",
"   <p>",
"    When RBCs from patients with HbH are separated by density into young, middle aged, and old cells, the level of soluble HbH is highest in young cells, where the number of inclusion containing cells is lowest. As the cells age (ie, became more dense), the amount of soluble HbH decreases while the proportion of inclusions increases. These observations led to the hypothesis that after about 45 days of in vivo aging, HbH began to precipitate within the RBC, forming inclusions which damage the RBC, leading to their removal at least partly in the spleen [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Inclusions have been described by electron microscopy in 67 and 79 percent of RBC in HbH and",
"    <span class=\"nowrap\">",
"     HbH/CS,",
"    </span>",
"    respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/22\">",
"     22",
"    </a>",
"    ]. The cytosolic levels of HbH differ between these two variants, with HbH RBC having mean levels of 9.3 percent HbH while the value is 15.3 percent in patients with",
"    <span class=\"nowrap\">",
"     HbH/CS",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/29\">",
"     29",
"    </a>",
"    ]. Thus, the cytosolic concentration of HbH is directly proportional to the number of inclusions.",
"   </p>",
"   <p>",
"    Convincing proof that these inclusions consisted of beta globin chains was obtained by combining electron microscopy with monoclonal antibodies against beta globin [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/30\">",
"     30",
"    </a>",
"    ]. The presence of inclusions, certainly those that are membrane bound, interferes with the ability of the RBC to undergo the requisite tank treading motion, thereby slowing its passage through the microvasculature.",
"   </p>",
"   <p>",
"    The heme moiety attached to the beta-4 tetramers undergoes oxidative alteration, with conversion to hemichromes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/31\">",
"     31",
"    </a>",
"    ]. These iron containing hemichromes are capable of generating reactive oxygen species (ROS), perhaps by acting as Fenton reagents (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35129?source=see_link&amp;anchor=H2#H2\">",
"     \"Pathophysiology and diagnosis of iron overload syndromes\", section on 'Iron toxicity'",
"    </a>",
"    ). These ROS can, in turn, oxidize adjacent RBC membrane proteins and lipids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. Thus, further RBC membrane damage may occur as a result of local oxidative damage.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     Phosphatidylserine signaling",
"    </span>",
"    &nbsp;&mdash;&nbsp;An important question is how a globin chain synthetic defect within the RBC leads to changes in the outer RBC membrane. One hypothesis is that the denatured HbH inclusions lying adjacent to the membrane damage it via oxidant mechanisms (see above), resulting in an alteration in the normal pattern of phospholipid bilayer asymmetry.",
"   </p>",
"   <p>",
"    One of the messages that macrophages identify on the surface of RBCs marked for removal is the presence of exposed phosphatidylserine (PS) which has \"flopped\" from the inner to the outer leaflet of the membrane phospholipid bilayer. In normal RBCs, PS is confined to the inner half of the membrane phospholipid bilayer and therefore does not provide a signal to macrophages [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/34\">",
"     34",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/2/13352?source=see_link\">",
"     \"Red blood cell membrane dynamics and organization\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hemoglobin H,",
"    <span class=\"nowrap\">",
"     HbCS/CS,",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     HbH/CS",
"    </span>",
"    have RBCs with PS on the outer leaflet of the membrane phospholipid bilayer, although the absolute number of such RBCs in the circulation is relatively small [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/35\">",
"     35",
"    </a>",
"    ]. However, the low number may reflect rapid removal of such RBCs from the circulation by the macrophages in the spleen and other reticuloendothelial organs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     Membrane IgG and complement",
"    </span>",
"    &nbsp;&mdash;&nbsp;Macrophages target RBCs for removal from the circulation by identifying the Fc domains of IgG on the RBC's outer membrane surface. Increases in membrane IgG and complement components are a likely contributor to the increased phagocytosis of alpha thalassemic RBCs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/36\">",
"     36",
"    </a>",
"    ]. Nonsplenectomized patients with HbH disease have RBC IgG levels that are normal. However, RBC IgG levels increase after splenectomy suggesting that such cells had been removed by the spleen.",
"    <span class=\"nowrap\">",
"     HbH/CS",
"    </span>",
"    RBCs, even from nonsplenectomized subjects, have more membrane associated IgG than either normal or HbH RBCs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/37\">",
"     37",
"    </a>",
"    ]. Increased expression of antigens that may be similar to senescent antigens may provide the signal for IgG deposition.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Macrophage colony-stimulating factor",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serum concentrations of",
"    <span class=\"nowrap\">",
"     macrophage/monocyte",
"    </span>",
"    colony-stimulating factor (M-CSF) are elevated in HbH disease and correlate inversely with the patient's hemoglobin concentration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/38\">",
"     38",
"    </a>",
"    ]. It has been proposed that M-CSF enhances the phagocytosis of HbH RBCs, thereby contributing to the severity of the anemia.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     BIOCHEMICAL AND CELLULAR ALTERATIONS LEADING TO HEMOLYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The challenge remains to discover how an impairment in synthesis of alpha globin chains produces the cellular alterations described above that in turn lead to hemolysis. Several biochemical studies provide a partial explanation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Membrane bound beta globin chains",
"    </span>",
"    &nbsp;&mdash;&nbsp;HbH disease is characterized by a prominent globin band seen on SDS polyacrylamide gel electrophoresis of the RBC membranes (",
"    <a class=\"graphic graphic_figure graphicRef53915 \" href=\"mobipreview.htm?11/63/12275\">",
"     figure 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/39\">",
"     39",
"    </a>",
"    ]. A variable amount of this globin consists of HbA, probably in the form of alpha-beta dimers. However, there is only beta globin when one isolates membrane skeletons. This probably represents excess unmatched beta globin that is now firmly attached to the membrane skeleton (",
"    <a class=\"graphic graphic_figure graphicRef63845 \" href=\"mobipreview.htm?24/17/24849\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/30,39\">",
"     30,39",
"    </a>",
"    ]. This membrane bound beta globin has also undergone partial oxidation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These findings are a direct mirror image of the situation in severe beta thalassemia in which partially oxidized alpha globin chains are bound to the RBC membrane skeleton [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/39\">",
"     39",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8058?source=see_link\">",
"     \"Pathophysiology of beta thalassemia\"",
"    </a>",
"    .) It has therefore been hypothesized that skeletal bound, partially oxidized beta globin chains account for much of the observed membrane pathophysiology in the alpha thalassemias. In both disorders, membrane damage produced by the accumulation of excess globin chains (ie, excess alpha globin chains in beta thalassemia and excess beta globin chains in alpha thalassemia) may be reduced by the action of proteases, which directly attack and destroy these excess globin chains [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/40\">",
"     40",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Hemoglobin Constant Spring (CS) variants provide an opportunity for further exploring the pathophysiology of the alpha thalassemias. As noted above,",
"    <span class=\"nowrap\">",
"     HbH/CS",
"    </span>",
"    usually produces a more severe anemia than seen in HbH disease. These RBCs are hyperhydrated and have more inclusions than HbH RBCs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/23,41\">",
"     23,41",
"    </a>",
"    ], are poorly deformable, and their membranes are very rigid and hyperstable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/28\">",
"     28",
"    </a>",
"    ]. The biochemical counterpart of these changes is the presence on the red cell membrane skeleton of partially oxidized alpha CS globin chains as well as partially oxidized beta globin chains; similar findings are seen in",
"    <span class=\"nowrap\">",
"     HbCS/CS",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Role of oxidant injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a recurrent theme that membrane skeletal-associated globin chains with attached hemes, hemichromes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/31\">",
"     31",
"    </a>",
"    ], and iron causes local oxidant damage to the membrane. The earliest reports of HbH disease noted the presence of inclusions which could be much increased by incubation with mild oxidants, such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/7/1143?source=see_link\">",
"     methylene blue",
"    </a>",
"    and brilliant cresyl blue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. A clinical counterpart is the observation that the hemolysis may be exacerbated when patients with HbH disease are exposed to oxidant drugs such as the sulfonamides [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In experiments designed to model the oxidant damage, normal RBCs were incubated with methylhydrazine (MHZ) and phenylhydrazine (PHZ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/42\">",
"     42",
"    </a>",
"    ]. MHZ induced the binding of oxidized beta globin chains to the membrane skeleton and the membranes became hyperstable, as is typical for severe alpha thalassemia. In contrast, PHZ induced the binding of oxidized alpha globin chains to the membrane skeleton. The resulting membranes were unstable as measured in the ektacytometer, exactly as seen in the RBCs in severe beta thalassemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8058?source=see_link\">",
"     \"Pathophysiology of beta thalassemia\"",
"    </a>",
"    .) Similar findings can be induced by resealing isolated and purified alpha and beta globin chains within normal RBCs, providing further support for the hypothesis that specific oxidized excess globin chains are responsible for the cellular pathophysiology of thalassemic RBCs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A variety of other observations are consistent with the hypothesis that the alpha thalassemic RBC is under considerable oxidant stress [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/44\">",
"     44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Hexosemonophosphate shunt activity is decreased in young HbH RBC [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/45\">",
"       45",
"      </a>",
"      ]. This metabolic pathway controls the recycling of oxidized to reduced glutathione, as well as the generation of the reducing agent NADPH.",
"     </li>",
"     <li>",
"      Superoxide dismutase, GSH peroxidase, and catalase are increased in HbH RBCs and even further increased in",
"      <span class=\"nowrap\">",
"       HbH/CS",
"      </span>",
"      RBCs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/46\">",
"       46",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Other evidence of RBC membrane damage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have provided additional evidence of RBC membrane damage in alpha thalassemia. As an example, one can prepare an integral protein-rich fraction of RBC membranes and measure the binding of the major skeletal protein, spectrin. This preparation is called inside-out vesicles (IOVs). Vesicles from HbH RBCs bind only one-half the amount of spectrin as vesicles from normal RBCs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/47\">",
"     47",
"    </a>",
"    ]. This defect can be reproduced by adding heme-containing alpha globin chains to normal RBC membranes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These findings suggest that assembly of the skeleton in alpha thalassemia RBCs is defective. Consistent with this hypothesis is the presence of spectrin, actin, and band-4.1 free in the supernatant wash medium during the preparation of RBC membranes by stepwise hypotonic lysis of alpha thalassemic but not normal RBCs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/1\">",
"     1",
"    </a>",
"    ]. However, the significance of these abnormalities is uncertain since they suggest that the membrane would be unstable, while, as noted above, the alpha thalassemic membrane is hyperstable [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     INEFFECTIVE ERYTHROPOIESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of observations suggest that it is the combination of ineffective erythropoiesis, a suboptimal increase in erythropoiesis, and peripheral hemolysis that leads to the anemia in HbH disease.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Some older studies showed that the erythropoietic rate could increase up to six times normal in HbH disease [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/24,25\">",
"       24,25",
"      </a>",
"      ]. However, ferrokinetic studies have shown that overall erythropoiesis was increased up to three times normal, while the red cell radioiron utilization rate, a measure of ineffective erythropoiesis, was slightly lower than normal at 75 percent (normal &gt;80 percent) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/49\">",
"       49",
"      </a>",
"      ]. Since the rate of hemolysis in HbH is only increased three-fold, it is not clear why the marrow, which normally has a five-fold or greater capacity to increase erythropoiesis, does not do so.",
"     </li>",
"     <li>",
"      Other signs of increased erythroid activity include increases in serum soluble transferrin receptor (sTfR) and the reticulocyte production index [",
"      <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/26,27\">",
"       26,27",
"      </a>",
"      ]. The magnitude of these findings is proportional to the HbH level.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In",
"    <span class=\"nowrap\">",
"     HbH/CS,",
"    </span>",
"    peripheral red cell destruction is increased, with a 51Cr red cell survival of 8.3 days (normal: 26 days); erythropoiesis is increased up to five times normal, and there is a modest component of ineffective erythropoiesis, with an iron reutilization level of 59 percent (normal &gt;80 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In",
"    <span class=\"nowrap\">",
"     HbCS/CS,",
"    </span>",
"    which should have the phenotype of an alpha thalassemia trait, subjects are anemic with hemoglobin values of 10.9",
"    <span class=\"nowrap\">",
"     g/dL,",
"    </span>",
"    a 51Cr survival of 13.7 days, an erythropoietic rate three times normal, and a modest degree of ineffective erythropoiesis (iron reutilization rate 58 percent).",
"   </p>",
"   <p>",
"    Several factors are thought to contribute to the ineffective erythropoiesis in HbH disease including excess beta globin chains, apoptosis (programmed cell death), and perhaps IgG deposition on the surface of erythroid precursors. Although the beta globin inclusions in HbH occur primarily in circulating red cells as they age [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/18\">",
"     18",
"    </a>",
"    ], excess beta globin chains also may accumulate and precipitate in marrow erythroid precursors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. This deposition of insoluble beta globin could provide the basis for oxidant or other cellular injury leading to the intramedullary death of RBC precursors. The increase in ineffective erythropoiesis in",
"    <span class=\"nowrap\">",
"     HbH/CS",
"    </span>",
"    and",
"    <span class=\"nowrap\">",
"     HbCS/CS",
"    </span>",
"    is probably due to the binding of alphaCS, in addition to beta chains, to the membranes of erythroid precursors.",
"   </p>",
"   <p>",
"    Ineffective erythropoiesis has been correlated with apoptosis of marrow erythroblasts in severe beta thalassemia, at rates which are about five times normal. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8058?source=see_link&amp;anchor=H26#H26\">",
"     \"Pathophysiology of beta thalassemia\", section on 'Apoptosis of red cell precursors'",
"    </a>",
"    .) In fact, the extent of erythroid apoptosis correlates very closely with the extent of ineffective erythropoiesis in both alpha and beta thalassemia variants (",
"    <a class=\"graphic graphic_figure graphicRef65431 \" href=\"mobipreview.htm?13/2/13358\">",
"     figure 4",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/49\">",
"     49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    One of the consequences and hallmarks of apoptosis is the movement of phosphatidylserine (PS) from the inner to the outer leaflet of the membrane phospholipid bilayer. As mentioned above, the movement of PS to the outer leaflet may be one of the signals that promotes removal of thalassemic cells by the reticuloendothelial system. The deposition of IgG on the cell surface may provide another such signal. Erythroblasts from patients with HbH have excessive amounts of IgG on their surfaces, suggesting that this may contribute to the ineffective erythropoiesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h1\">",
"     HYDROPS FETALIS AND HEMOGLOBIN BART'S",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hydrops fetalis syndrome with hemoglobin Bart's is the most severe form of alpha thalassemia as there is no alpha globin chain production. Because alpha chains are produced after the fifth or sixth week of fetal life, affected fetuses have great difficulty in synthesizing a functional hemoglobin. Gamma chains accumulate and form gamma-4 tetramers (Hb Bart's); HbBart's binds oxygen but cannot release it to tissues because its affinity for oxygen is at least 10 times greater than HbA. Unlike HbH, HbBart's has little propensity to precipitate and form inclusions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/52\">",
"     52",
"    </a>",
"    ]. Similar abnormalities are seen with homozygous alpha globin gene deletion in mice; induction of a human alpha globin transgene can rescue these animals from perinatal death [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    If the molecular defect allows the fetus to synthesize zeta chains, an embryonic variant of the alpha chain, then the fetus can make HbPortland (zeta 2 gamma 2) and survive in utero until the third trimester [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/54\">",
"     54",
"    </a>",
"    ]. These fetuses are functionally severely anemic, despite the fact that the measured hemoglobin concentration may be as high as 10",
"    <span class=\"nowrap\">",
"     g/dL",
"    </span>",
"    due to the presence of HbBart's and HbPortland. The RBC are hypochromic and microcytic, and erythropoiesis is vastly expanded to compensate for the resulting profound tissue hypoxia, with compensatory extramedullary erythropoiesis in the liver and spleen. A small component of hemoglobin H (beta-4 tetramers) may also be present if the fetus can synthesize beta chains.",
"   </p>",
"   <p>",
"    The severe functional anemia causes heart failure with anasarca and capillary leak (\"hydrops\"). The capillary leak may be caused by increased secretion of vascular endothelial growth factor (VEGF) by the stressed fetal heart [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/55\">",
"     55",
"    </a>",
"    ]. Other defects include a massively enlarged placenta and severe maternal complications, such as hypertension and polyhydramnios.",
"   </p>",
"   <p>",
"    Hydrops fetalis is incompatible with extrauterine life. However, antenatal diagnosis with transfusional",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    parental stem cell infusions followed by allogeneic bone marrow transplantation has resulted in some surviving patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?35/11/36025/abstract/56,57\">",
"     56,57",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12451800\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Thalassemia refers to a spectrum of diseases characterized by reduced or absent production of one (or rarely more) of the globin chains of hemoglobin. Alpha thalassemia is due to impaired production of alpha globin chains, which leads to a relative excess of gamma globin chains in the fetus and newborn, and beta globin chains in children and adults.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In alpha thalassemia, excess beta globin chains are unstable and some precipitate within the cell, leading to a variety of laboratory findings (eg, hypochromic, microcytic red cells) and clinical manifestations (eg, anemia, ineffective erythropoiesis, decreased red cell deformability, hemolysis, oxidant sensitivity), depending upon how many of the four normally present alpha globin chain genes are deleted or mutated. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Definitions'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/13/38106?source=see_link&amp;anchor=H29#H29\">",
"       \"Clinical manifestations and diagnosis of the thalassemias\", section on 'The alpha thalassemia syndromes'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Since all normal hemoglobins of postnatal life contain alpha chains, homozygous alpha (0) thalassemia (ie, loss of all four alpha globin genes) is incompatible with extrauterine life, leading to hydrops fetalis",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      death shortly after delivery, unless blood transfusion",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hematopoietic cell transplantation can be performed in time. (See",
"      <a class=\"local\" href=\"#H25\">",
"       'Hydrops fetalis and hemoglobin Bart's'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/1\">",
"      Yuan J, Bunyaratvej A, Fucharoen S, et al. The instability of the membrane skeleton in thalassemic red blood cells. Blood 1995; 86:3945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/2\">",
"      Chui DH, Fucharoen S, Chan V. Hemoglobin H disease: not necessarily a benign disorder. Blood 2003; 101:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/3\">",
"      Chen FE, Ooi C, Ha SY, et al. Genetic and clinical features of hemoglobin H disease in Chinese patients. N Engl J Med 2000; 343:544.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/4\">",
"      Weatherall D. The molecular basis for phenotypic variability of the common thalassaemias. Mol Med Today 1995; 1:15.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/5\">",
"      Clegg JB, Weatherall DJ. Thalassemia and malaria: new insights into an old problem. Proc Assoc Am Physicians 1999; 111:278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/6\">",
"      Flint J, Hill AV, Bowden DK, et al. High frequencies of alpha-thalassaemia are the result of natural selection by malaria. Nature 1986; 321:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/7\">",
"      Williams TN, Maitland K, Bennett S, et al. High incidence of malaria in alpha-thalassaemic children. Nature 1996; 383:522.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/8\">",
"      Allen SJ, O'Donnell A, Alexander ND, et al. alpha+-Thalassemia protects children against disease caused by other infections as well as malaria. Proc Natl Acad Sci U S A 1997; 94:14736.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/9\">",
"      Mockenhaupt FP, Ehrhardt S, Gellert S, et al. Alpha(+)-thalassemia protects African children from severe malaria. Blood 2004; 104:2003.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/10\">",
"      Pattanapanyasat K, Yongvanitchit K, Tongtawe P, et al. Impairment of Plasmodium falciparum growth in thalassemic red blood cells: further evidence by using biotin labeling and flow cytometry. Blood 1999; 93:3116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/11\">",
"      RIGAS DA, KOLER RD, OSGOOD EE. Hemoglobin H; clinical, laboratory, and genetic studies of a family with a previously undescribed hemoglobin. J Lab Clin Med 1956; 47:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/12\">",
"      Gouttas A, Fessas PH, Tsevrenis H, et al. Description d'une nouvelle vari&eacute;t&eacute; d'an&eacute;mie h&eacute;molytique cong&eacute;nitale. Vox Sang 1955; 26:911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/13\">",
"      DANCE N, HUEHNS ER, BEAVEN GH. The abnormal haemoglobins in haemoglobin-H disease. Biochem J 1963; 87:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/14\">",
"      Wood WG, Stamatoyannopoulos G. synthesis during erythroid cell maturation in alpha thalassemia. Hemoglobin 1976-77; 1:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/15\">",
"      Gabuzda TG. Hemoglobin H and the red cell. Blood 1966; 27:568.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/16\">",
"      Nathan DG, Gunn RB. Thalassemia: the consequences of unbalanced hemoglobin synthesis. Am J Med 1966; 41:815.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/17\">",
"      Lehmann H. Different types of alpha-thalassemia and significance of haemoglobin Bart's in neonates. Lancet 1970; 2:78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/18\">",
"      RIGAS DA, KOLER RD. Decreased erythrocyte survival in hemoglobin H disease as a result of the abnormal properties of hemoglobin H: the benefit of splenectomy. Blood 1961; 18:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/19\">",
"      BENESCH R, BENESCH RE. PROPERTIES OF HAEMOGLOBIN H AND THEIR SIGNIFICANCE IN RELATION TO FUNCTION OF HAEMOGLOBIN. Nature 1964; 202:773.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/20\">",
"      GABUZDA TG, NATHAN DG, GARDNER FH. THE METABOLISM OF THE INDIVIDUAL C14 LABELED HEMOGLOBINS IN PATIENTS WITH H-THALASSEMIA, WITH OBSERVATIONS ON RADIOCHROMATE BINDING TO THE HEMOGLOBINS DURING RED CELL SURVIVAL. J Clin Invest 1965; 44:315.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/21\">",
"      Schrier SL, Rachmilewitz E, Mohandas N. Cellular and membrane properties of alpha and beta thalassemic erythrocytes are different: implication for differences in clinical manifestations. Blood 1989; 74:2194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/22\">",
"      Bunyaratvej A, Sahaphong S, Bhamarapravati N, Wasi P. Different patterns of intraerythrocytic inclusion body distribution in the two types of haemoglobin H disease. An ultrastructural study. Acta Haematol 1983; 69:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/23\">",
"      Bunyaratvej A, Butthep P, Fucharoen S, Saw D. Erythrocyte volume and haemoglobin concentration in haemoglobin H disease: discrimination between the two genotypes. Acta Haematol 1992; 87:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/24\">",
"      PEARSON HA, McFARLAND W. Erythrokinetics in thalassemia. II. Studies in Lepore trait and hemoglobin H disease. J Lab Clin Med 1962; 59:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/25\">",
"      Malamos B, Gyftaki E, Binopoulos D, et al. Studies of haemoglobin synthesis and red cell survival in haemoglobinopathy. Acta Haematol 1962; 28:124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/26\">",
"      Papassotiriou I, Traeger-Synodinos J, Kanavakis E, et al. Erythroid marrow activity and hemoglobin H levels in hemoglobin H disease. J Pediatr Hematol Oncol 1998; 20:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/27\">",
"      Rees DC, Williams TN, Maitland K, et al. Alpha thalassaemia is associated with increased soluble transferrin receptor levels. Br J Haematol 1998; 103:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/28\">",
"      Schrier SL, Bunyaratvej A, Khuhapinant A, et al. The unusual pathobiology of hemoglobin constant spring red blood cells. Blood 1997; 89:1762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/29\">",
"      Adirojnanon P, Wasi P. Levels of haemoglobin H and proportions of red cells with inclusion bodies in the two types of haemoglobin H disease. Br J Haematol 1980; 46:507.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/30\">",
"      Wickramasinghe SN, Lee MJ, Furukawa T, et al. Composition of the intra-erythroblastic precipitates in thalassaemia and congenital dyserythropoietic anaemia (CDA): identification of a new type of CDA with intra-erythroblastic precipitates not reacting with monoclonal antibodies to alpha- and beta-globin chains. Br J Haematol 1996; 93:576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/31\">",
"      Rachmilewitz EA, Peisach J, Bradley TB, Blumberg WE. Role of haemichromes in the formation of inclusion bodies in haemoglobin H disease. Nature 1969; 222:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/32\">",
"      Waugh SM, Low PS. Hemichrome binding to band 3: nucleation of Heinz bodies on the erythrocyte membrane. Biochemistry 1985; 24:34.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/33\">",
"      Hebbel RP. Auto-oxidation and a membrane-associated 'Fenton reagent': a possible explanation for development of membrane lesions in sickle erythrocytes. Clin Haematol 1985; 14:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/34\">",
"      Allen TM, Williamson P, Schlegel RA. Phosphatidylserine as a determinant of reticuloendothelial recognition of liposome models of the erythrocyte surface. Proc Natl Acad Sci U S A 1988; 85:8067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/35\">",
"      Kuypers FA, Yuan J, Lewis RA, et al. Membrane phospholipid asymmetry in human thalassemia. Blood 1998; 91:3044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/36\">",
"      Chinprasertsuk S, Wanachiwanawin W, Pattanapanyasat K, et al. Relation of haemolytic anaemia and erythrocyte-bound IgG in alpha- and beta-thalassaemic syndromes. Eur J Haematol 1997; 58:86.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/37\">",
"      Wiener E, Wanachiwanawin W, Kotipan K, et al. Erythroblast- and erythrocyte-bound antibodies in alpha and beta thalassaemia syndromes. Transfus Med 1991; 1:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/38\">",
"      Wiener E, Wanachiwanawin W, Chinprasertsuk S, et al. Increased serum levels of macrophage colony-stimulating factor (M-CSF) in alpha- and beta-thalassaemia syndromes: correlation with anaemia and monocyte activation. Eur J Haematol 1996; 57:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/39\">",
"      Advani R, Sorenson S, Shinar E, et al. Characterization and comparison of the red blood cell membrane damage in severe human alpha- and beta-thalassemia. Blood 1992; 79:1058.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/40\">",
"      Sancar GB, Cedeno MM, Rieder RF. Rapid destruction of newly synthesized excess beta-globin chains in HbH disease. Blood 1981; 57:967.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/41\">",
"      Pootrakul P, Winichagoon P, Fucharoen S, et al. Homozygous haemoglobin Constant Spring: a need for revision of concept. Hum Genet 1981; 59:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/42\">",
"      Schrier SL, Mohandas N. Globin-chain specificity of oxidation-induced changes in red blood cell membrane properties. Blood 1992; 79:1586.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/43\">",
"      Scott MD, Rouyer-Fessard P, Ba MS, et al. Alpha- and beta-haemoglobin chain induced changes in normal erythrocyte deformability: comparison to beta thalassaemia intermedia and Hb H disease. Br J Haematol 1992; 80:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/44\">",
"      Cheng ML, Ho HY, Tseng HC, et al. Antioxidant deficit and enhanced susceptibility to oxidative damage in individuals with different forms of alpha-thalassaemia. Br J Haematol 2005; 128:119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/45\">",
"      Nathan DG, Stossel TB, Gunn RB, et al. Influence of hemoglobin precipitation on erythrocyte metabolism in alpha and beta thalassemia. J Clin Invest 1969; 48:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/46\">",
"      Prasartkaew S, Bunyaratvej A, Fucharoen S, Wasi P. Comparison of erythrocyte antioxidative enzyme activities between two types of haemoglobin H disease. J Clin Pathol 1986; 39:1299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/47\">",
"      Shinar E, Rachmilewitz EA, Lux SE. Differing erythrocyte membrane skeletal protein defects in alpha and beta thalassemia. J Clin Invest 1989; 83:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/48\">",
"      Shalev O, Shinar E, Lux SE. Isolated beta-globin chains reproduce, in normal red cell membranes, the defective binding of spectrin to alpha-thalassaemic membranes. Br J Haematol 1996; 94:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/49\">",
"      Pootrakul P, Sirankapracha P, Hemsorach S, et al. A correlation of erythrokinetics, ineffective erythropoiesis, and erythroid precursor apoptosis in thai patients with thalassemia. Blood 2000; 96:2606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/50\">",
"      Fessas P, Yatachanas X. Intraerythroblastic instability of hemoglobin beta-4 (Hgb H). Blood 1968; 31:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/51\">",
"      Wickramasinghe SN, Hughes M, Fucharoen S, Wasi P. The fate of excess beta-globin chains within erythropoietic cells in alpha-thalassaemia 2 trait, alpha-thalassaemia 1 trait, haemoglobin H disease and haemoglobin Q-H disease: an electron microscope study. Br J Haematol 1984; 56:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/52\">",
"      Chui DH, Waye JS. Hydrops fetalis caused by alpha-thalassemia: an emerging health care problem. Blood 1998; 91:2213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/53\">",
"      P&aacute;szty C, Mohandas N, Stevens ME, et al. Lethal alpha-thalassaemia created by gene targeting in mice and its genetic rescue. Nat Genet 1995; 11:33.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/54\">",
"      Randhawa ZI, Jones RT, Lie-Injo LE. Human hemoglobin Portland II (zeta 2 beta 2). Isolation and characterization of Portland hemoglobin components and their constituent globin chains. J Biol Chem 1984; 259:7325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/55\">",
"      Brandenburg H, Bartelings MM, Wisse LJ, et al. Increased expression of vascular endothelial growth factor in cardiac structures of fetus with hydrops as compared to nonhydropic controls. Fetal Diagn Ther 2006; 21:84.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/56\">",
"      Ng PC, Fok TF, Lee CH, et al. Is homozygous alpha-thalassaemia a lethal condition in the 1990s? Acta Paediatr 1998; 87:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?35/11/36025/abstract/57\">",
"      Hayward A, Ambruso D, Battaglia F, et al. Microchimerism and tolerance following intrauterine transplantation and transfusion for alpha-thalassemia-1. Fetal Diagn Ther 1998; 13:8.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7103 Version 9.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0605-61.234.146.186-0B2EC3AACF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_11_36025=[""].join("\n");
var outline_f35_11_36025=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H12451800\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DEFINITIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Alpha (0) thalassemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Alpha (+) thalassemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8671883\">",
"      Complex alpha thalassemia variants",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Anemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Protection against severe malaria",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      HISTORICAL PERSPECTIVE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Consequences of impaired alpha globin synthesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MORPHOLOGY OF ALPHA THALASSEMIC RED BLOOD CELLS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Red blood cell size and shape",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Red blood cell hydration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      HEMOLYTIC ANEMIA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      REMOVAL OF ALPHA THALASSEMIC RED BLOOD CELLS BY SPLEEN AND MACROPHAGES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      RBC deformability",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - Membrane features",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Red blood cell inclusions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      Phosphatidylserine signaling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      Membrane IgG and complement",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Macrophage colony-stimulating factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      BIOCHEMICAL AND CELLULAR ALTERATIONS LEADING TO HEMOLYSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Membrane bound beta globin chains",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Role of oxidant injury",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Other evidence of RBC membrane damage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      INEFFECTIVE ERYTHROPOIESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      HYDROPS FETALIS AND HEMOGLOBIN BART'S",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12451800\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7103\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7103|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?6/32/6656\" title=\"figure 1\">",
"      Alpha and beta globin gene clusters",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?11/63/12275\" title=\"figure 2\">",
"      Globin bands Hb H disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?24/17/24849\" title=\"figure 3\">",
"      Beta globin bands Hb H disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?13/2/13358\" title=\"figure 4\">",
"      Apoptosis in thalassemia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?18/3/18489?source=related_link\">",
"      Approach to the diagnosis of hemolytic anemia in the adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?25/39/26234?source=related_link\">",
"      Causes and diagnosis of anemia due to iron deficiency",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/13/38106?source=related_link\">",
"      Clinical manifestations and diagnosis of the thalassemias",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?36/22/37224?source=related_link\">",
"      Control of red blood cell hydration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/58/9129?source=related_link\">",
"      Molecular pathology of the thalassemic syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/60/43977?source=related_link\">",
"      Overview of hemolytic anemias in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/19/35129?source=related_link\">",
"      Pathophysiology and diagnosis of iron overload syndromes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?7/55/8058?source=related_link\">",
"      Pathophysiology of beta thalassemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?20/23/20858?source=related_link\">",
"      Protection against malaria in the hemoglobinopathies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/41/17046?source=related_link\">",
"      Red blood cell mechanics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/2/13352?source=related_link\">",
"      Red blood cell membrane dynamics and organization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/30/36326?source=related_link\">",
"      Red blood cell survival: Normal values and measurement",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?22/29/23001?source=related_link\">",
"      Structure and function of normal human hemoglobins",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f35_11_36026="Pyogenic granuloma histology 1";
var content_f35_11_36026=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F71936%7EDERM%2F50978&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F71936%7EDERM%2F50978&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pyogenic granuloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 343px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pyogenic granuloma from the neck of a 4-year-old boy. Histologic sections of skin show a polypoid lesion with an epidermal collarette. There is a vague lobular architecture to the vascular proliferation, and in this case, not much inflammation.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Greg Hosler, MD, PhD, Dermatlas;",
"     <a href=\"file://www.dermatlas.org\" target=\"_blank\">",
"      file://www.dermatlas.org",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    Pyogenic granuloma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pyogenic granuloma from the neck of a 4-year-old boy. At higher power, the lesion consists of condensed small-caliber vessels with scattered red blood cells. The stroma is fibromyxoid with scattered inflammatory cells. Cytologic atypia and mitoses are not present, but can be seen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Copyright &copy; Greg Hosler, MD, PhD, Dermatlas;",
"     <a href=\"file://www.dermatlas.org\" target=\"_blank\">",
"      file://www.dermatlas.org",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_11_36026=[""].join("\n");
var outline_f35_11_36026=null;
var title_f35_11_36027="Stress fx risk factors";
var content_f35_11_36027=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F79279&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F79279&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Risk factors for stress fractures",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Known risk factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prior stress fracture",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poor bone health (osteopenia and osteoporosis)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Substantial increase in intensity and volume of activities (eg, boot camp)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Decreased physical fitness level",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Dietary disorders (eg, low calcium intake, eating disorders)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Family history of osteopenia or osteoporosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Poor body biomechanics",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Female gender",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Menstrual irregularity in females",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Prolonged glucocorticoid use",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Factors of uncertain risk",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Shoe type",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Foot anatomy (eg, extreme high arch)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Muscle inflexibility",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low testosterone levels in men",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Factors disproven as risk factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Running surface",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Moderate alcohol use",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_11_36027=[""].join("\n");
var outline_f35_11_36027=null;
var title_f35_11_36028="ACC AHA manage high risk for HF";
var content_f35_11_36028=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F75241&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F75241&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Prevention of chronic heart failure (HF): Patients at high risk of developing HF (stage A)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class I - There is evidence and/or general agreement that the following approaches are effective in the management of patients at high risk of developing HF:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        &bull;&nbsp; The following problems should be treated according to recommended guidelines:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        1. Systolic and diastolic hypertension.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        2. Lipid disorders.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        3. Blood glucose control in diabetes mellitus.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        4. The above and other secondary prevention measures in patients with atherosclerotic vascular disease.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        5. Thyroid disorders.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Avoidance of behaviors that may increase the risk of HF, such as smoking, excessive alcohol consumption, and illicit drug use.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; The ventricular rate should be controlled or sinus rhythm restored in patients with supraventricular tachyarrhythmias.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Periodic evaluation for signs and symptoms of HF.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Noninvasive determination of left ventricular ejection fraction in patients with a strong family history of cardiomyopathy or those treated with cardiotoxic interventions.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The weight of evidence or opinion is in favor of the usefulness of the following approach for the management of patients at high risk of developing HF:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Angiotensin converting enzyme inhibitors or angiotensin II receptor blockers to prevent HF in patients at high risk for developing HF due to a history of atherosclerotic vascular disease, diabetes mellitus, or hypertension with associated cardiovascular risk factors.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Angiotensin II receptor blockers can be useful to prevent HF in patients at high risk for developing HF who have a history of atherosclerotic vascular disease, diabetes mellitus, or hypertension with associated cardiovascular risk factors.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - There is evidence and/or general agreement that the following approach is not useful or may be harmful in the management of patients at high risk of developing HF:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull;&nbsp; Routine use of nutritional supplements solely to prevent the development of structural heart disease.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Hunt, SA, Abraham, WT, Chin, MH, et al. ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation: endorsed by the Heart Rhythm Society. Circulation 2005; 112:e154.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_11_36028=[""].join("\n");
var outline_f35_11_36028=null;
var title_f35_11_36029="Exercise after LVRS or lung transplantation";
var content_f35_11_36029=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F54892&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F54892&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Exercise after lung volume reduction surgery (LVRS) or lung transplantation in emphysema",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 373px; height: 230px; background-image: url(data:image/gif;base64,R0lGODlhdQHmAOYAAP///4CAgAAAAMDAwEBAQNDQ0BAQEHBwcCAgIKCgoDAwMFBQUPDw8LCwsODg4JCQkPL388DN5vDz+Wafd2BgYP/AwEBms/9AQICZzKzLtf+AgBBAn//w8P8QEMjczi58Rf+goP8gIJC5nEqNXgAzmf/g4KCz2TBZrP9gYP8AACBzOWCAvzyFUtDZ7OTu51Bzudbl21iWa7DA33SohIKwkJ7Cqf9QUP+wsLrUwv+QkP9wcHCNxv/Q0P8wMCBNpgI3k5Cm0+Dm8wY/hydwV7TI02SbfRpnS6rHu8bY1BdQh0x+jwQ7jRZfVwpHe48mU485HLjQyJ2ymE2CifGXk2qUoVF2s4+pjHNXNPEHA0MuZjmAV68/X9DJ3BRbXTBsdu8DCb8MJo9mkyA8lYShwB5vP8ccDjZ4Y5KqzQxLdQAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAAB1AeYAAAf/gACCg4SFhoeIiYqLjI2Oj5CRkpOUlZaXmJmam5ydnp+goaKjpKWmp6ipqqusra6vsLGys7S1tre4ubq7vL2+v8DBwsPExcbHyMnKy8zNzs/Q0dLT1NXW19jZ2tvc3d7f4OHi4+Tl5ufo6aoJA4INDYwOAwyDDg8BCfX38IIMCfj01AkciIhAAEEHCChi0ECBgHYAChgw4FChg4kODwiqKEABwY8EBwgYSXKBIpEjIQYQoHEkgAMCHgAwIIChAJMLBPADydNcAQIGEBAgsKAAIwIPBUm8KSAf0nZPVx6UCmBAgKtYIfbcuo0dpKeCHChAQJMCALBRBUxVWxXrVYNc/+NmK+BwAAKZi8ACyDkPwcOc8BwWeMDyZcxDV+UqrqZg4oCECwc4fGCUggAKDWg6SHCzgQAEABx8tivAAeKDi1ND00nAqsJEKEcqZJCzI78DNBUYBZDAL4J8p1ULb2bgAYEGCMyySjy8ObKVJLWqYu68OjHjC3auom69+y8G8+a14u69fC7ODxVoXI7afLQMNTycQzDW9fj27plBEMFixIwRKvgXnzgPtQYZe/kx48IMH0wg3yAe1DABCwHSkAEM3SSnQAAGrLcdfgkW48EEH8zggiIQeCDChCrEYCGGqgwgo3gAgLdbRDPKeKMlno1kgGkIhlhMBiOwIAIEkaS4Iv+FLl5oCkkCGNCOSK+dBaUAVVIiXgEBPABkkEICs19/GWQCAQ4ixPDBBzGIgMOJoLgE00FUDlLAAJZRMMCOkzx0AHCvkBemLgs2+KAnLqCpJptuwqnJSAGMZVqdhFCFyU1CYQXodCAOesuIJTpKSqJprtkmDkhaIptfdGJZiKWXwHRllqkI6uksRBqZKiswZEBDDCqwMIEIHuz6iEsAuETpILBeQpeeOt53ay1jjlBmLb3+GuywxTaSEmGgiYTAVcA1q4yt065SqIO9ZAugsAMiAiUBRsXmKgDmJoNuuqeAaiIxEf4X4AyHirMvv6PkeuQyERYczsEIe1Ltte4VkED/QB9GXMq6DpsnkgEBYHyIPCLbg09Y+wziD0CIQKzxJf6KGqJrnfbTUFKCcGYAUaFhVBgAHHkU3MueKGxsgg0E4EAAfBYSG0SiIYAxTDLRZBNOOg1NtJn8WXurrAMsoJwiehHW2GFoPUQVVVa5BdfWl3CcrgEUKGBfXjivhJlmaVvFFttuBfA23JPEjHCBeNJ6SNlsPQUY0AIMVhjVWhP+iNEaEzBWTnghAt5kRkWdmQH+dPZZaKP59WWlNVt+yMRbL9WRyIbY+1pvn+2GW0e74f5by627Pojclu8ZaPCuGz5Q0gHwc2dA4OVI4yULeHQR8qO4TDQORS48EAMVOXSQ/172ppRJ1i8pfor2GkPwQQ08rbReAfDoFX1K06t6m/qmsB/xBBPoCXoMshu9DAJZmlhAhygHJuEBAAcfOBpBOEQSp+DsgALgRAH8MjtpORAA7sPBVgJSAJgoxICCQOAmjOcK/6VrAjPgiuDYYZnxXeYqQFIhJgqwgKEQwEOc+mAGWCDBU0ggAkhMogkwwMQmNhEISYyiFCMgAVMMACmfQQ0WzZesDG6Cg7LxoOtc8IGONeKIUlyiEzHwAgu48Y0kiKMcSfDGN75gjU5cQR33WMc5+nGOG+CjIHeAxwjI4iaxcKGnXDQIGTSxjXv8Ix33eMc1mmCKVYRFEKbISTxiwP+QsVgAEMVIuBoQURAt2AAhMXBJKWZSYxTY2VBGiQpFComMD5LABkzwwUFs8V4ZsxwjASCBE6wgLvK40fPuJKPVNcOWCTJlql7wArkU4HSCIIuVSELLSzDgHuQi5ctwKYgVnOCV4OBABdbJThBo4J0VOIRf4CESszxFNF7cRG3C2MCXDdMEG0BnMdTJznW6850ItcEFFsrQFDj0oSlgKENtgNB4GoIwZrGMUZ5yTdBwgiUFwp4ooGmeGowASTLYQAtwUYKDakChEr0ARB8a0wtQFKHvBEFB18kBTDAgSgygiCC2aICmXeIhPxKcOBEGgw9gKJUysMUNdBCCDtxUAzr/3WlPZ5ETpOAFKbIyqiUMkIAFkIV/pSCpd0YgAmLuchY8yIFMe6ADi/6iRzUZqto+Q7tLJCABEilqPPJXFRqZbCcruxjwiCaCERDTmLDgAAhQUFUUgGCrw/DL2MDikLFlogBAAu1CbiYd9LTjIhT5WdAWqzEYqABD1HRFBTTQg4jmgAdbeZtSYROdetAkKZSzmmewph1miTREbAWAOQVaipbaoAMh0MENMMuTnwRlKDs7ygV9mJS+rY0tbcPK4PjVWAAAlLmimGpVbZCDEiymfAYo7uJw9oAf9c1KflsLnQI33mm5FgYpXSkp4jrXujrnT1/B2S//kjXBEEYjDHzV/3Hdw1aoikKylO2AZanbnL/SxrOH+FxMjMLMyZQuO6eLGmmcKQi1DqexuuTlJ2Zb2wvc1j13scxheEuSLOlld7rJmW82xTp+NRUJkOWEc6ErXQ6XJz0/RCspXJwaCIygBrHVhHqt2l5PgUwtuw3mrX613EsQOAV0tevXUqIAENdywtbxwAfGEFBKYLiyl9XYNxvAAKYtNUEQYIEUVCoJGtsWt70Uc5hoMIQNRPURILgAk6dLuALN68/u8QAZfiDjRtwgBCHosvDolRAfdrN/cB4OBLQghGM2ogIXCAEIEl0LKnOFBk2oJiNg3YFZ09qHwD51WlOtGg+g4ZyL4LUGnP/swCvxU9HugYAX6pyIEjx32bQ2BAIgQgFic8LWPKECoRFRAhR0ANvZNsSODwTt8hDhB482RLlTgAJmp9tKmrsMpqsT40NwAAX0du+9PVebBfR1fd7mSjGrYAgOaEDDAh/4LsA9kBckwVgOt2rEJT7xhPdkBUKAwiAyfgE1c7zj5jHBD4owCBB0oOQnl8TBUV0eGfxgCEgCQQhgHvNGHCAgZd13alLJBBzoPAQ36PkjCLDtrg4WY1w6Gcqap7J/KLZyzdFlF64Aal8r3REblA2LCcGQumBwJBpBbUY2gqWOsNY5xcxCGWT9dZn3kBFPG0Q+rpnB4NZkuHtBn4StEwb/MGBhCnWHhLOBmQgUog403v0bePnr8XTw+glWSPxXgD1L7Uon8PXr7l712xa3Vd4c1v6CE6JwSs2LwoAMQApwHufgye148Kkpdwe2IAYilNH1jwhcOBMhYsqEpiI45AyKQaNi1WF9K/NGARccPUzge8vZUrZdVa7UDiD3bshv38q/Ax5jaVrfEdKLVj8/knEUuLeYKyDn+SHBTBa2WyAZt0HEY1v9+fv80uuXDiSnZstlUkXkf4iwM2qBAMI2ZaeHDS7Hc4NwXk0FIwjoLSLRZyYRgOWgcxLYSISWXBfoCKxRPVKWPQ84DUeXdIZgYeU1go5wAM0zEkT2ZuhQAT1A/3eH0G//BYORUABiRXPlwGs5kAjwJwgi6IOMIDbyFUTjoHvohghZ9oJKuIQl0YRCmE4ApwP2Nghl1oNV2AibgRQnOFIpiAztt3GIcF5I2FZhyAgl5BAgI3TVkAMvh2iLEGCCQIVvSDZYEoRZqA0eaHKJYGEAUIF9yAhlFSWYQYfQUAFd9wj9BkJXlohg53QcGA285nVnlGQA8CuWyAgBwEFzmInOYG3n1oVSqGsAIGcyE4qGwHQHgIUIVw3zFoWPUGYgxALwA4uKMHb3xwxpOAlsKAig6Iu9QHG48HAXoIaPAFAC1oof8IrIaAkkow9UN3WIZXUzp4y1MIiVgAFvJf8IgdaL1ehTpBUWPpN268h2SCE0huCNsvBpSFcJErACPhCNnxgD57gQCcFDtLh9XOR3DECQgPc48XiGswBrOkgJQXACFoBOrtiPiVAbeLKBfggRfRN5pBdeb6GQsFACkoaLkhABqlQIgUYxFKluxnE3GalXUGFpMZlf+DJ5pocMUKiKjWACJNBpgzADAbSS8tIArcEzeAMRtBc5SSk5EHZ7RTZQGhBwmLAC40YIEHSAQhlLQdEUkQE6vGE6oKF8nsF8qVMaz+cL+eeMklBMyIaSHyBCQklwUdKAAslP3ocQufF9n1GDLQaSqACOmNACPrAC6AVAcZkIohURwDhswXD/dIRICQAFBK9TAxF0mAWBGmHmhL3AkJx4CTuwAaA0CBCQAROgAhMAl5ZJCNYlFEBRhqEgj6DAAyO5CRLwAicQjaNZmhOQAVh5mPAVkCi4Czm5CS1wAi9QRblpmryZmoyAYLAAm5vAATpAbzoZCSa5A8m5m73JnKqZI4AYnLYwjJwABD+gBLq5nNy5dAAYjK4QgY9pCfe4BEagnekpCf9wFU5ZK36JCZ/WA+9JCaNZBEJwAkewnfXZCATgZrU4CzfQmZaQnGbwA652oJTATJnhmqAAna+QnRlwBj1JoZbwS/sJCRq6ChyKJJ8ZmiA6CfcpdaboCycqCBJgAScQBCvq/ywz8p1mWAwxOgiCSZg3agmy8mya+Qs9SggphQFBelQgM3zsaQtHWgjiGG9LSgnjkkgjKjGkqZxYeY/5WKWx0hrq96QbuqX0qQgPGZFgegm/hKGfUKKVEKWJcJ1rigkt6qJFCgsjwqXP+KF1+gomAyiHVXUsc5at4AHomYtV+aeTQGrB9oM+YxHtCDnvGH7CwJboxajHckXr6Qjy00WGUTV/h0gIiXvD8KOZqqmnsBQ5YUEz+V37dZPDEJmqmgnfpCmRIBZkoW8cWZOxKl5ZSgopWquZAEaM1wh8wQB+ETYNFjkPFqqGmgu1eZvEej4LkKORkCeZURpimWJlOXZw6v8JxXmc1ZoJB6CgjkAbI6EAt5GXQraXlqoLdFqumYAeRKqfvgAE40ivlyJLP+SIsOCl+sivlnClzxmstHkCbUmwmHAA4+KkeVoLqTShDIsJbQqwrMCTPlmxOIqtL9oKw8qxz4Sw9kijNiqyIyuxg5mqKFsM4RoJSdqyz/CykCADVCqzDRsQDkCXO4qz0AAUMpJdH+uzxCAW67qYDki00CArPNuzSssMOYGfGBmxT3sM2SEIYYOxVesLIjNzjLm1yOCopqa1YJsLltZjZFu20hCo2kioV5eQamsMXGIUCQGciKAzPKN2qtV28GiqcSsMDvtNvQUJUTM1hyFcpCp4T/n/t8Lwr7LXZpFgNjQhE70KOG5jEMKXuZq7uZzbuZ77uaAbuqI7uqRbuqZ7uqibupn7easAF1GCL27aYpexrQ5QuTYpXpirurorOLm7u6k7FL6ru8AbvL/bu8Rbuv21CrhhGSZBAbELAIRhQ8waGM5qe52zuFhKCzQbfCQrCdvrqd0rhr81D6X4CKIzESc2lo+3YtFKpvg6C9/bCPEriuHbCFzSDlyCtHfrG7rjrrwBfu1LtWkLnrIwv4tgwCgHv/XLvdq7wODbwOWAwIkgwfHaQg4svxdMv+UgI7TAwbPgwbIAwrEgwrBAwox7wiicwoeZWF4bCtIDdgTAl5CQI5XQ/zas+1n38LavsDIZXDs3YjIP0MLfsFqpcCXoxxaqQhKCla0doVme0KmtsBRMF8UrUSVb1LfkcJCKWwr40w730GIykQBDcbUi8YAuQRgmgQ9cUiOCc7WFoHyC0Kr4kgDG8YD5gE9O0zwLYHAzpBTO+3Oc4BdGZRUNsMd9FsN+/ENCjKDPxmfKekGh0TzOSz//WiMJQQE6egywWsRglg8adU1mIUqjWBplfFQZVCdR4hKNESmRUwgICXhzyTmX8BhIzCxRIodn4wAXsSFCpQkd5RdTW5OpRRGascscgsVacqwA4HyDgBJIERR+kQ+r3Bj6q8mSl8GXJhIHQBinJTjLWv/KSczK+eB2EYElAVBD0CGTWOsqrvJTz2sIYvwzttwOrrISA0AY8AATmdwIImE3DrEp9pwsCmHP+GwY+3wSx/qshFDKSLF9TFMYnnG9zvCsEfYk+ZRNCjAWPaMACWAZMlLLlCAbiCzQ65y7AyAPMlKQO/as96LMjQrJAV3Pe9UOAf1ZMo0fMT3QM12TNxwJy2IYbsbQp6wWpQzO0NB8ZokKkMIcstIq1/oURh3SF03SgjAR7PAARIZafzURptEReJKfM7whsrI6Oc3T13St2vRFOmF280zS9nzWdmEAO2Q24pETDysdQu3QM9F0rSwNviPDomDEqJPUlpFaH23GUw3WTDw0EgggX4t9E7sRJTTRtIlgtJ9RXGUd0LgTZJtAF1FCZJmdFJt90I0HJfQMJfiR16Xs2b/DnS6twgTx2rA927Rd27Z927id27q927zd277928BNOPWnI2JM2sHNDAvWGkpz3NtwJ3myJ1ZhGv9AlD83yVjbQ4DM3OeCxAGNFAjgFwoIGsMFE8Gs3S7L3aKn1w0dtaNs3vqC3jGp3hmEFG7h3s8B31Yi39B7EwPQAOhq379gKd091DbUYhxU3gCe4Aq+4Aze4A7+4BAe4RI+4RRe4ccdCAA7);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Comparison of six-minute walk distance before and after volume reduction (VR), single lung transplantation (SLT), and bilateral lung transplantation (BLT). The following differences were significantly different: VR greater than BLT (p &lt;0.05) at initial evaluation; VR less than BLT at six months (p &lt;0.001), and VR at evaluation versus six months (p &lt;0.001).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Redrawn from Gaissert HA, Trulock EP, Cooper JD, et al, J Thorac Cardiovasc Surg 1996; 111:296.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_11_36029=[""].join("\n");
var outline_f35_11_36029=null;
var title_f35_11_36030="Normal amniotic fluid volume";
var content_f35_11_36030=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F59704&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F59704&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 485px\">",
"   <div class=\"ttl\">",
"    Mean amniotic fluid volume during normal pregnancy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 465px; height: 333px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    These values represent the 50th percentile. There is considerable variability around the mean. The 5th, 50th, and 95th percentiles at 33 weeks of gestation are approximately 300, 800, and 1900 mL, respectively.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Brace, RA, Wolf, EJ, Am J Obstet Gynecol 1989; 161:382.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_11_36030=[""].join("\n");
var outline_f35_11_36030=null;
var title_f35_11_36031="Mouth retraction";
var content_f35_11_36031=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F68341&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F68341&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 474px\">",
"   <div class=\"ttl\">",
"    Retraction of the corner of the mouth by an assistant",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 454px; height: 248px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Retraction of the corner of the mouth by an assistant's index finger will provide ample room for unobstructed passage of the endotracheal tube.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Murphy MP, Barker TD, Schneider RE. Endotracheal intubation. In: Manual of Emergency Airway Management, 3rd ed, Walls RM, Murphy MF (Eds), Lippincott Williams &amp; Wilkins, Philadelphia 2008. Copyright &copy; 2008 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f35_11_36031=[""].join("\n");
var outline_f35_11_36031=null;
